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ABSTRACT 
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DISSECTING INTERACTIONS WITHIN FOCAL ADHESIONS: STUDIES ON 
VINCULIN 
 
by Clare Louise Cox 
 
Vinculin and paxillin are proteins that localise to focal adhesions.  Focal adhesions are 
specialised sites of cell attachment between the cytoplasmic side of the cell membrane and 
the extracellular matrix.  They consist of receptors that link extracellular matrix ligands to 
the actin cytoskeleton via various protein assemblies.  They act as mechanical links and as 
sites of signal transduction to transduce signals for cell locomotion, cell attachment and 
detachment, apoptosis and gene expression. A range of cellular responses depend critically 
on the composition and regulation of focal adhesions. 
   
Vinculin and paxillin will interact in vitro.  The tail domain of vinculin interacts with a  
motif on paxillin called an LD motif.  The interaction between LD motifs and their target 
proteins is important for regulation of focal adhesion signalling, yet little is known 
regarding recognition mechanisms between LD domains and interaction partners. 
 
In this thesis, the molecular nature of the vinculin tail (Vt) and paxillin LD motif 
interaction has been studied using purified Vt, synthesised LD peptide mimics and 
recombinant paxillin His-LD1/LD2. The 
1H-
15N-HSQC spectrum of a Vt/I997S mutant 
has been assigned and the NH assignments transferred to a wild-type Vt spectrum.  
Chemical shift perturbation studies have subsequently been undertaken using wild-type Vt 
and paxillin. 
 
The data presented here is consistent with specificity for LD motifs and points to an 
interaction between Vt and LD1 and LD2.  In contrast there is little or no interaction with 
LD4.  Two binding models are proposed; a single binding site on Vt face 3-4 where LD 
motifs bind in an extended conformation, or a two-site binding on Vt face 3-4 with two 
LD motifs bound as α-helices.  Both models need further analysis.  NMR data for the 
paxillin His-LD1/LD2 construct suggests a predominantly unstructured molecule in 
solution that can catalyse precipitation of Vt when Vt is added to excess. 
 
It is clear that the mechanism of interaction between Vt and paxillin LD motifs is distinct 
from that of focal adhesion kinase interacting with paxillin.  Further investigation is 
required to elucidate the precise mechanism of binding.  A comparison of this data with 
other LD-protein interactions suggests there are little similarities between the target 
sequences that LD motifs recognise and that target proteins can be structurally different.   III 
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1  Introduction 
1.1  Aims 
 
Vinculin, paxillin and focal adhesion kinase are proteins that localise to regions of the cell 
called focal adhesions.  Focal adhesions are discrete sites that mediate cell adhesion, 
motility, differentiation, development and apoptosis (1-4).  This study aims to determine 
the nature of the interaction between the tail domain of vinculin and paxillin LD motifs.  A 
comparison to other known protein-LD motif interactions will be made in an attempt to 
elucidate common interaction motifs.  At the beginning of this study, the only characterised 
interactions were using vinculin and focal adhesion kinase with paxillin LD motifs (5-9).  
Since then the field has advanced significantly with the structure of Git1 (10) and actopaxin 
(11) in complex with the LD motifs of paxillin. 
 
The main technique used in this study is nuclear magnetic resonance (NMR) however other 
biophysical techniques have been employed.  
 
1.2  Cell-extracellular matrix connections: Focal Adhesions 
 
Cells such as platelets, fibroblasts and epithelial cells make numerous contacts with the 
extracellular matrix (ECM) (12).  Observations that fibroblast cells do not adhere uniformly 
to a substrate, but at discrete focal points (13) led to the identification of regions in the cell 
that were named focal adhesions (14).   Since then, an increasing number of components 
have been identified within focal adhesions and their spatial and temporal organisation has 
been realised (2;15-20). 
 
A classical focal adhesion is a specialised site of cell adhesion between the cell membrane 
and the ECM (18).  They consist of receptors that link ECM ligands to the cytoskeleton via 
various protein complexes.  Since their initial identification, focal adhesions have   2 
subsequently been divided into various forms depending on their protein composition, 
method of formation and position in the cell (16;21).  The term focal complex is used to 
determine newly forming dot-like adhesions at the edge of lamellipodia that either turnover 
or become focal adhesions (18;22-25).  Focal adhesions are larger mature adhesions 
associated with actin (18;25) and fibrillar adhesions develop from focal adhesions and 
define an elongated form typically containing fibronectin receptors and tensin (25;26). 
 
The reason for these different forms is a consequence of the dynamic and flexible nature of 
these adhesions.  They act as signalling hubs that can integrate many complex signals to 
control key processes in the cell (27).  Consequently, continual regulation and 
rearrangement of adhesion to the ECM and changes in the cytoskeleton is necessary.  Thus 
focal adhesion components are highly regulated and turn over in response to mechanical 
and chemical information to maintain the correct functioning of the cell. 
 
As a result, adhesion sites between the cell and the ECM can be highly variable and 
heterogeneous (18;19;28).  For the purpose of this report the term focal adhesion (FA) will 
be used when describing connections between the cell and the ECM.  Where appropriate 
the distinction will be made as to early, immature FAs or late, more mature FAs, but it is 
important to remember that at any moment in time a FA will be dynamically regulated to 
respond to the constantly changing cellular environment. 
 
FA formation is primarily integrin mediated and indirectly links ligands of the ECM to the 
actin cytoskeleton (29;30).  Integrins are heterodimeric transmembrane receptors that 
transmit signals across the membrane in both directions; outside-in signalling between the 
ECM and the cytoplasm, and inside-out signalling between the cytoplasm and the ECM 
(3;31;32).  Integrin binding to the ECM and to intracellular components can lead to integrin 
activation and clustering with a concomitant recruitment of cytoskeletal proteins to the 
adhesion site (33).   
 
The initial weak link between small clusters of integrins and the cytoskeleton is thought to 
be mediated by the binding of the cytoskeletal protein talin1 (34)(see Figure 1.2.1.B). 
Initial adhesions also contain proteins such as actin (35), paxillin, vinculin and focal   3 
adhesion kinase (FAK) and show high levels of tyrosine phosphorylation (18). Figure 
1.2.1C shows a snapshot of a FA and some of the possible interactions. 
 
Currently there are over 90 proteins that have been reported to associate with FAs (36) and 
their complex interactions regulate many cellular processes such as cell motility, cell 
survival, transcription, cytoskeletal organisation and cell proliferation (3) and so play roles 
in  embryonic development, immunity, wound healing and attachment and detachment 
from the extracellular matrix (1;2).  If this regulation functions abnormally, altered rates of 
cell motility and resistance to apoptosis can occur which can lead to cancer (4).  Other 
effects of disregulation include abnormally migrating inflammatory cells such as in chronic 
inflammation and asthma (37).  Developmental abnormalities can also occur making many 
FA mutants embryonic lethal (36).   
 
   4 
 
Figure 1.2.1 Potential interactions occurring at focal adhesions 
A: representation of a fibroblast cell plated onto ECM ligands (such as fibronectin).  FAs 
are sites between the cell membrane and the ECM, shown as green circles.  They are 
attached to actin stress fibres, shown in red.  B:  Likely composition of the initial weak link 
in early formation of FAs (34).  The cell membrane is shown in black. C: Possible 
interactions in a maturing FA.  While many of these interactions have been shown in vitro, 
less is known about their cellular context. The interaction between vinculin and paxillin is 
poorly understood so these are possible but speculative in this picture.  Many of the 
interactions can be found in references (3;38-49). 
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1.2.1  Maturation and turnover of focal adhesions 
 
Once an adhesion contact is formed it can either turn over or mature into a more organised 
structure (50;51). The fate of a FA is largely determined by the environmental cues that the 
cell is experiencing.  Maturation and turnover can be regulated by the phosphorylation state 
of proteins in the FA such as FAK, Src and paxillin (50;52), tyrosine phosphatases such as 
PTP-PEST (53) and proteases such as calpains (31).  The dynamics are thought to be 
controlled by the small GTPases, Rac and Rho; Rac activity is required for formation of 
early FAs, and Rho activity is required for maturation (26).  Force will also control FA 
dynamics as FAs can function as mechanosensors.  When a force is applied from within the 
cell (for example via the actin cytoskeleton) or externally from the ECM, FAs will increase 
in size and maturate as more proteins are recruited.  FAs will also shrink if this force is 
relaxed and this occurs proportionally to the size of the force (54-56).  
 
Migrating cells are continuously forming and disassembling FAs at the leading edge of a 
cell protrusion (50).  Some of these remain fixed as other proteins are recruited and the cell 
migrates over them while others turnover and are recycled (57).  At the rear of the cells FAs 
are being disassembled and released by the cell causing contraction of the cell and motion 
forward, the mechanisms of which are distinct from turnover and disassembly at the leading 
edge (21). 
 
Once a FA is formed in motile cells they do not appear to move relative to the substrate 
(15;29).  In contrast, stationary cells appear to have motile FAs that move within the cell.  
One suggestion is that motile FAs prevent the cell from generating the traction required for 
movement, but enables a connection that is ready to be remodelled when migratory signals 
are received, thus the cell is in an ‘idling’ state, ready to respond to environmental cues 
(15).  Clearly both states require tight regulation to ensure correct functioning. 
 
Understanding the interactions between the proteins involved in FA dynamics and the 
complex interplay between signalling pathways that control cell migration is challenging.  
Many of the pathways are not linear and involve feedback loops and interconnections   6 
between pathways.  For example FAK, which is an important player in FA dynamics, can 
promote cell migration via multiple pathways involving interactions with Src (58), PI3K 
(59), Grb7(60;61), p130Cas (62) and N-WASP (63;64), and each of these interactions 
appears to be required for the promotion of cell migration (52).   
 
Consequently, understanding the regulation of FA formation and turnover is of key 
importance.  FAs are dynamically assembled and disassembled within cells, and this 
turnover is partly governed by the transient interactions between the proteins involved (2).  
So while the composition of the FAs is important, the binding events that take place 
between the proteins is equally important to understand.  This requires an intimate 
understanding of the molecular nature of the individual reactions, their relative affinities 
and the stoichiometries of binding.  At present it is difficult to study direct protein-protein 
interactions in vivo, although methods are emerging that are beginning to make this 
feasible, such as proximity of proteins using FRET (e.g. (19)) and binding kinetics using 
FRAP (e.g. (2)).  In vitro experiments that identify binding partners have been useful in 
exploring potential interactions, and now that the dynamic and heterogeneous nature of FAs 
is fully realised it is now becoming feasible to ask very specific questions about the 
function of binding partners within FAs.   
 
This thesis builds on in vitro observations about the interactions of the cytoskeletal protein 
paxillin with vinculin and FAK.  The following sections introduce the three proteins and 
explore the current knowledge about the roles and interactions within FAs. 
 
1.3  Introducing selected cytoskeletal components  
 
A key feature of many proteins involved in FAs is that they are made of different modules 
that can provide a platform for binding a number of other proteins and signalling molecules 
(65).  The following section introduces paxillin, FAK and vinculin which are three 
important cytoskeletal proteins involved in FA signalling. 
   7 
1.3.1  Paxillin 
 
Paxillin is a 68kDa cytoskeletal protein identified in 1989 as a phosphotyrosine containing 
protein in Src-transformed cells (66).  It was characterised as a vinculin binding partner and 
named paxillin after the Latin paxillus, meaning a small stake or peg (67).  The name arose 
from the belief that paxillin acted as a passive structural link between actin and the ECM 
(68), but it is now realised that paxillin is an active signalling molecule within FAs, not just 
a passive tether. 
 
Paxillin is recruited early in the formation of FAs (69).  It contains no intrinsic enzyme 
activity but facilitates multiple protein-protein interactions that can drive the formation of 
protein complexes, hence it is termed an adaptor protein (5). Paxillin null cells form FAs 
but they have delayed spreading and delayed cell migration when plated on fibronectin 
(70).  This is consistent with the idea that paxillin is involved in the regulation of FA 
turnover rather than formation of FAs.  
 
The domain structure of paxillin is shown in Figure 1.3.1.  It is a modular protein that 
contains a number of domains that are interaction sites for other proteins. The C-terminus 
contains four tandem LIM domains and a number of phosphorylation sites while the N-
terminus contains five LD domains, several phosphorylation sites and a proline rich region 
that may serve as a potential SH3 docking motif (68).   
 
 
Figure 1.3.1 Domain structure of paxillin (human numbering) 
Paxillin contains five LD domains, four LIM domains, multiple phosphorylation sites (not 
all sites are represented here) and a proline-rich region (PPPVPPPP)   8 
There are many known interaction partners of paxillin, some of the best characterised can 
be found in Table 1.3.1.  The C-terminal LIM domains are double zinc finger motifs that 
are known to mediate protein-protein interactions (71). LIM3 is required for targeting of 
paxillin to focal adhesions (5) and phosphorylation of LIM2/3 regulates this process (72), 
but the protein that functions to target paxillin to FA remains elusive (68).  Proteins that can 
bind to LIM domains of paxillin include PTP-PEST (73;74) and α- and γ-tubulin (75). 
 
Table 1.3.1 Interaction partners of paxillin  
Paxillin domain  Binding partner  Reference 
LIM1  None identified   
LIM2  α-tubulin, γ-tubulin  
unidentified kinase 
(75;76) 
(72) 
LIM3  α-tubulin, γ-tubulin  
FA localisation 
PTP-PEST 
unidentified kinase 
(75;76) 
(5) 
(73;74) 
(72) 
LIM4  PTP-PEST  (73;74) 
LD1  Actopaxin (α-parvin) 
ILK 
Vinculin 
E6 protein 
(11;77) 
(78) 
(5;79;80) 
(81) 
LD2  Vinculin 
FAK 
Git1 
(5;79) 
(5;6;79) 
(10;80;82) 
LD3  None identified   
LD4  Actopaxin (α-parvin) 
FAK 
Vinculin 
PKL 
Git1 
Bcl-2 
(11;77) 
(5;6;79) 
(5;79;80) 
(80) 
(10;80;82) 
(83) 
LD5  None identified   
Proline-rich 
region 48-57 
Src 
Crk 
(84) 
(84) 
 
The N-terminus of paxillin contains five leucine rich sequences called LD motifs.  LD 
motifs can mediate binding to proteins such as vinculin and FAK (5;79), Git1(10;80;82), 
ILK (78), actopaxin (77) and PKL (80) (Table 1.3.1).  They were identified by sequence   9 
analysis of similar regions of paxillin that bound to FAK and vinculin and have a consensus 
sequence of LDxLLxxL (5;81;85).  Paxillin LD motifs 1 to 5 are shown in Figure 1.3.2.   
 
The LD motifs in paxillin are predicted to form amphipathic α-helices with each of the 
leucine residues being positioned on one face of the helix (85).  This would form a 
hydrophobic binding interface down one face of the helix
 that could interact with other 
proteins.   The interaction domain on molecules that interact with paxillin has been named 
the paxillin binding subdomain (PBS) (86), these regions are expected to share similarities 
that direct LD binding (85).   
 
Whether LD motifs always adopt α-helical arrangements is still under some debate as 
subsequent studies have provided contradictory results. An LD2 peptide was shown to be 
predominantly α-helical in aqueous solution (as judged by circular dichroism and NMR 
data) (7;8),  yet LD4 was unstructured in solution and forms a helix on binding (7).  
Hoellerer et al. (6) showed that LD2 and LD4 were helical in the crystal structure of LD 
bound to the FAT domain of FAK, but suggest that the peptides were unstructured alone 
(65). It is likely that phosphorylation plays a major role in the structure of LD motifs as 
recent data has shown that phosphorylation of LD4 at serine S272 reduces the binding of 
the FAT domain of FAK by destabilising the helicity of LD4 (87).   
 
 
Figure 1.3.2 Paxillin LD motifs (human numbering) 
The LD motif is shown in red, the consensus residues in bold.   10 
 
Paxillin phosphorylation is vital for its correct function.  A large number of potential 
phosphorylation sites have been identified (88) and it is important to determine their 
function in signalling, the proteins that phosphorylate them and any interaction partners. 
Two well-characterised phosphorylation sites are tyrosine Y31 and tyrosine Y118 (89;90), 
mutations in these cause slower FA disassembly (91) and the integrity of these sites is 
important to promote adhesion turnover (51).  The SH2 domains of Crk and CrkL, PI3K 
and p120RasGap can interact with phospho-tyrosine pY31 and pY118 to regulate cell 
migration and FA turnover (68;92;93).  Other less well-characterised tyrosine 
phosphorylation sites include tyrosine Y40, Y88 and Y181 (94;95).   
 
There are important serine and threonine phosphorylation sites within the LIM domains 
(threonine T396/401 in LIM2, serine S455/479 in LIM3) that are involved in regulating 
paxillin localisation within FAs (72), other sites include threonine T344 and serine S361 
within LIM1 and serine S272 and S308 within LD4 and LD5 respectively (88).   
 
There are increasing numbers of proteins being implicated as interaction partners of 
paxillin.  These include the integrin tails of α4, α9, β1 and β3 (96-99) and PABA1 
(100;101).  For a thorough review of paxillin interactions, the reader is directed to papers 
by Brown and Turner (68) and Deakin and Turner (102). 
 
1.3.2  Focal adhesion kinase 
 
Focal adhesion kinase (FAK) is a 125kDa cytoplasmic non-receptor protein tyrosine kinase 
(42;103;104).  It is a multidomain protein consisting of a central catalytic kinase domain 
with non-catalytic N- and C-terminal domains (Figure 1.3.3).  One role of the N-terminal 
FERM domain is to bind the cytoplasmic domain of β1-integrins (97;105) and there is 
evidence to suggest the FERM domain plays a role in the regulation of localisation and 
catalytic activity of FAK (106;107).  The C-terminus consists of a FAT domain which 
targets the protein to FAs (108;109) and can bind to paxillin (110) and talin (48).  There are 
three proline-rich sequences, PRR1-3; PRR2 can bind to the SH3 domain of p130Cas (111)   11 
and PRR3 can bind the SH3 domains of GRAF and ASAP1, which are GTPase activating 
proteins (112;113).  In addition there are multiple phosphorylation sites within the domains 
of FAK (103;105).  
 
FAK kinase-dead mutants retain most of the functions of FAK (114), and its modular 
structure implicates FAK as an adaptor protein as well as a kinase (115). 
 
FAK localises to early FAs.  FAK null fibroblasts show excessive formation of focal 
adhesions and reduced cell motility (116).  Inhibition of endogenous FAK results in 
reduced motility and cell death (116;117). Conversely, enhancing FAK signaling increases 
cell motility and can promote cell survival (58;118). Thus, FAK has been implicated in 
regulating FA turnover, cell motility and cell survival.  
 
 
 
 
Figure 1.3.3 Domain structure of focal adhesion kinase 
Consists of a FERM domain, a central kinase domain and a focal adhesion targeting 
domain (FAT). There are three proline-rich motifs, PRR1-3 and several phosphorylation 
sites are shown.  FAK autophosphorylates tyrosine Y397 which creates a docking site for 
the SH2 domain of Src. 
 
FAK is a complex protein to investigate as it can couple to many signalling pathways 
(Figure 1.3.4).  The best characterised of these is the Raf-MEK-ERK signal transduction 
pathway (42;119), but FAK is also proposed to couple to p130Cas-Crk-DOCK-ELMO 
(105) to activate Rac1 as well as to PI3K-Akt to promote cell survival (103).  FAK also has 
a role in signalling to the JNK pathway (120;121). 
   12 
FAK can interact with a number of different partners. FAK autophosphorylation on 
tyrosine Y397 creates a docking site for SH2 domains of Src-family PTKs.  Src binding to 
FAK promotes further FAK activity by phosphorylating FAK in the kinase domain (109).  
This FAK-Src signalling complex can phosphorylate proteins like p130Cas and paxillin 
thus affecting FA dynamics (62;89;90).  Phosphorylation of tyrosine Y861 and Y925 in the 
C-terminus of FAK creates a Grb2 docking site which couples FAK signalling to the Ras-
MAPK pathway (103;122).  As previously stated, FAK can also couple to other signalling 
pathways (94) so is an important mediator in regulation of FA dynamics. 
 
FAK is also an important target for cancer therapy. FAK is over-expressed in many 
tumours and over-expression is related to increased tumour malignancy (123).  It is 
believed that FAK plays a role in tumour proliferation, invasion and enabling anchorage 
free growth (115).  Thus there is great interest in elucidating the signalling pathways and 
interactions that FAK mediates. 
 
 
Figure 1.3.4 Summary of integrin signalling pathways in which FAK is involved  
FAK plays a role in these signalling pathways after integrin stimulation.  The Raf-MEK-
ERK pathway is best characterised, the others are less well defined.  For more detail on the 
signal transduction cascades and references to the primary data, refer to (42;103;105;124-
127).   13 
1.3.3  Vinculin 
 
Vinculin is a cytoskeletal protein of 116kDa that is found in FAs and cell-cell junctions 
(128).  It was first isolated in the mid-to-late 1970s, with several groups identifying a 
130kDa protein from chicken gizzard (129-133), but it appears in the literature as vinculin 
from 1980 (134). 
 
Vinculin is not absolutely required for FA formation as vinculin null cells still assemble 
FAs (135).  Cells lacking vinculin are less adherent and less well spread when plated on 
fibronectin than wild-type cells and exhibit increased cell motility and wound closure 
(136;137).  They also show increased FAK activity and increased phosphorylation of FAK, 
paxillin and p130Cas (128;138).  They also have a resistance to apoptosis induced by serum 
withdrawal and detachment from the cellular substrate (anoikis) (4). Vinculin over-
expression reduces cell motility (139).  The lack of a defined phonotype for vinculin 
knockout cells is consistent with the multiple roles vinculin appears to possess.  It is a 
negative regulator of cell motility (137), acts to strengthen FAs (140), plays a role in 
mechanotransduction (141), regulates FA dynamics (137;142) and can regulate FAK-
paxillin signalling and apoptosis (4). 
 
The domain structure of vinculin (Figure 1.3.5) shows that it consists of five domains.  D1-
D4 form the head domain of vinculin, Vh; and D5 is the vinculin tail, Vt.  Vinculin binds to 
many ligands and is an important regulatory protein within FAs.  
 
The first structural investigations into vinculin showed vinculin as a compact globular 
molecule (143) or as a roughly globular head attached to an elongated extended tail 
(144;145). High-resolution imaging by Winkler et al. (146) suggested that there were 
multiple conformations of vinculin; in some molecules an extended tail could be seen that 
appeared to have four spherical regions that are likened to pearls on a string while in others, 
the tail could be seen packing close to the head domain.  The proline rich linker, which had 
been predicted from the primary sequence of chick vinculin (147;148) was suspected to 
provide the flexibility to create these multiple forms.     14 
 
 
Figure 1.3.5 Domain structure of vinculin (1-1066) 
There are five domains, D1 (red), D2 (green), D3 (blue), D4 (yellow) and D5 (magenta).  
D1 to D4 make up the head domain of vinculin, Vh.  D5 comprises the tail domain, Vt.  
Several ligand binding sites are indicated. An intra-molecular head-tail interaction (HTI) 
occurs between D1 and D4 with Vt, shown as a dotted line.  
 
Ligand binding studies with vinculin show that there is competition between the globular 
vinculin head (Vh), vinculin tail (Vt) and their ligands.  For example, talin and vinculin tail 
will compete for binding to the head domain of vinculin (149), α-actinin will bind more 
strongly to isolated vinculin head than to intact vinculin (150), and vinculin tail will co-
sediment and cross link with F-actin, but neither co-sedimentation or cross linking occurred 
with intact vinculin (151).  Consequently, a hypothesis has been proposed where an intra-
molecular interaction between the head and tail domain will affect how vinculin can 
interact with its ligands (149). 
 
Crystal structures of the full-length molecule provide a structural basis for the regulation of 
vinculin binding to its ligands (152;153).  All five domains of vinculin are α-helical, and 
the tail domain is held between two ‘pincers’ that are formed by D1 and D3 (Figure 1.3.6).  
The interaction sites for PIP2 and F-actin are partially occluded in this structure suggesting 
that it represents a closed ‘autoinhibited’ form of vinculin where the ligand binding sites are 
sterically blocked (41;152).  Binding of talin and α-actinin were shown to require   15 
conformational changes in D1; a mutant of D1 which retained the α-helical structure of that 
in the crystal bound strongly to Vt but not to α-catenin or talin.  A conformational change is 
required to reverse this scenario, showing that ligand binding to vinculin is regulated 
sterically and allosterically (152).  
 
The Kd for this head-tail interaction (HTI) has been estimated to be below 1nM (152).  The 
principle intra-molecular binding site is between D1 (residues 1-258) and the top of the Vt 
helical bundle (152-154), yet in solution this D1 domain binds only weakly to Vt, with a Kd 
of 11.5µM being reported (155).  The autoinhibitory site in vinculin was found to be 
bipartite with a second interaction determined between D4 and Vt (155).  The Kd D1-Vt 
was measured as 10
-5M, for D4-Vt was estimated as 10
-2M, yet together they create a Vh-
Vt complex with a Kd of 10
-7M.  Once Vt is bound to D1, there will be a large local 
concentration of residues at the D4-Vt interface to act as a molecular latch that stabilises 
the autoinhibited state.  Tethering of the two domains by the proline linker probably 
enhances the affinity further.  
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Figure 1.3.6 Crystal structure of full-length autoinhibited vinculin 
Top: The five domains are shown, D1 (red), D2 (green), D3 (blue), D4 (yellow) and D5(Vt) 
(magenta).  The proline rich linker region is in orange.  Vt is held between D1 and D3 with 
additional connections from D4.  A: there are extensive connections between Vt and D1, 8 
hydrogen bonds and 26 hydrophobic interactions between M1, P2, V3, F4, E10, E14, A17, 
I20, V24, I25, E28, V32, D33, I109, R113 of C1 and G942, K944, R945, I948, T993, Q994, 
I997, L998, Q1021, M1022, H1025 and N1029 (154).  B: the interactions between D3 and 
Vt (153).   C:  the interaction between D4 and Vt (155). 
   17 
 
The closed, autoinhibited form represents a low affinity binding form where the head 
interacts with the tail to prevent ligand binding.  The flexible elongated form is suggested to 
represent a high affinity binding form of vinculin where binding sites are available that 
were sterically and allosterically blocked in the closed form.  This head-tail interaction 
(HTI) hypothesis presents a picture of a dynamic vinculin molecule that exists in multiple 
forms, a closed autoinhibited form, and active forms where the HTI is disrupted and ligand 
binding ensues.  A cartoon of this is shown in Figure 1.3.7.   
 
Figure 1.3.7 Cartoon of vinculin in its closed, autoinhibited form (A) and in an open, 
activated form (B) 
In A, interactions between D1 (red) and D4 (yellow) hold Vt in and autoinhibitory state.  
Upon activation, Vt is released and binding sites are exposed in Vh and Vt. 
 
Direct evidence for an open, activated form and closed, autoinhibited form of vinculin has 
been provided using FRET (156).  This study shows that vinculin exists in an autoinhibited 
form in the cytoplasm and in an activated form in focal adhesions.  Interestingly, there was 
heterogeneity in vinculin active states amongst different focal adhesions, vinculin can be 
observed in FAs but be in a closed form; thus vinculin recruitment and activation are 
distinct processes. 
 
An important aim is to determine the ligands that can recruit and activate vinculin. The 
hypothesis goes that the vinculin HTI could be regulated by vinculin ligands (149). In   18 
theory, any domain-specific vinculin binding partner could be a candidate for disrupting the 
head-tail interaction.  Table 1.3.2 shows many of the binding partners of vinculin. 
 
The mechanism of activation of vinculin is controversial and not fully understood.  The 
HTI is predicted to have a Kd of <10
-9M (152) which needs to be disrupted to activate 
vinculin.  One attractive mechanism is that a combinatorial input of ligands may be 
required to do this (152;155;157).  Several molecules may need to bind to the closed form 
before vinculin is fully activated.  This presents a model in which vinculin is able to 
respond to the spatial co-localisation of its binding partners (152), and means that the 
activation of vinculin would only occur when the environmental signals were exactly 
correct, thus providing a tight regulatory mechanism.  Ligands that have been implicated in 
activating vinculin include talin (154;158), F-actin (41) and PIP2 (159), although the latter 
now appears to be required for focal adhesion turnover rather than activation of vinculin 
(142).  
 
The combinatorial input hypothesis proposes that binding of a singular ligand is not 
sufficient to activate vinculin (152;155;157;160).  An alternative model is that the vinculin 
binding sites of both talin and α-actinin are sufficient to relieve the autoinhibitory property 
of vinculin (158;161;162).  The vinculin binding sites (VBS) within talin are buried and 
have a low affinity for Vh (152;163;164) but when activated are proposed to be sufficient 
to activate vinculin (161).  Talin VBSs can bind to Vh via a mechanism called helical 
bundle conversion (154) which causes massive conformational changes within vinculin D1 
that displaces Vt (161).  Instead of directly competing with Vt, the new D1 conformation is 
incompatible with binding to Vt and binds talin with higher affinity (165).  This alone 
could be sufficient to activate vinculin.  Consequently, it is of great importance to elucidate 
the mechanism by which vinculin is activated. 
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Table 1.3.2 Binding partners of vinculin 
 
Vinculin therefore acts as an important regulatory protein that can function as a molecular 
switch to regulate downstream signalling events (165).  With so many diverse interaction 
partners it is clear that vinculin is a multifunctional protein.  Interacting with Arp2/3 
suggests a link to actin polymerisation and membrane protrusion (180), binding to F-actin 
Ligand  Domain of 
vinculin 
Binding residues on vinculin  Key 
references 
F-actin  Vt  893-985 
1016-1066 
 
upper patch : 925, 927, 931, 934, 935, 
938-942, 944, 945, 948 
lower patch : 962, 965, 966, 969, 970, 
977, 1049-1055 
(151;166;167) 
 
 
(41) 
Paxillin  Vt  PBS1: 952-971  
PBS2: 978-1000  
(4;86;110) 
Talin  Vh (D1)  1-258 
two sites? C-terminal helical bundle 
and N-terminal helical bundle 
(154;157;168) 
(169) 
(170) 
Acidic 
phospholipids 
Vt  916-970 
Basic ladder: helix3 
C-terminal arm: 1052-1066 
(40;171) 
(142) 
(172) 
PIP2  Vt  893-985 
1016-1066 
C-terminal arm  
(173;174) 
 
(137;152) 
α-actinin  Vh (D1)  1-107  (150;162;175) 
 
VASP  Proline rich 
linker 
842-846  (176;177) 
Vinexin  Proline rich 
linker 
849-893  (178;179) 
Arp2/3  Proline rich 
linker 
850-881  (180) 
IpaA  Vh (D1)  1-265  (181;182) 
Ponsin  Proline rich 
linker 
837-878  (183) 
PKCα  Vt  1016-1066 
S1033/S1045 phosphorylated 
(184;185) 
α-catenin  Vh (D1-D3)  1-718  (152;186) 
β-catenin  Vh  1-718  (187)   20 
has been shown to be a crucial link between FAs and the cytoskeleton and may act to 
stabilise FAs (188), and vinculin also plays a role outside of FAs via its interaction with α- 
and β-catenin (186).   
 
1.3.3.1 The crystal structure of Vt contains two molecules in the unit cell 
 
The crystal structure of wild-type Vt (172) contains two Vt molecules in the asymmetric 
unit (Figure 1.3.8) where the N-terminus of one molecule packs against the C-terminus of 
another molecule.  There is also crystal packing between molecules from apposing unit 
cells, and the authors discuss a crystallographic dimer interface which is centred around the 
most hydrophobic portion of the molecule at residues isoleucine I997 and methionine 
M1022 (these residues are indicated in Figure 1.3.8).  This interaction is distinct from the 
N- and C- terminal interactions that occur within the unit cell. An example of the crystal 
packing can be seen in Figure 1.3.9 where isoleucine I997 and methionine M1022 are 
involved in a hydrophobic interaction between unit cells.  These two interactions could 
potentially impact on solution NMR studies. 
 
Figure 1.3.8 The crystal structure of Vt has two Vt molecules in the asymmetric unit 
There is a potential interaction between the C-terminus of one Vt molecule (green) and the 
N-terminus and helix 2 of a second Vt molecule (cyan).  Residues I997 and M1022 are 
indicated.   21 
 
 
Figure 1.3.9 Crystal packing of Vt molecules in the lattice 
The cyan and green molecules are from one unit cell, the magenta and orange are from 
another.  Potential salt bridges are indicated between the cyan and green molecules within 
a unit cell.  The I997 and M1022 hydrophobic interaction occurs between two molecules 
from different unit cells and is indicated between the green and magenta molecules.  
Picture kindly prepared by Dr. Stuart Findlow (University of Southampton) using Pymol 
(DeLano Scientific).. 
 
1.4  Some current knowledge regarding vinculin, paxillin and FAK  
 
In vitro data shows that vinculin and FAK can bind to paxillin LD motifs (5;79;80;110).  
Interestingly, the vinculin and FAK binding sites overlap, and recent data suggests that 
FAK and vinculin may compete for binding to paxillin (4) which would affect the 
downstream signalling events within FAs. The following section attempts to cover some of 
the knowledge about the three proteins from both cellular and in vitro observations.  
   22 
FAK, paxillin and vinculin are all recruited into early FAs (18;28) and phosphorylation of 
FAK and paxillin also occurs at early stages in adhesion (19).  Both FAK null and paxillin 
null cells show delayed cell spreading (70;189) implicating them in FA turnover.  
Expressing FAK in paxillin null cells shows that FAK disassembly from FAs is slower than 
in control cells (51).   Table 1.4.1 summarised the cellular properties of paxillin, FAK and 
vinculin null cells.  Many of the phenotypes seen for paxillin -/- cells are similar to that 
seen in FAK -/- cells, whereas the vinculin null phenotypes are generally different (with the 
exception of cell spreading). Whilst these observations provide clues to the function of 
these proteins in FAs, their precise roles are difficult to elucidate as the molecular basis 
behind these phenotypes are complex. 
 
Table 1.4.1 Phenotypes of null and knockout cells 
 
Paxillin null cells or 
paxillin deficient cells 
FAK null cells or  
FAK deficient cells 
Vinculin null cells or 
vinculin deficient cells  
Delayed cell spreading 
(70;190) 
Delayed cell spreading 
(105) 
Delayed cell spreading (136;137) 
Less motile (70)  Less motile (116;117)  More motile (137) 
Abnormal FA formation 
(70) 
Excessive FA formation 
(116) 
Fewer, smaller FAs (137) 
Unknown  Promotes cell death 
(116;117) 
Promotes cell survival (4) 
Adhere same as wt (70)  Adhere same, poorly 
spread (116) 
Less adherent and poorly spread 
(136;137) 
Embryonic lethal (70)  Embryonic lethal (103)  Embryonic lethal (128) 
 
1.4.1  The FAK-paxillin interaction 
 
The precise role of the FAK-paxillin interaction is not fully understood.  A direct 
interaction between FAK and paxillin was detected in vitro using GST pull-down 
experiments and immunoblotting (79;110).  The N-terminus of paxillin was shown to 
interact with the C-terminal FAT domain of FAK, and there were two discrete regions in 
FAK that supported this binding, PBS1 (FAK 919-935) and PBS2 (FAK 1034-1039) (110). 
Within paxillin, regions in the N-terminus containing LD2 and LD4 were shown to bind to 
FAK and mutations in both LD2 and LD4 are necessary to decrease binding of paxillin to   23 
FAK (5;191).  Subsequently, the binding sites of LD peptides have been mapped onto the 
structure of the FAT domain of FAK; this has shown that LD motifs will interact at two 
sites in the FAT domain (6;7;9).  This will be discussed in more detail in Section 1.5. 
 
One potential role of the FAK-paxillin interaction is to direct tyrosine phosphorylation of 
paxillin (192). The paxillin binding site in FAK has been found to be necessary for cell 
spreading (91).  In this study, inhibition of paxillin tyrosine phosphorylation could be 
rescued by both wild-type FAK and catalytically inactive FAK, showing that the kinase 
activity of FAK was not responsible for tyrosine phosphorylation of paxillin.  However, 
when FAK was expressed with a deficient Src kinase binding site (Y397F), the 
phosphorylation of paxillin was not restored.  This suggests that the interaction of Src with 
FAK is necessary for phosphorylating paxillin.  As both Src binding and paxillin binding to 
FAK is necessary, a model was suggested where FAK simultaneously binds to Src and 
paxillin to bring them into close proximity for phosphorylation to occur which promotes 
cell spreading.   
 
Tyrosine phosphorylation of paxillin through a FAK/Src complex is important in its 
function as an adaptor molecule (43;89;90;94), and while FAK binding is not essential for 
tyrosine phosphorylation of paxillin, association with FAK may enhance its level of 
tyrosine phosphorylation (191).   Two important phosphorylation sites on paxillin are 
tyrosine Y31 and tyrosine Y118 (89;90).  If paxillin null cells are transfected with paxillin 
that has mutated tyrosine Y31 and tyrosine Y118 phosphorylation sites, disassembly of FAs 
is slower compared to control cells (91).  It has been shown that paxillin is phosphorylated 
in dynamic adhesions and that the integrity of the tyrosine Y31 and Y118 paxillin 
phosphorylation sites was important to promote adhesion turnover (51).   
 
A study by Zaidel-Bar et al. (25) studied adhesion complexes at different stages of 
maturity; early forming focal contacts (FX), focal adhesions (FA) and fibrillar adhesions 
(FB).  They found that phosphorylation states of paxillin between adhesions varied, with 
the highest levels of phospho-paxillin found in early forming FXs, variable levels in FAs 
and no phospho-paxillin in FBs.  It was shown that phospho-paxillin was required for FA   24 
assembly, where it can then bind to FAK to initiate turnover.  Phospho-paxillin bound more 
strongly to FAK than paxillin that was not phosphorylated. A constitutively phosphorylated 
paxillin (where Y31 and Y118 had been mutated to glutamate) enhanced the number of FX 
and increased the turnover of FXs, confirming the role of phospho-paxillin in assembly and 
turnover.  In contrast the number of FAs was not changed but turnover of these was 
increased. 
 
Thus, the phosphorylation state of paxillin is important in FA dynamics and this is in part 
due to the interaction with FAK.  Downstream consequences of phosphorylating paxillin 
Y31 and Y118 generates SH2 binding sites for Crk adaptor proteins which can couple to 
the protein p130CAS.  Alternatively, phospho-paxillin can interact with raf-MEK-ERK or 
with Grb/Sos-ras to couple to the MAPK/ERK signalling pathway.  Cell migration, cell 
invasion and cell survival has been shown to be regulated by these two pathways (124). 
 
The interaction between FAK-Src-paxillin-Crk-p130CAS may also couple to the rac-PAK-
JNK signalling cascade which is important in mediating cell motility signals (93;193).  
MAPK/ERK signalling is equally important as ERK can act to serine phosphorylate 
paxillin on serine S83 (126;127;194;195) which may be important for increased FAK-
paxillin interactions (196). Phosphorylated paxillin can also couple to Csk which is a 
negative regulator of Src (197).   
 
1.4.2  The vinculin-paxillin interaction 
 
The role of the vinculin-paxillin interaction within cells is poorly understood.  Observations 
in vinculin null cells indicate that the paxillin and FAK interaction and the level of paxillin 
and FAK phosphorylation is enhanced compared to wild-type cells (4). Vinculin null cells 
have more dynamic FAs (137), and vinculin is involved in stabilising FAs and preventing 
turnover (140;141) although this may be an effect unrelated to or distinct from the vinculin-
paxillin interaction.  Vinculin recruitment to FAs has been shown to increase the strength of 
an adhesion in response to force (140).  One mechanism of relieving this may be due to   25 
PIP2 (137;142), and it also appears necessary to disrupt the talin-vinculin interaction to 
cause FA turnover (157). 
 
Paxillin was identified as a vinculin binding protein in 1990 by Turner and colleagues (67).  
The paxillin binding site was found to reside in the tail domain of vinculin (Vt), and using 
iodinated GST-fusions the region was delineated to Vt 978-1000 (86).  GST pull-down 
experiments between GST-paxillin and chicken gizzard crude lysate show that both 
vinculin and FAK can be pulled down (79). 
 
A novel motif on paxillin was characterised by Brown et al. (5) that binds to vinculin.  C-
terminal truncated GST-paxillin constructs were incubated with smooth muscle lysate and 
western blots were carried out with antibodies to vinculin.  Paxillin regions spanning 143-
164 were shown to be necessary for binding and deletion of this region from full length 
paxillin results in no binding to vinculin.  Analysis of this region in paxillin identified 13 
amino acid stretches of conserved residues which were named LD motifs.  LD motifs 1-4 
were originally identified (5), a fifth LD motif was later predicted by virtue of its binding to 
papillomavirus E6, and was renamed LD3 (85).  The sequences of the LD motifs can be 
seen in Figure 1.3.2.  Vinculin has been shown in vitro to interact with LD1, LD2 and LD4 
(5;80). 
 
Cellular evidence of the role of paxillin-vinculin interaction is scarce.  They can co-localise 
with one another in FAs (18;67;138;198), but a direct interaction between the two in vivo 
has not been identified to date.  Vinculin appears not to affect the residency time of paxillin 
in FAs, and vinculin conformation may not be important in paxillin dynamics (157).  It is 
also not responsible for recruitment of paxillin to FAs (5). 
 
In a study by Bubeck et al. (199), when the binding activities of vinculin were studied by 
targeting Vt to mitochondria, Vt recruited F-actin but not paxillin.  The failure of Vt to 
recruit paxillin was unexpected.  More recently, Humphries et al. (188) found that while 
vinculin head and paxillin co-localised in protruding lamellipodia, vinculin tail and paxillin 
did not.  Some co-localising was seen in retracting areas between Vt and paxillin.  Again,   26 
while this result was unexpected, it provides evidence contrary to a vinculin-paxillin 
interaction in vivo.  In the study by Humphries et al. (188) much of the Vt in the cells was 
associated with actin, and this may explain why the paxillin-vinculin interaction could not 
be identified as the two binding sites may be mutually exclusive.  Similarly, it may be that 
the cellular situation was not appropriate for detecting this interaction.  But it remains a 
possibility that while paxillin and Vt will interact in vitro, within cells the interaction may 
not be a functional one.  
 
An interesting study by Subauste et al. (4) provides convincing evidence that vinculin can 
modulate the FAK-paxillin interaction to control cell motility and apoptosis. Vinculin null 
cells are resistant to apoptosis induced by serum withdrawal and detachment from the 
cellular substrate (anoikis).  Vt (811-1066) was shown to restore cell death signals to wild-
type levels.  In vinculin null cells, ERK1/2 activity was elevated in response to detachment 
from the substrate and Vt rescued these cells and restored ERK1/2 activity to wild-type 
levels.   ERK antisense oligonucleotides and the MEK inhibitor PD98059 could also restore 
apoptosis.  This data suggests that Vt is modulating the ERK1/2 pathway (4) .  
 
In the same study, the paxillin-FAK interaction was elevated in vinculin null cells and Vt 
rescue cells returned the interaction to a wild-type level.  The FAK-paxillin interaction is 
important for phosphorylation of FAK at Y397 and paxillin at Y118 and Y31 (192;200). 
Vinculin null cells have increased phosphorylation of these residues, and upon detachment 
the levels of phospho-tyrosine pY397 and pY118 rapidly decreased. In contrast, vinculin 
null cells rescued with Vt show wild-type levels of phosphorylation both constitutively and 
during anoikis (4). Overexpression of paxillin mutated at residues phosphorylated upon 
FAK interaction, Y31F/Y118F (192), restored anoikis in vinculin null cells and also 
inhibited ERK1/2 activity during anoikis (4). 
 
Similar effects were seen for cell motility, vinculin null cells were more motile and the 
MEK inhibitor decreased the rate of cell motility.  The paxillin Y31F/Y118F mutant also 
inhibited the enhanced migration in vinculin null cells.  Taken together, the data points to a 
role of Vt in modulating the interaction of FAK and paxillin to regulate ERK1/2 signalling   27 
cascades. The hypothesis goes that FAK and Vt will compete for binding of the LD motifs 
in paxillin (4).   
 
Paxillin will interact with FAK via LD2 and LD4, while vinculin will interact with LD1, 
LD2 and LD4.  The above hypothesis presumes that binding to the LD motifs is mutually 
exclusive.  It is feasible to imagine that the competition between FAK and vinculin for 
paxillin could be due to a number of factors, such as relative affinities for binding sites, 
conformation of proteins involved, phosphorylation states of proteins and relative local 
concentrations of binding partners. 
 
1.5  Structural basis of study 
 
Great effort has been made to investigate the interaction between vinculin and talin 
(149;154;158;163;164;169;201-203) and vinculin and F-actin (41;151;166;167;204), but 
the vinculin-paxillin interaction has seen much less attention.  This thesis builds on 
previous structural data regarding the FAT domain of FAK binding to paxillin (6-9).  
Paxillin LD motifs have been shown to bind to the FAT of FAK and Vt using biophysical 
binding assays (5;79;80;110), and alongside the structural knowledge of the binding event 
between FAK and LD motifs, predictions have been made as to the binding event occurring 
between Vt and LD motifs (6). 
 
1.5.1  FAT of FAK and Vt are structural homologues that both bind to 
LD motifs 
 
The crystal structures of the FAT domain of FAK (205) and Vt (172) are shown in Figure 
1.5.1.  For simplicity, the FAT domain of FAK will be referred to from now on as FAT.  
FAT and Vt have been shown to be structural homologues (205).  The α-helices in FAT are 
straight and antiparallel connected by short turns which makes the structure very compact 
and symmetrical (205).  In contrast the α-helices in Vt are less parallel to one another and 
helix 4 is kinked resulting in a less compact form.  Vt helices 1-4 are basic and helix 5 is 
acidic (172).  The structure of the Vt domain alone has subsequently been shown to be very   28 
similar to the structure of Vt in the full length molecule (152;153). 
 Recently the structure 
of another structural homologue, Git1 has been solved (10) which can also be seen in 
Figure 1.5.1 and shares the antiparallel helix topology. 
 
Git1 can bind to paxillin LD motifs LD2 and LD4 (10;80;82), FAT will bind to LD2 and 
LD4 (5-9) and Vt can bind to LD1, LD2 and LD4 (5;80).  Since all these proteins share 
structural features it is possible that the mode of binding to LD motifs is similar. 
 
This thesis aims to determine how Vt interacts with paxillin LD motifs and then compare 
this to what is known from the FAT binding data.  A comparison will then be made 
between Vt, FAT and the new data from Git1 binding in an attempt to understand the 
features that determine binding and specificity for LD motifs.   29 
 
Figure 1.5.1 Crystal structures of the FAT domain of FAK, Vt and the PBD of Git1 
A: crystal structure of FAT (blue) showing 4-helix up-down antiparallel topology (205), 
crystal structure of Vt (magenta) showing 5-helix up-down antiparallel topology (172) and 
solution structure of GIT1 PBD (molecule 0001-orange-red) showing 4-helix up-down 
antiparallel topology (10).  B: comparison of the helices in the two structures. Green: FAT 
H1, Vt H2, PBD H1; yellow: FAT H2, Vt H3, PBD H2; orange: FAT H3, Vt H4, PBD H3; 
red: FAT H4, Vt H5, PBD H4.  Vt has an extra helix H1 shown in dark blue.   30 
1.5.2  LD motif binding and specificity  
 
While the individual domains of paxillin have been intensively studied, there is no 
structural data on the full length molecule.  The LD motifs have been predicted to be α-
helical (85) and the LIM domains are double zinc finger motifs, but it is possible that 
paxillin is relatively unstructured and becomes more organised upon binding and/or 
modifications such as phosphorylation (206). 
 
The LD motif has been defined as a novel binding module involved in protein-protein 
interactions (5;85), but it remains unclear precisely how they interact with their target 
proteins.  Analysis of GST- LD fusions and their propensity for binding FAT and vinculin 
show that LD2 binds to vinculin and LD2 and LD4 binds to FAT (5) (Table 1.5.1.).  
Further analysis reveals that there is strong binding between vinculin and GST-LD2, low 
binding to GST-LD4 and binding to GST-LD1 (80).  These combined results tell us that 
FAT will bind to paxillin LD2 and LD4 while vinculin will bind to paxillin LD1, LD2 and 
LD4.  As previously stated, GIT1 can bind to paxillin LD2 and LD4 motifs (10;80;82). 
 
Table 1.5.1 Summary of paxillin LD interaction with FAT domains  
Paxillin LD motifs  Vinculin binding
(a)  FAK binding
(a)    (c)  Vt  FAT  Git1 
LD2-LD5  ++++  ++++    LD1  ￿     
LD2-LD3  ++             + (++)
(b)    LD2  ￿  ￿  ￿ 
LD2  ++  +    LD3       
No LD  -  -    LD4  ￿  ￿  ￿ 
LD3-LD5  -  +++    LD5       
LD3  -  -           
 
(a) results from (5). (b)  two separate fusions spanning LD2 and LD3 were tested for FAT, 
the first paxillin 54-265 showed + binding and the second paxillin 133-265 showed ++.  
The reason for this is unclear. (c) summary of LD binding for Vt, FAT and Git1. 
 
The region of FAT that binds to paxillin was initially suggested to consist of two regions, 
called  PBS1 (FAK 919-935) and PBS2 (FAK 1034-1039) (110).  These sites create a 
binding interface on helix 1 and helix 4 of FAT (face 1-4).  PBS1 and PBS2 were also   31 
suggested in Vt by virtue of sequence alignment with the experimentally determined 
regions of FAT.  PBS2 had previously been determined by Wood et al. (86) as Vt residues 
978-1000, and PBS1 was predicted to reside in Vt 952-971 (110). PBS1 and PBS2 create a 
binding interface on Vt face 3-4 (Figure 1.5.2).  
 
 
Figure 1.5.2 Crystal structure of Vt showing paxillin binding subdomains 1 
(PBS1:red) and 2 (PBS2:blue) (86;110) 
PBS2 is experimentally determined by in vitro binding assays, PBS1 is predicted by virtue 
of sequence alignment with FAT 
 
More recently there have been several studies that map the regions of FAT that bind to 
paxillin using NMR and X-ray crystallography (6-9).  Figure 1.5.3 shows a cartoon of the 
FAT domain bound to two LD peptides taken from (6).  Two sites for binding are shown, 
on opposite faces of the FAT domain.  One site is formed on FAT face 1-4 and a second 
site is on FAT face 2-3.  Both peptides were shown to bind simultaneously.   
 
There is some debate as to whether the LD motif is promiscuous.   Hoellerer et. al. (6) 
showed that both LD2 and LD4 would bind equally to either site thus the LD peptides were 
promiscuous binding motifs.  In contrast, Bertolucci et al. (7) suggests that LD2 will bind 
to both faces of FAT, but LD2 favours face 1-4 and has a higher affinity for this site.  LD4 
would only bind to face 2-3, and LD4 has a higher affinity for this site than LD2. A recent   32 
study appears to confirm the latter which suggests that there is specificity between LD 
motifs (207). 
 
 
 
Figure 1.5.3  The FAT of FAK with two LD4 peptides bound 
FAT of FAK is shown, helix1 in blue, helix 2 light blue, helix 3 white and helix 4 red.  LD4 
peptides are shown in magenta, with the first LD of the motif shown in green on both 
peptides and Y925 (Grb site) shown on FAK.  Picture reproduced from (6). 
 
Both FAT and Vt will bind to LD2 and LD4, with Vt also showing binding to LD1.  
Structure based sequence alignment suggested conservation of a number of residues 
between FAT and Vt that were involved in the FAT-LD interaction (6).   These structural 
similarities between FAT and Vt make it possible that Vt would bind to LD motifs in the 
same manner, by forming two separate binding sites on opposite sides of the Vt molecule.  
The alignments made by Hoellerer et al. (6) are shown in Figure 1.5.4. and reveal the 
predicted residues for the Vt-paxillin LD interaction. 
   33 
 
Figure 1.5.4 Sequence alignment of FAT and Vt (human numbering) aligned based on 
their crystal structures as in (6) 
Shown in boxes are the experimentally determined residues affected by LD peptides 
binding to FAT (6) and the corresponding predictions for the sequence of Vt.  Blue boxes 
refer to residues on FAT face 1-4 and green refer to FAT face 2-3. 
 
Mapping these residues onto the crystal structure of Vt reveals the two faces that could be 
affected by LD motifs (Figure 1.5.5).  The binding interface formed by helix 3-4 is 
potentially accessible for binding, yet the face formed by helices 5-2 is occluded by helix1.  
Hoellerer et al. (6) state that Vt face 5-2 resembles the binding interface of FAT whereas 
Vt face 3-4 does not. 
 
 
Figure 1.5.5 Predicted binding residues on Vt based on experimental data using the 
FAT domain of FAK binding to LD2 and LD4 (6) 
Pale green residues make up binding interface Vt 3-4 (FAK 2-3) and pale blue make up 
face Vt 5-2 (FAK 1-4).   34 
 
This thesis aims to verify the interaction between Vt and paxillin LD motifs in vitro.  The 
molecular basis of the interaction between Vt and LD1, LD2 and LD4 will be analysed and 
compared to the experimentally determined PBS1 and PBS2, (which create a one site 
binding interface on Vt face 3-4), and the predicted binding residues from Hoellerer et al. 
(6) (which create two binding interfaces on opposite faces of Vt, face 2-3 and 3-4).   
 
The interaction studies will primarily be carried out using high resolution NMR to study the 
precise molecular nature of this interaction.  After this, it should be possible to carry out a 
detailed comparison between FAT and Vt, and also using the recent GIT1 data (10) to 
analyse the mechanism of binding to paxillin LD motifs. 
 
Being able to dissect these interactions in vitro, and on a molecular scale, is highly useful as 
it facilitates directed studies of in vivo functions, for example specific domains can be 
produced with pre-determined mutations and then the effects within FAs and on cells can 
be analysed explicitly.  Because of the complexity of FA signalling and 
mechanotransduction, in vivo studies can be difficult to interpret fully as they can be 
looking at averages of interaction partners and at defined time-points within the cell.  To 
this end in vitro experiments can be very useful in exploring all possible interactions which 
can then be specifically searched for in an appropriate form of FA or in particular cell 
types.    35 
2  Materials and Methods 
2.1  Recipes 
2.1.1   Protein expression and detection 
 
Luria Broth (1L) pH7.5 
10g Bactotryptone 
5g Yeast Extract 
10g NaCl 
2mL Glycerol 
0.27g MgCl2.7H2O 
 
Minimal M9 Media (1L) pH7.4 
6g Na2HPO4 
3g KH2PO4 
0.5g NaCl 
0.5g MgSO4.7H2O 
15mg CaCl2.2H2O 
 
After autoclaving: 
Add 
15N NH4Cl at 1g/L  
Add 
13C Glucose at 2-4g/L, add unlabelled glucose at 4g/L 
 
Triple Labeled Minimal M9 Media (1L) pH7.4 
Made up in 70% D2O, 30% H2O 
 
6g Na2HPO4 
3g KH2PO4 
0.5g NaCl 
0.5g MgSO4.7H2O 
15mg CaCl2.2H2O   36 
 
After autoclaving: 
Add 
15N NH4Cl at 1g/L  
Add 
13C Glucose at 2-4g/L 
1mL/L of 1mg/mL biotin 
1mL/L of 1mg/mL thiamine 
Make final solution 10% Silantes CND medium 
 
IPTG 
1M stock: 4.76g IPTG made up to 20mL using double distilled water.  Sterile filter using a 
0.22µm syringe filter. Freeze at -20°C in 1mL aliquots. 
 
Ampicillin 
100mg/mL stock: 2g ampicillin in 20mL of double distilled water.  Sterile filter using a 
0.22µm syringe filter. Freeze at -20°C in 1mL aliquots. 
 
LB-agar 
To 100mL LB add 1.5g powdered agar.  Autoclave. 
 
Disruption buffer/reducing sample buffer (10mL) 
2.5mL 1M Tris-HCl pH6.8  
4.0mL 20% SDS  
0.5mL 0.4% Bromophenol blue  
2.0mL Glycerol  
1.0mL ddH2O  
860µl β-mercaptoethanol 
 
SDS-PAGE 
10% gel 
  Stacking gel  Running gel 
Protogel 33% acrylamide soln.  0.66mL  3.33mL   37 
Water  2.90mL  2.03mL 
Glycerol  -  1.30mL 
3M Tris, 0.3% SDS pH 8.45  1.24mL  3.33mL 
TEMED  10µl  10µl 
 
Just prior to pouring, make up ammonium persulphate at 100mg/mL in about 1mL of 
water.  To the running gel add 50µl and to the stacking gel add 25µl.  
 
Running buffers 
Cathode (1L)  
100mM Tris pH8.2  
100mM Tricine 
0.1% SDS 
 
Anode (1L) 
200mM Tris pH8.9 
 
Run SDS-PAGE gels at 120V for 1 hour 
 
Coomassie Blue (1L) 
0.2% Brilliant Blue 
40% methanol 
10% acetic acid 
50% ddH2O 
Dissolve the brilliant blue into methanol first, then add the other ingredients 
2.1.2  Molecular biology  
 
Pfu polymerase and buffer, dNTPs, Dpn1 and buffer B were obtained from Promega 
Primers for PCR were designed by R.Hagan and obtained from MWG Biotech.  Sequences 
can be found in Appendix 5.3.   
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1% Agarose gel 
40mL TBE + 0.4g agarose.  Microwave for 1 minute.  Add 3µl Ethidium Bromide 
(10mg/mL).  Run at 120V for 30 minutes. 
 
For samples, add 14µl DNA loading buffer, 6µl sample. 
 
1x TBE (1L) 
10.8g Tris pH8.3 
5.5g Boric acid 
0.93g EDTA 
 
10x DNA loading buffer 
50% Glycerol 
0.4% Bromophenol Blue      
0.4% Xylene Cyanol          
 
SOC media (100mL) 
2% Bactotryptone (2g) 
0.5% Yeast extract (0.5g) 
10mM NaCl (0.6g) 
2.5mM KCl (0.02g) 
10mM MgCl2 (0.2g) 
10mM MgSO4 (0.25g) 
20mM Glucose (0.36g) 
2.1.2.1  Fusion protein constructs 
 
Wild-type vinculin (residues 879-1066) in pET-15b was a kind gift from Professor D. 
Critchley (University of Leicester).  The plasmid contains the wild-type gene with an N-
terminal histidine affinity tag and a thrombin cleavage site.  After thrombin cleavage, the 
protein contains an extra GSHM at the amino terminus. Mutants have been produced from 
this wild-type template.  Protein sequences can be found in Appendix 5.2.   39 
 
Constructs of pGEX-4T-1-LD1/LD2 and pET-15B-LD1/LD2 were obtained from Prof D. 
Critchley (University of Leicester) and were transformed into E.coli BL21 (DE3) cells. 
Sequence of paxillin His-LD1/LD2 containing the histidine tag and extra N-terminal 
residues can be found in Appendix 5.4. 
 
2.2  Expression and purification methods 
2.2.1  Standard expression of wild-type and mutant vinculin tail 
 
The plasmid was expressed in E.coli BL21 (DE3) cells.  Wild-type Vt was streaked onto an 
agar plate containing ampicillin at 100µg/mL and incubated overnight at 37°C.  Overnight 
cultures were prepared by taking 15mL LB with added ampicillin at 100µg/mL and 
inoculating this with one colony from the agar plate.  This was grown overnight at 37°C, 
160rpm. 
 
2.2.1.1 Standard culture growth 
 
1.2L of LB media was prepared and 400mL aliquotted into three 2L baffled flasks.  The 
flasks were covered with aluminium foil and autoclaved.  Prior to use, ampicillin at 
100µg/mL was added.  5mL of overnight culture was used to inoculate each 2L flask, and 
the resulting cultures were grown at 37°C, 160rpm.  When the OD600  reached ~0.8, flasks 
were treated with  IPTG (final concentration 1mM) and the cells grown for a further 3-4 
hours at 30°C, 160rpm.  The cells were pelleted using a Beckman J2-21 centrifuge with a 
JLA 10.500 rotor at 7000rpm (6037g) for 25 minutes, resuspended in 10mL of 20mM Tris-
HCl pH 7.0, 150mM NaCl and frozen at –20°C prior to use. 
 
2.2.1.2 
15N Minimal media growth 
 
1.2L of M9 minimal media was prepared and 400mL aliquotted into 3 x 2L baffled flasks.  
The flasks were covered with aluminium foil and autoclaved.  Prior to use, 
15N ammonium   40 
chloride was added at 1g/L and glucose was added at 4g/L.  1.2g of 
15N ammonium 
chloride was dissolved in 15mL ddH2O, 0.22µm-filtered and 5mL dispensed into each 
flask.  4.8g of 
12C glucose was dissolved in 90mL ddH2O, 0.22µm-filtered and 30mL 
dispensed into each flask. Ampicillin was added to each flask at 100µg/mL.  30mL of LB 
overnight culture was pelleted at 900g for 15mins and the cells resuspended in 30mL M9 
minimal media.  10mL of the cell suspension was used to inoculate each flask, and the 
cultures grown at 37°C, 160rpm until OD600 ~0.6-0.8.  At this point, flasks were treated 
with IPTG (final concentration 1mM) and the cells grown for a further 16-18 hours at 
30°C.  The cells were pelleted at 6037g for 25 minutes, resuspended in 10mL of 20mM 
Tris-HCl pH 7.0, 150mM NaCl and frozen at –20°C prior to use. 
 
2.2.2 
15N, 
13C, 
2H Triple labelled expression of Vt/I997S 
2.2.2.1 Partial deuteration 
 
In order to adapt the BL21 (DE3) cells to 
2H2O, overnight cultures were prepared in the 
following way.  10mL of LB with ampicillin at 100µg/mL were inoculated using a colony 
from a Vt/I997S agar plate and the culture grown at 37°C, 160rpm, until OD600 ~0.8. Five  
sterilins containing 10mL LB made with 50% 
2H2O (with ampicillin at 100µg/mL) were 
inoculated using 1mL of the culture and incubated overnight at 37°C, 160rpm. 
 
2L of M9 minimal media were prepared using 70% 
2H2O, 30% 
1H2O split equally between 
five 2L baffled flasks, covered with aluminium foil and autoclaved.  Prior to use, 
15N 
ammonium chloride and 
13C glucose were added at 1g/L and 4g/L respectively. (2g of 
15N 
ammonium chloride was dissolved in 5mL ddH2O, 0.22µm-filtered and 1mL added to each 
flask; 8g of 
13C glucose was dissolved in 50mL ddH2O, 0.22µm-filtered and 10mL was 
added to each flask).  Ampicillin was added at 100µg/mL.  In addition to this, the following 
supplements were added to enhance growth and expression: 1mL of 1mg/mL biotin per 
litre medium; 1mL of 1mg/mL thiamine per litre medium; 100mL of Silantes CND medium 
per litre medium. 
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One 10mL overnight culture was used to inoculate each flask containing 400mL media 
using the following procedure.  The overnight cultures were pelleted at 2500rpm in a 
bench-top centrifuge for 15 minutes and each pellet was resuspended using 10mL of the 
minimal M9 media taken from a flask. The resuspended cells were then used to inoculate 
the media which were subsequently incubated at 37°C, 160rpm until the OD600 ~0.6-0.8.  
At this point, IPTG was added to each flask (final concentration 1mM) and the grown at 
30°C, 160rpm for 16-18 hours.  The cells were then pelleted at 6037g for 25 minutes.  They 
were resuspended in 10mL of 20mM Tris-HCl pH 7.0, 150mM NaCl and frozen at –20°C 
prior to use. 
 
2.2.2.2 Perdeuterated, 
15N 
13C Vt/I997S 
 
When attempting to fully deuterate Vt/I997S it was important to minimise the presence of 
any 
1H in the sample.  All of the chemicals used in this preparation are dissolved in 
deuterium oxide and freeze dried to exchange any 
1H with 
2H.  To ensure sufficient protein 
is obtained, 2L of M9 minimal media is required.  The following chemicals were weighed 
and dissolved in deuterium oxide. 
 
Chemical  Mass/g  Volume of Deuterium 
Oxide added/mL 
To make Solutions 
 
Na2HPO4  12  60  2L M9 
KH2PO4  6  20  2L M9 
NaCl  1  10  2L M9 
MgSO4.7H2O  1  10  2L M9 
CaCl2.2H2O  0.03  10  2L M9 
15NH4Cl  2  10  2L M9 
Ampicillin  0.5  5  100mg/mL 
IPTG  1.2  5  1M 
Biotin/Thiamine  0.005 of each  5  1mg/mL 
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The D2O solutions were sterile filtered using a 0.2µm syringe filter and then freeze dried 
for two days to remove any residual 
1H. 
 
The following media were prepared to enable the BL21 (DE3) cells to adapt to growing in 
2H2O. 
Media Type  % 
1H2O  % 
2H2O  Volume made/mL 
Luria broth  100  0  50 
Luria broth  50  50  50 
M9  50  50  100 
M9  0  100  100 
 
These were autoclaved with an additional 5 empty 2L baffled flasks.  These flasks are for 
making up the final deuterated M9 media.  It is important not to autoclave the final media 
once it is prepared as H2O/D2O exchange will occur which will reduce the percentage of 
2H 
in the solution. 
 
The BL21 (DE3) cells were adapted in the following way.  50ml 100% 
1H2O LB 
(ampicillin 100µg/ml) were inoculated with cells containing the Vt/I997S plasmid. The 
culture was grown overnight at 37°C, 160rpm.  The following morning, two 1mL aliquots 
were used to inoculate two sterelins containing 10mL 50% 
2H2O LB.  These were grown at 
30°C, 160rpm for 8 hours after which 1mL was used to inoculate a further 10mL 50% 
2H2O.  These were grown at 37°C, 160rpm overnight.  After about 20 hours of growth, the 
cells were pelleted and the LB media discarded.  Cell pellets were resuspended in 10mL of 
M9 media containing 50% 
2H2O which was subsequently added to the remaining 90mL of 
the same media.  This was grown for 24 hours to a high cell density (OD600>1), before 
10mL was used to finally inoculate 100mL of M9 made with 100% 
2H2O.   
 
Under sterile conditions, 2L of M9 minimal media was made using the freeze dried salts 
and using 
2H2O in the place of water.  The measured pH of the media was 6.9 and was not 
adjusted to minimise addition of  
1H to the media.  As pD is pH + 0.41 (208), then the   43 
media is at equivalent pH7.3.  This media was split between the five 2L baffled flasks, 
400mL in each. 
 
Prior to induction, the freeze-dried ampicillin was made up to 100mg/mL using 
2H2O and 
was added to the flasks at 100µg/mL.  2g freeze-dried 
15NH4Cl was dissolved in 10mL 
2H2O, and 2mL added to each flask.  Deuterated, 
13C-glucose (Cambridge Isotope Labs) 
was then added at 2g/L. Finally, the biotin/thiamine mix was dissolved in 
2H2O to 1mg/mL 
and 1mL was added per litre media.  To stabilise the bacterial growth, Silantes CND media 
was added to a final concentration of 10% vol/vol. 
 
10mL of the 100% 
2H2O overnight culture was added to each flask.  Cultures were grown 
at 37°C, 160rpm until OD600 0.6-0.8.  At this point, the freeze-dried IPTG was redissolved 
in 
2H2O to a final concentration of 1M.  This was added to the flasks to a final 
concentration of 1mM to induce the culture. 
 
Cultures were incubated at 30°C, 160rpm for 16 hours.  After this time the cells were 
pelleted using a Beckman J2-21 centrifuge with a JLA 10.500 rotor at 9000rpm. These cell 
pellets were softer than observed for a 
1H2O growth.  The cell pellet was then stored in 
20mM Tris pH7, 150mM NaCl at -20°C. 
 
2.2.3  Selective 
14N-unlabelling of arginine residues in Vt/I997S 
 
1L of M9 minimal media was aliquotted equally into two 2L baffled flasks and autoclaved.  
Prior to use, 
15N ammonium chloride was added at 1g/L and unlabeled glucose at 4g/L.  1g 
of 
15N ammonium chloride was dissolved in 10mL ddH2O, 0.2µm-filtered and 5mL added 
to each flask.  4g of 
12C glucose was dissolved in 100mL ddH2O, 0.2µm-filtered and 50mL 
added to each flask. Ampicillin was added at 100µg/mL to each flask.  20mL of LB 
overnight culture was pelleted at 900g for 15mins and resuspended in 20mL M9 media.  
10mL of the cell suspension was used to inoculate each flask, and the cultures grown at 
37°C, 160rpm to OD600 ~0.4.  At this point an excess amount of unlabeled arginine was 
added to 0.1g/L.  Growth was continued at 37°C, 160rpm until OD600 0.6-0.8.  IPTG was   44 
added to each flask to a final concentration of 1mM and the flasks incubated at 30°C, 
160rpm for 16-18 hours.  The cells were then pelleted at 6037g for 25 minutes.  They were 
resuspended in 10mL of 20mM Tris-HCl pH 7.0, 150mM NaCl, and frozen at –20°C prior 
to use. 
 
2.2.4  Selective 
15N-labelling of amino acids in Vt/I997S 
 
2L of M9 minimal media were aliquotted equally into two 2L baffled flasks and 
autoclaved.  To each flask, 4g/L 
12C-glucose, 1µg/mL biotin and thiamine, and ampicillin at 
100µg/mL were added.  Each flask was labelled with leucine, lysine, valine or isoleucine.  
Prior to inoculation, 0.1g/L of each unlabelled amino acid was added, except for the amino 
acid that the flask is labelled with.  Each flask was inoculated with a 10mL LB overnight 
culture cell pelleted resuspended in M9 minimal media.  Cultures were grow at 37°C, 
160rpm to OD600 ~0.4.  At this point, 0.1g/L of 
15N labelled amino acid, 
15N-leucine, 
15N-
lysine, 
15N valine or 
15N-isoleucine was added to the appropriately labelled flask.  Growth 
was continued at 37°C, 160rpm to OD600 0.6-0.8.  IPTG was added to a final concentration 
of 1mM and the flasks incubated for 16 hours at 30°C, 160rpm.  The cells were pelleted at 
6037g for 25 minutes and stored in 20mM Tris pH7, 150mM NaCl at -20°C. 
 
2.2.5  Expression of GST-LD1/LD2 and His-LD1/LD2 
2.2.5.1 Standard growth 
 
Glycerol stocks of pGEX-GST-LD1/LD2 and pET-15b-His-LD1/LD2 were streaked onto 
agar plates containing ampicillin at 100µg/mL and grown at 37°C overnight.  Colonies 
were used to inoculate two 10mL LB media containing ampicillin at 100µg/mL which were 
grown at 37°C, 160rpm for 16 hours.  1.2L of LB media was prepared and 400mL 
aliquotted into three 2L baffled flasks, covered with aluminum foil and autoclaved.  
Ampicillin was added to each flask to a final concentration of 100µg/mL.  Each flask was 
inoculated with 5mL culture and grown at 35°C, 160rpm until OD600=0.5.  At this point, the 
temperature was dropped to 16°C and the cells cooled for 30min.  IPTG was then added to   45 
a final concentration of 1mM and the cells grown for 21 hours at 16°C, 160rpm.  The cells 
were pelleted at 6037g for 25 minutes, resuspended in 10mL of 20mM Tris-HCl pH 7.0, 
150mM NaCl and frozen at –20°C prior to use. 
 
2.2.5.2 
15N Minimal media growth for His-LD1/LD2 
 
1.2L of M9 minimal media was prepared and aliquotted equally into three 2L baffled 
flasks.  The flasks were covered with aluminium foil and autoclaved.  Prior to use, 
15N 
ammonium chloride and 
12C glucose was added at 1g/L and 4g/L respectively.  (1.2g of 
15N 
ammonium chloride was dissolved in 15mL ddH2O, 0.2µm-filtered and 5mL added to each 
flask.  4.8g of 
12C glucose was dissolved in 90mL ddH2O, 0.2µm-filtered and 30mL added 
to each flask). Ampicillin was added to each flask at 100µg/mL.  30mL of LB overnight 
culture was pelleted at 900g for 15mins and resuspended in 30mL M9 media.  Each flask 
was inoculated with 10mL of  cell suspension and were grown at 35°C, 160rpm until 
OD600=0.5.  At this point, the temperature was dropped to 16°C and the cells cooled for 30 
minutes.  IPTG was then added to a final concentration of 1mM and growth continued for 
21 hours at 16°C, 160rpm.  The culture was pelleted at 6037g 25 minutes, resuspended in 
10mL of 20mM Tris-HCl pH 7.0, 150mM NaCl and frozen at –20°C prior to use. 
 
2.2.6  Expression of other proteins: Calexcitin 
 
Glycerol stocks were streaked onto an agar plate containing ampicillin at 100µg/mL and 
grown at 37°C overnight.  Colonies were used to inoculate two 10mL LB media containing 
ampicillin at 100µg/mL which were grown at 37°C, 160rpm for 16 hours. 1.2L of LB 
media was prepared and 400mL aliquotted into three 2L baffled flasks, covered with 
aluminum foil and autoclaved.  Ampicillin was added to a final concentration of 100µg/mL.  
Each flask was inoculated with 5mL culture and grown at 35°C, 160rpm to OD600=0.5.  At 
this point, the temperature was dropped to 16°C and the cells cooled for 30 minutes.  IPTG 
was then added to a final concentration of 1mM and the cultures grown for 21 hours at 
16°C, 160rpm.  The cultures were pelleted at 6037g for 25 minutes, resuspended in 10mL 
of 20mM Tris-HCl pH 7.0, 150mM NaCl and frozen at –20°C prior to use    46 
This method of expression was used so that calexcitin could be expressed simultaneously 
with GST-LD1/2.  Calexcitin expression can also be carried out at 30°C for ~6 hours after 
induction with IPTG. 
 
2.2.7  Purification of wild-type and mutant vinculin tail 
 
Buffer A: 20mM Tris pH7.0, 150mM NaCl 
Buffer B: 20mM Tris pH7.0, 150mM NaCl, 250mM Imidazole 
Buffer C: 20mM Tris pH7.0, 25mM NaCl 
Buffer D: 20mM Tris pH7.0, 1M NaCl 
 
Wild-type E.coli cell pellets from 1.2L growths were thawed and resuspended in 50mL of 
buffer A.  The suspension was sonicated using an XL-2020 sonicator at power 9 for a total 
of twenty 30 second bursts, with cooling in an ice bath between bursts for 50 seconds.  The 
sonicated cells were centrifuged at 16000rpm in a Beckman J2-21 centrifuge (Rotor JA-20) 
for 25 minutes.  The supernatant was collected. 
 
2.2.7.1 Nickel-NTA affinity chromatography 
 
25mL of Ni-NTA beads (Qiagen) were packed into an Amersham XK26 column and 
equilibrated using 4CV of buffer A.  The sonicated supernatant was loaded into a 50mL 
superloop, pumped onto the column at 1mL/min and washed to UV280nm baseline.  The 
column was eluted using the following percentages of buffer B: 0%B 2CV, 18%B 4CV, 
100%B 4CV.  An SDS-PAGE gel was run to visualise the elution profile and the 
appropriate peak was pooled.  The approximate protein concentration was measured by an 
A280 reading against a buffer B blank.   
2.2.7.2 Thrombin cleavage 
 
5mM CaCl2 was added to the pooled protein and a 200µl sample was taken as a non-
enzyme control.  This control was incubated at 37°C, 65rpm, alongside the cleavage   47 
reaction to monitor spontaneous cleavage and degradation.  A 50µl sample was taken as 
time-point zero, 50µl of disruption buffer was added and was boiled for 5 minutes, ready 
for SDS-PAGE.  Thrombin was added to the main pool at 1U/1-2mg protein and was 
incubated overnight at 37°C, 65rpm.  After 21 hours, the cleavage was checked on an SDS-
PAGE gel and should be >99% complete. 
 
2.2.7.3 Cation exchange  
 
This step removes thrombin and any remaining impurities. A 50mL SP Sepharose (HiLoad 
26/10 HP) was equilibrated using buffer D followed by buffer C.  The cleavage pool was 
diluted ½ using buffer C to reduce the NaCl concentration.  The sample was loaded into 
50mL superloop, loaded at 1mL/min and washed to UV baseline.  The protein is eluted 
using 0-100%D over 4.5CV.  The elution was held at 100%D for 1.5CV and then washed 
back to 0%.  The peak fractions were run on an SDS-PAGE gel and the appropriate 
fractions were pooled.  The protein was concentrated to ~1mg/mL in the same buffer as it 
elutes from the column, and snap frozen and stored at –80°C. 
 
Dialysis into lower salt concentrations was performed thus: Vt was concentrated to 
1mg/mL in the elution buffer (high salt~400mM).  Next dialysis was performed overnight 
into the desired buffer for 16 hours with one change.  Typically, Vt was dialysed into 
20mM Tris pH7, 150mM NaCl, 50mM arginine, 50mM glutamate.  After dialysis the 
protein was concentrated to the desired concentration.  However, if a high concentration of 
Vt is required without the addition of 50mM arginine, 50mM glutamate, the protein was 
concentrated in the presence of the elution buffer containing high NaCl concentrations 
before dialysis.  This reduced the chance of Vt precipitating. 
 
2.2.8  Purification of paxillin His-LD1/LD2 
 
Buffer A: 20mM Tris pH7.0, 150mM NaCl, 6M Urea 
Buffer B: 20mM Tris pH7.0, 150mM NaCl, 250mM Imidazole 
Buffer C: 20mM Tris pH7.0, 25mM NaCl, 2mM DTT   48 
Buffer D: 20mM Tris pH7.0, 1M NaCl 
 
1.2L of E.coli cell pellets containing expressed paxillin His-LD1/LD2 were thawed and 
resuspended in 50mL of buffer A.  The suspension was sonicated using an XL-2020 
sonicator at power 8 for a total of twelve 30 second bursts, with cooling between bursts in 
an ice bath for 50 seconds.  The sonicated cells were centrifuged at 16000rpm in a 
Beckman J2-21 centrifuge (Rotor JA-20) for 25 minutes.  The supernatant was collected. 
 
2.2.8.1 Nickel-NTA affinity chromatography 
 
10mL of Ni-NTA beads (Qiagen) were packed into an Amersham XK16 column and 
equilibrated using 4CV of buffer A.  The sonicated supernatant was loaded into a 50mL 
superloop, loaded onto the column at 0.5mL/min and washed to UV280nm baseline.  The 
column was eluted using the following percentages of buffer B: 0%B 2CV, 10%B 4CV, 
100%B 4CV.  An SDS-PAGE gel was run to visualise the elution profile and the 
appropriate peak was pooled.  
 
2.2.8.2 Anion exchange  
 
This allows the construct to flow through the column and impurities bind to the column.  A 
25mL Q-Sepharose column was equilibrated using buffer D followed by buffer C.  The 
cleavage pool was diluted ½ using buffer C to reduce the NaCl concentration.  The sample 
was loaded into 50mL superloop, loaded at 1mL/min and washed to UV280nm baseline.  
The impurities were eluted using a 100%D step until the UV returns to baseline.  The 
unbound flow-through fraction was retained and pooled. 
 
2.2.8.3 Desalting and freeze-drying  
 
The protein cannot be concentrated to a lower sample volume using spin concentrators as 
the protein passes through the membrane. The flow-through fraction was desalted using a   49 
25 mL sephadex G25 superfine column.  The column was equilibrated into double distilled 
water and 5mL aliquots of the pooled protein was added each run.  A water isocratic 
gradient was carried out and the construct eluted first and the salts second.  The protein 
peak was pooled each time and an A280 reading is taken.  The protein pool was separated 
into 10mL aliquots and frozen in dry ice for 1 hour prior to freeze drying. 
 
2.3  Protein characterisation theory and methods  
2.3.1  Mass spectrometry 
 
Electrospray ionization mass spectrometry (ESI MS) was carried out to determine the 
molecular weight of proteins in this study.  In this method, proteins are buffer exchanged 
into a highly volatile solvent and then passed through a highly charged needle which 
disperses the protein solution into a fine mist.  The solvent evaporates resulting in highly 
charged protein ions.  Protons are added when the protein travels through the needle to give 
additional charge.  The mass-to-charge ratio (m/z) is then analysed in a vacuum chamber. 
 
The m/z spectrum shows a range of species with different charges and mass differences, 
each successive peak differs by a charge of 1 and a mass of 1 (from the proton).  The mass 
can then be determined from any two neighboring peaks, but in practice the peaks are 
averaged to produce a more accurate result. 
  
Mass spectrometry in this project was carried out by Neville Wright at the University of 
Southampton. 
 
2.3.2  Analytical size exclusion chromatography 
 
All analytical SEC was carried out using a Superdex-75 column (24ml volume).  Column 
was calibrated and run using 50mM Na2HPO4, 150M NaCl.  Samples were injected onto 
the column using a 200µl sample loop.  100µl of 1mg/ml protein samples were used. 
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2.3.3  Far UV circular dichroism 
 
Circular dichroism (CD) can be used to study the secondary structure of proteins and 
measures the optical activity of proteins in solution.  The CD phenomenon occurs by 
passing left and right circularly polarised light through an optically active molecule.  These 
two beams can be absorbed differentially so that after they have passed through the same 
sample, their sum is no longer plane polarised but elliptically polarised (209).   
 
Figure 2.3.1 shows characteristic spectra of different conformations of poly-L-lysine (210).  
α-helices are characterised by minima at 208nm and 222nm, β-sheets have positive peaks 
around 195nm and a negative peak at 216nm, and random coil produce minima below 
200nm and a positive peak at around 218nm (211). 
 
 
Figure 2.3.1 Far UV circular dichroism spectra of the α-helical (red), β-sheet (blue) 
and random coil (green) forms of poly-L-lysine (210) 
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Many proteins are a mixture of different types of structural motifs and a given CD spectrum 
contains information on the proportions of each.  The problem is how to calculate these 
proportions.  In this thesis, CD spectra have been analysed empirically, noting where 
minima and maxima occur, and some of the data has been submitted to an online server 
running SOMCD (212), which will calculate the predicted contribution of α-helical, β-
sheet, β-turn and random coil structure.  
 
Thermal denaturation can be followed using far UV circular dichroism.  By measuring the 
ellipticity at a set wavelength, a denaturation or ‘melting’ curve can be measured.  The 
midpoint of the transition will give the melting temperature, Tm.  The effect on the melting 
temperature can be monitored by adding ligands to the desired protein and seeing if the 
stability is affected.   
 
2.3.4  Far UV CD wavelength scans and thermal melting 
 
Far UV circular dichroism experiments were carried out on a JASCO-J-720 spectrometer.  
Wavelength scans were recorded in the far UV range, 190-250nm with the following 
parameters set: pathlength 1cm, band width 1nm, sensitivity 200mdeg, resolution 0.2nm, 
response 1s, speed 100nm/min.  Scans were repeated 9 times. Thermal denaturation time 
scans were recorded once for 65 minutes with the following parameters: pathlength 1cm, 
band width 2nm, sensitivity 50mdeg, resolution 10s, response 0.125s. 
 
Wavelength scans to determine secondary structure were carried out on wild-type Vt and 
mutants.  All proteins were at 500µM in a starting buffer containing 20mM Tris pH7, 
150mM NaCl, 50mM arginine, 50mM glutamate.  They were diluted into double distilled 
water (at pH7) to 0.5µM which gave a satisfactory CD signal.  His-LD1/LD2 was diluted 
into water from a 224µM stock that was in the same starting buffer to a final concentration 
of 0.5µM.  LD peptides were measured at 50µM in water (diluted from the same buffer) 
which was the highest concentration achievable without compromising the HT value.  All 
final samples were between pH7-7.1. 
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Thermal melting experiments were carried out using the same protein concentrations as 
above.  Samples were made in a 2mL volume.  The spectrometer was thermally insulated 
and a heated waterbath was used to control the temperature.  The temperature cannot be 
recorded directly using this setup, so it was necessary to record the temperature 
independently of the CD measurements.  The first stage was to calibrate the temperature 
difference between the temperature reading on the water bath and the reading in the 
cuvette.  This was done by placing a digital thermometer in the 2mL cuvette containing the 
buffer and starting a temperature drive from 25ºC to 85ºC.  Every 2 minutes the 
temperature was recorded for the waterbath and the cuvette and these data were used to 
make a calibration curve.  A graph of cuvette thermometer reading (y) vs. the heatbath 
reading (x) showed that the data was linear which meant that for a recorded heatbath 
temperature the actual cuvette temperature could be calculated.  The lag phase between the 
two readings was negligible due to efficient thermal insulation. This graph produced the 
equation y = 0.9776x – 2.9606 which was used to calculate the temperature in the cuvette 
from a given heatbath reading (value A).  A second factor to account for was that when the 
digital thermometer was placed in the waterbath it did not read the same temperature as the 
heatbath.  Consequently the heatbath was shown to be the correct reading.  The relationship 
between the digital reading (x) and the real heatbath temperature (y) was also linear and 
gave rise to an equation y = 1.0114x – 2.1146 which is used to convert value A into the real 
temperature value (value B).  This means that experimental data collected was subjected to 
these two equations to create the temperature vs. CD data. 
 
After this calibration, protein melting experiments could be carried out.  A complete 
experiment is carried out thus:  the desired sample was placed into the spectrometer with a 
sealed cap over the cuvette.  A wavelength scan was recorded at 25ºC to monitor the 
conformation.  A stop clock was set to 65 minutes and the countdown was started and the 
time scan was begun (measuring at 220nm).  The sample was left to equilibrate at 25ºC for 
10 minutes before a temperature gradient from 25-85ºC was started.  Every two minutes 
since the start of the countdown the temperature was recorded from the waterbath.  Once at 
85ºC the sample was left until the time runs out (usually 5-10mins).  A wavelength scan 
was measured at 85ºC.  The waterbath was cooled back to 25ºC using ice and after 15   53 
minutes a wavelength scan was repeated at 25ºC. Experiments were carried out each time 
with new Vt samples made from the same stock.  For each set, both the free ligand and the 
complex Vt plus ligand was measured. 
 
Wavelength scans were analysed by subtracting the free ligand spectra from the spectra 
recorded of the complex.  Thermal denaturing data was imported into Excel (Microsoft) 
using the program Standard Analysis (JASCO).  It was subjected to calibration equations in 
Excel and the data was exported into the program Origin7 (OriginLab) where the data was 
smoothed using 10 point adjacent averaging and the differential was calculated.  This was 
fitted using the non-linear curve fitting algorithms in Origin7 to find the Tm (Figure 2.3.2). 
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Figure 2.3.2 Finding the midpoint of the melting curve for wild-type Vt 
a: the melting curve for Vt.  b: The derivative of this melting curve.  c: Non-linear curve fit 
to the derivative to find the Tm. 
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2.4  Site directed mutagenesis of Vt 
 
The method of mutagenesis used was the Stratagene Quikchange method.  It is a non-PCR 
based method as the primers only amplify the parental strand and not the mutated strand.  
The primers are designed to anneal to the parent plasmid and are complementary to 
opposite strands of the template.  The primers for SDM can be found in Chapter 3.2.3 
(Figure 3.2.2).  
 
To create Vt/I997S, Vt/M1022S and Vt/∆C mutant, the following procedure was followed.  
Three 10mL overnight cultures in LB with ampicillin (100µg/mL) were prepared and 
inoculated using wild-type Vt.  The entire 10mL was used to produce a DNA miniprep 
using the Promega Wizard plus SV miniprep kit.  The final miniprep concentration was 
calculated by diluting the DNA 1/100 in double distilled water and taking an A260nm 
reading.  This value was used to calculate the concentration in the following manner:   
 
A260nm x 100 x 50 = DNA concentration (ng/µl) 
 
Site directed mutagenesis on the wild-type template was carried out in order to create the 
desired mutation.  The following amplification reaction mixture was set up (all volumes are 
in µl): 
  I997S  M1022S  ∆C 
10x Pfu buffer  5  5  5 
100ng template  determined  by miniprep  concentration 
125ng forward primer  0.934  0.968  0.892 
125ng reverse primer  0.914  0.968  0.915 
dNTP mix  1  1  1 
Sterile water  up to 50  up to 50  up to 50 
 
The reaction mixes were put into a PCR block at 94°C for 1min to ensure that the DNA 
was completely denatured, then 1µl Pfu polymerase was added to the mixtures.  The 
following amplification cycle was carried out:   56 
 
Step  Temperature  Time  Cycles 
Denaturation  94°C  1min   
Annealing  55°C  1min  18 cycles 
Extension  68°C  13min    
Final extension  68°C  10min  1 cycle 
Hold  4°C  ∞   
 
At this time overnight cultures of BL21 (DE3) cells in LB without ampicillin were prepared 
and left to incubate at 30°C, 160rpm for 18 hours. 
 
After the amplification was complete, a 1% agarose gel was run to ensure amplified DNA 
bands were present.  Next, 1µl Dpn1 and 5µl of the Dpn1 buffer B was added to each 
reaction mix and incubated for 1hour at 37°C to digest the methylated parental DNA. 
 
Next, the overnight culture of BL21 (DE3) cells were made competent.  The following 
provides cells for two transformations:  500µl of overnight culture was used to innoculate 
10mL of LB with no antibiotic added and growth was carried out at 37°C, 160rpm to OD600 
~0.6.  The cells were pelleted in a benchtop centrifuge at 3000rpm for 15 minutes and the 
supernatant discarded.  The pellet was resuspended in 5mL ice-cold 50mM CaCl2 and 
chilled for 20 minutes on ice.  The centrifugation was repeated and the pellet resuspended 
in 500µl ice-cold CaCl2.  The resuspended pellet was then aliquotted in 250µl volumes into 
sterile ependorfs and stored on ice until needed. 
 
The competent cells were transformed with the amplified DNA.  25µl of the amplification 
reaction mixture was added to 250µl competent cells, chilled on ice for 20mins and heat 
shocked at 42°C for 90 seconds.  200µl of SOC media containing no antibiotic was added 
to the transformation mixture and incubated at 37°C, 160rpm for 1 hour.  This mixture was 
spread on an LB-agar plate containing 100µg/mL ampicillin and grown overnight at 37°C, 
160rpm. 
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Transformants were picked from the plate and used to inoculate 10mL LB aliquots 
containing 100µg/mL ampicillin which were grown overnight at 37°C, 160rpm.  1mL of 
culture was taken and used to inoculate 10mL LB with 100µg/mL ampicillin and grown to 
OD600 ~0.6.  At this point the cells were pelleted, resuspended in 800µl LB and 200µl 
sterile glycerol was added.  This was placed into a cryovial and stored at –80°C as a 
glycerol stock.  The remaining 9mL of overnight culture was pelleted and a mini-prep was 
prepared using the Promega Wizard plus SV miniprep kit.  This mini-prep was then ethanol 
precipitated ready for sequencing reactions.  2.5 volumes of ice-cold ethanol was added to 
the mini-prep DNA.  Next, 1/10 of the original DNA volume of sodium acetate pH5.2 was 
added.  The samples were frozen at –80°C for 20 minutes.  Next, they were spun in a 
benchtop centrifuge at maximum speed for 10min and the supernatant was discarded.  1mL 
of ice-cold 70% ethanol was added to the pellet and the centrifugation was repeated.  The 
supernatant was removed again and the pellets left to air-dry overnight. 
 
To make the mutant Vt/I997S/M1022S the template was changed and Vt/I997S was used 
with the M1022S primers. 
 
2.5  Nuclear magnetic resonance (NMR) 
 
Solution-state NMR is a powerful tool that can be used in the determination of molecular 
structure, intra-molecular dynamics, protein folding and ligand-protein interactions.  NMR 
enables the observation of individual nuclei in a protein thus reports with atomic resolution.  
It is a rapidly advancing field with the first application of NMR to a biological sample 
being reported in 1954 (213).   
 
One useful feature of NMR is that it is possible to utilise the phenomenon without requiring 
a full quantum-mechanical understanding or description of the processes involved.  There 
are a number of excellent textbooks that describe in further detail the experiments described 
here, including pulse sequences and quantum mechanics (214-218).  In this thesis I have 
attempted to introduce the techniques that I have used and discussed some of the theory 
behind the important aspects of my work.    58 
 
NMR occurs due to the property of spin.  
1H (protons) are spin ½ nuclei and are thus 
magnetically active.  Naturally abundant 
12C is not magnetically active and 
14N has 
unsuitable properties in solution, so it is necessary to incorporate isotopes such as 
15N or 
13C which are spin ½ and magnetically active.  This enables the NMR spectra of biological 
molecules to be obtained.   
 
A spin ½ nuclei can orient itself in two ways when placed in an external magnetic field, 
either parallel to the field (α-state) or antiparallel (β-state).  This creates two energy levels 
with a small excess of spins being in the parallel, low energy orientation.  The small excess 
parallel to the magnetic field causes net magnetisation in this direction (this is z-
magnetisation).  Application of a radiofrequency pulse perpendicular to the external field 
causes transitions between energy levels and an NMR spectrum can be recorded.  As there 
is only a small excess of molecules in the low energy state, NMR is a relatively insensitive 
technique.  To counteract this, large sample concentrations are used to increase this 
apparent excess of ground state molecules so that transitions can be measured. 
  
When a macromolecular sample is placed in an external magnetic field, the nuclei will 
align with the magnetic field and z-magnetisation is created. NMR experiments are based 
on manipulating this z-magnetisation using radiofrequency pulses to reorient nuclear spins 
and then detect the return to equilibrium (z-magnetisation).  The position of a nuclei in an 
NMR spectrum is dependant on the effective magnetic field at the nucleus.  This is known 
as the chemical shift and is determined by shielding effects of electrons and influences by 
surrounding atoms. 
 
2.5.1  Multidimensional NMR 
 
One dimensional (1D) NMR spectra are plots of intensity vs. frequency.  A 1D-NMR 
experiment consists of a preparation stage and a detection stage (Figure 2.5.1).  During the 
preparation stage, magnetisation is transferred to the desired nuclei in a predetermined 
manner (for example a 90º pulse that rotates the magnetisation from the z-axis and places it   59 
along the x-axis).   During the detection stage the signal is recorded.  This signal will 
eventually decay back to equilibrium along the z-axis via different relaxation mechanisms 
(see Section 2.5.8.1) and is thus called the Free Induction Decay (FID).   In order for this 
FID to be recorded and stored by the computer the FID must be digitised.  In practice this 
requires regular sampling of the signal during the detection period by incrementing the t1 
delay. 
 
 
Figure 2.5.1  Basic building blocks for a one-dimensional NMR spectrum 
During preparation, equilibrium magnetisation is manipulated to transfer magnetisation 
onto the desired nuclei, in this case by a 90º pulse that places it on the x-axis.  The signal is 
then detected during the detection stage during time t1 as it decays back to the z-axis. 
 
2.5.2  Two-dimensional NMR  
 
For simple molecules and organic compounds, 1D-NMR is sufficient for many purposes.  
In proteins however, 1D-NMR gives rise to complicated spectra comprising many, heavily 
overlapped peaks that makes interpretation almost impossible.  In order to resolve some of 
this overlap a second dimension can be added to record spectra, known as 2D-NMR.  2D-
NMR spectra consist of two separate frequency axes and one intensity axis.  To build a 2D-
NMR experiment there are four stages, preparation, evolution, mixing and detection.  
Preparation is the same as for a 1D experiment, to create magnetisation in a desired form 
(see Figure 2.5.2 where it is a 90º pulse).  Next there is an evolution time where the spins 
are allowed to precess freely and relax back to equilibrium.  The mixing time follows where 
magnetisation is transferred between spins and manipulated into a signal that can be 
detected.  Detection follows in time t2.  
   60 
 
Figure 2.5.2 Basic building blocks for a two-dimensional NMR spectrum 
During preparation, magnetisation is transferred onto the desired nuclei, in this case by a 
90º pulse that places it on the x-axis.  Evolution allows frequency labelling of the 
precession spin, and mixing enables transfer of magnetisation between spins. The signal is 
then detected during the detection stage during time t2 as it decays back to the z-axis. 
 
The evolution time t1 is not fixed but can be varied incrementally to produce a series of 
separate data.  During this time the magnetisation is labelled with the chemical shift 
frequency of the first nucleus.  Importantly, no observations are made during t1 so complex 
magnetisation can be created.  During the mixing time, magnetisation is transferred 
between different nuclei and manipulated into an observable signal.  The mixing period is 
important in establishing the relationship between the two dimensions and the pulses in the 
mixing period will determine the ultimate content of the spectrum. 
 
The t2 detection period is direct detection in real time and is sampled at regular intervals as 
for a 1D experiment. By incrementing the evolution period the collection of data in a 
second, ‘indirect’ dimension is enabled and is the basis of 2D-NMR.  The evolution time t1 
is first set to zero and an FID recorded during t2.  The spins are allowed to return to 
equilibrium and then the pulse sequence is executed again but with a t1 delay and an FID 
recorded as before.  This is repeated incrementally thus building up a series of data that can 
be Fourier transformed to give two frequency axes. 
 
As molecular weight increases past 20kDa, it becomes difficult to study molecules by 2D 
methods alone. Larger proteins contain more resonances and because they have longer 
rotational correlation times (see Section 2.5.9) and therefore faster transverse relaxation the 
linewidths are larger, leading to increased overlap of resonances.  Increased transverse   61 
relaxation rate also decreases overall sensitivity due to less magnetisation surviving through 
the pulse sequence.  The overlap problem can be overcome by using three dimensional 
NMR.   
 
2.5.3  Three dimensional NMR 
 
A 3D-NMR experiment is a further extension of the 2D scheme. It can be constructed by 
joining two, 2D experiments together, leaving out the first detection period and the second 
preparation pulse. An additional evolution and mixing time is added (Figure 2.5.3) and t1 
and t2 are incremented independently with direct detection during t3. 
 
 
 
Figure 2.5.3 Basic building blocks for a three-dimensional NMR spectrum 
This is an extension of the 2D scheme, with an extra mixing and evolution period added. 
 
In this thesis, two and three dimensional experiments have been carried out.  NMR 
experiments can be homonuclear (considering one type of spin such as protons) or 
heteronuclear (considering more than one type of spin).  This thesis only uses heteronuclear 
experiments observing correlations between 
1H, 
15N and 
13C. 
 
2.5.4  Heteronuclear 2D-NMR: 
1H-
15N-HSQC 
 
Heteronuclear NMR allows the detection of protons correlated to other spin active nuclei 
such as 
13C and 
15N.  The natural abundance of these isotopes in proteins is low, and they 
have low gyromagnetic ratios which impacts on their relative sensitivity.  Therefore 
isotopic enrichment is required of 
13C and 
15N, and to overcome the lower sensitivity of 
carbon and nitrogen, NMR experiments are carried out by transferring magnetisation from 
the more sensitive proton, to the heteroatom (such as 
15N) then back onto proton where it is 
detected.     62 
 
The 2D-heteronuclear experiment used throughout this thesis is the 
1H-
15N Heteronuclear 
Single Quantum Correlation Spectroscopy (
1H-
15N-HSQC) (219;220).  This experiment 
records one-bond correlations between protons and 
15N by transferring magnetisation from 
protons onto nitrogen using an INEPT transfer (insensitive nuclei enhanced by polarisation 
transfer)(221).  During the evolution period the 
15N nuclei acquire a frequency label 
specific to nitrogen (the 
15N chemical shift) and this labelled magnetisation is transferred 
back to protons where it is detected.  This experiment is an important building block in 3D 
heteronuclear and triple resonance experiments and the basic HSQC experiment has been 
developed in various ways (218). The experiment used in this thesis is the gradient 
enhanced 
1H-
15N-HSQC (222).   
 
Proton detection is useful as it increases the sensitivity of the experiment. Protons have a 
higher larmor frequency (the frequency of precession) and will therefore have larger 
starting equilibrium magnetisation that ensures a maximum starting signal.  A larger 
amount of magnetisation can therefore be transferred to less sensitive 
15N, effectively 
increasing the signal obtained from this nuclei.   
 
The 
1H-
15N-HSQC experiment produces a 2D spectrum with the 
1H
N measured in the direct 
dimension and 
15N measured in the indirect dimension.  Thus resonances arise that have a 
proton and nitrogen resonance and correspond to each backbone NH in the protein, i.e. one 
resonance for each amino acid in the protein. The exception to this is proline, which has no 
free NH.  Also observed in this spectrum are NH2 groups from the sidechains of asparagine 
and glutamine and the indole H
N protons of tryptophan.  An example of a 
1H-
15N-HSQC 
spectrum can be seen in Section 3.1.2.4, Figure 3.1.9. 
 
1H-
15N-HSQC spectra can be used to determine whether a protein is folded or whether it 
shows unstructured properties. Unfolded proteins produce overlapping chemical shifts 
centered in the middle of the spectrum as all residues are experiencing a similar 
environment due to the aqueous surroundings.  In folded proteins the amino acids 
experience different chemical environments, reflected in the dispersion of chemical shifts.   63 
 
The chemical shifts of NH resonances in a 
1H-
15N-HSQC spectrum are also very sensitive 
to changes in local environment, so addition of ligands and small molecules can cause 
changes in the peak positions and can be used to map specific interaction sites on proteins.  
This will be explored further in Section 2.5.13. 
 
The 
1H-
15N-HSQC spectrum of vinculin tail has been assigned in this thesis and used for 
chemical shift perturbation experiments.  In order to assign the spectrum, three-dimensional 
NMR experiments were required.  These are described in the following sections. 
 
2.5.5  3D-
1H-
15N-TOCSY-HSQC  
 
TOCSY stands for total correlation spectroscopy (223;224). Experiments making use of 
TOCSY transfers act to transfer magnetisation through bonds via strong J-couplings (also 
known as scalar couplings). The J-couplings for bonds within amino acid residues are 
shown in Figure 2.5.4.  Atoms with a coupling constant over four bonds (
4J) are extremely 
weak, so TOCSY transfers are restricted to atoms within an amino acid.  Crosspeaks are 
generated between atoms in a spin system in a pattern which is specific to the amino acid 
type.  Magnetisation is transferred during the mixing time, generally crosspeaks due to 
direct couplings will build up maximum intensity in 1/2J while larger couplings will need 
longer mixing times in the region of 100-200ms.  Relaxation also occurs during the mixing 
time which can lead to loss of signal intensity; losses due to relaxation are larger when 
going through larger couplings.  
 
The 3D 
1H-
15N-TOCSY-HSQC (225) provides correlations between atoms in a spin 
system, but they are edited according to the 
15N amide so that the protons that are observed 
are the ones directly bound to the nitrogen, thus reducing the overlap seen in 2D-TOCSY 
experiments.  It will give amino-acid specific information but no sequential connectivities.  
It is usually used in concert with the 3D 
1H-
15N-NOESY-HSQC (see next section). 
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Figure 2.5.4 J-coupling constants between nuclei in a protein 
 
2.5.6  3D-
1H-
15N-NOESY-HSQC  
 
NOESY stands for nuclear Overhauser enhancement spectroscopy (226;227).  The nuclear 
Overhauser effect is caused by dipolar relaxation which can give rise to transfer of 
magnetisation through space. When two spins come together in space they will ‘sense’ the 
magnetic field of the other and cause splitting of a signal.  In solution, molecular tumbling 
averages these splittings but generates a fluctuating magnetic field which enables spins to 
transfer magnetisation between them.  The efficiency of transfer through space depends on 
distance such that NOEs can only be observed between atoms less than 5Å apart.  Short 
mixing times (50-150ms) are required to minimise spin diffusion in larger proteins with 
long correlation times.  The size of an NOE is inversely correlated to nuclear distance. 
 
The 3D-
1H-
15N-NOESY-HSQC (225;228-230) is used to resolve crosspeaks between 
1H 
spins by using the 
15N heteronucleus that they are directly bound to.  Only magnetisation on 
protons attached to 
15N is selected for detection, despite all protons being frequency 
labelled.  This results in only crosspeaks that are crossrelaxing with amide protons.  
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The difference between the 3D-TOCSY and the 3D-NOESY experiment is that while the 
TOCSY relies on through bond transfers and only gives amino acid specific information, 
NOESY data can provide information on the order of amino acids in a protein as it transfers 
magnetisation through space.  The NOESY experiment should provide the connectivities 
between different amino acids.  The two experiments are usually used in concert to assign 
protein spectra or for structural determination. 
 
In this thesis, TOCSY transfers were inefficient so the 
1H-
15N-NOESY-HSQC experiment 
has been utilised in a different manner.  The vinculin tail is a highly α-helical protein, in an 
α-helix the 
1H
N-
1H
N distance (dNN) is such that sequential NOEs can be detected between 
the amides of neighbouring amino acids (for a useful description of this see (215). Thus, 
one can sequentially walk along the protein backbone via the NOEs between NH groups.   
 
2.5.7  Triple resonance experiments 
 
Three dimensional triple resonance experiments have been carried out that correlate 
backbone NH, 
15N, 
13Cα, 
13Cβ and 
13CO.  They have been used to assign the protein 
backbone in addition to the 
1H-
15N-NOESY-HSQC experiment.  Figure 2.5.5 shows the 
correlations that are observed for the experiments used in this thesis, namely the HNCA 
(231-233), HNCACB (234), HN(CO)CA (233;235), HN(CO)CACB (236) and HNCO 
(231;233;237). These experiments correlate the backbone NH resonance with the carbons 
through one and two bond couplings and give rise to sequential information.  The HNCA 
experiment will show a Cα resonance peak for a specific amino acid (linked to its NH) and 
a weaker Cα peak corresponding to the amino acid that precedes it in the sequence (i-1 
peak).  Therefore you can walk along the sequence using the Cα resonances.  The 
HNCACB provides further specificity by giving the Cβi and Cβi-1. The pattern of Cα and 
Cβ chemical shifts for a given amino acid can provide amino acid specific information.  
Figure 2.5.6 shows the patterns that can be expected for each amino acid.     66 
 
Figure 2.5.5 Triple resonance experiments used in this thesis 
Red atoms are those which are frequency labelled and detected, yellow are those through 
which magnetisation passes but the atoms are not labelled.  Arrows denote the scalar 
couplings used for the magnetisation transfers.   67 
 
Figure 2.5.6  Expected carbon chemical shifts for amino acids in the protein backbone 
 
2.5.8  TROSY 
 
TROSY stands for transverse relaxation optimised spectroscopy (238).  The TROSY effect 
can be exploited to improve the lineshapes in NMR spectra at high magnetic field strengths. 
In this thesis, TROSY has been used in many experiments at 800MHz and 900MHz and 
produced much improved spectra.  In order to understand TROSY it is necessary to briefly 
introduce some concepts of relaxation in NMR. 
 
2.5.8.1 T1 and T2 relaxation 
 
Relaxation is the process by which magnetisation returns to equilibrium. At equilibrium 
there is no transverse magnetisation (along x or y axes) but there is longitudinal 
magnetisation along the z-axis caused by alignment of the spins in the external magnetic 
field.  RF pulses can be applied to create transverse magnetisation and relaxation occurs 
that drives transverse magnetisation to zero and longitudinal magnetisation to a steady state 
value. 
 
The bulk magnetisation is an average of the magnetic moments of all the individual spins.  
At equilibrium the z-magnetisation is in the longitudinal plane while the x/y contributions 
average to zero in the transverse plane.  Application of the RF pulse changes this and   68 
causes net magnetisation in the transverse plane and a reduction in the z-magnetisation.  
After the RF pulse the transverse magnetisation precesses and returns to equilibrium along 
z.  This is how the FID is created and measured. 
 
Relaxation back to equilibrium is a natural process and occurs due to naturally occurring 
magnetic fields in the sample. Longitudinal relaxation (or T1 relaxation) causes z-
magnetisation to return to equilibrium through interaction with the local fields in the 
environment.  Each spin has its own magnetic moment that can act as a local field to affect 
neighboring spins.  Due to thermal motion in the sample, the local fields vary in size and 
orientation and a fluctuating local field is produced. If the fluctuation should be close to  
that of the larmor frequency of the precessing spins then this can cause the magnetisation to 
be transferred to the surroundings.  This relaxation is inefficient due to the fluctuating field 
being very weak and the variety of frequencies present in the local field. 
 
Transverse relaxation (or T2 relaxation) causes the transverse magnetisation to return to 
zero.  After application of the RF pulse to create transverse magnetisation the spins precess 
freely at their larmor frequency.  The size of this transverse magnetisation decays slowly 
because the individual spins cannot remain exactly synchronous with one another.  After a 
certain time the individual spins become out of phase with one another, they lose coherence 
due to the local fields affecting each spin slightly differently.  Eventually the transverse 
relaxation will return to zero as the spins become completely dephased.   
 
2.5.8.2 Dipolar and CSA relaxation mechanisms 
 
Two dominant relaxation mechanisms for spin ½ nuclei are dipolar and chemical shift 
anisotropy (CSA).  The dipolar mechanism occurs via a local field produced by the 
magnetic moment of one spin affecting a second spin.  This local field depends on the 
distance between the two spins, the gyromagnetic ratio of the spins and the orientation of 
the vector joining the spins relative to the applied magnetic field.  The field of a 
neighboring spin can act to transfer magnetisation between spins sensing this field and can   69 
act to dissipate the energy of excited spins, thus making important contributions to T1 and 
T2 relaxation. 
 
CSA relaxation involves only one spin, in this case the local field is caused by electron 
currents in the nucleus in response to the external magnetic field.  The nucleus experiences 
both the applied external field and the local field which will alter the larmor frequency by a 
small amount (this is the basis for the chemical shift). As the molecules tumble in solution 
the size and direction of this local field changes.  Fluctuations in this local magnetic field as 
the molecule rotates is a source of relaxation.   
 
Usually the dipole-dipole interaction is the dominant source of relaxation, however as the 
magnetic field strength increases, CSA becomes more important .  
 
2.5.8.3 The TROSY effect 
 
A nucleus in an NMR sample is likely to experience dipolar interactions from other nuclei 
and CSA from its own electrons.  If these two effects are dependent on each other then 
cross-relaxation (or cross-correlation) is observed.   
 
In the example of the 
15N-
1H spin pair, cross-relaxation will lead to affects on the doublets 
that arise due to dipolar couplings.  In a situation where there is little or no cross-relaxation 
between 2 spins it is normal to observe a doublet of peaks where the splitting is equal 
between the two and relaxation occurs similarly for both spins (Figure 2.5.7a).  Cross-
relaxation between two spins such as in the case of 
15N-
1H produces an asymmetric doublet 
where one peak has a small linewidth and one has a very large linewidth (Figure 2.5.7c).  In 
an NMR experiment it is normal to decouple these peaks to produce an average peak in the 
centre.  As shown in Figure 2.5.7b and d, averaging the first situation keeps the linewidth 
the same but doubles the intensity, while in situation two the linewidth and intensity is an 
intermediate between the two.  The line narrowing effect observed for one line of the 
doublet is particularly pronounced at higher fields. 
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Figure 2.5.7 Cross-relaxation effect between two nuclei 
a: little or no cross-relaxation between 2 spins presents as an equal splitting between two 
nuclei.  Decoupling these two peaks keeps the linewidth the same but doubles the intensity 
(b).  c: Cross-relaxation between two spins such as in the case of 
15N-
1H produces an 
asymmetric doublet where one peak has a small linewidth and one has a very large 
linewidth, decoupling leads to the linewidth and intensity becoming an intermediate 
between the two (d). Image adapted from (214). 
 
In a conventional 
1H-
15N-HSQC spectrum it is usual to collapse the doublets (of which 
there are four) to produce one central peak (Figure 2.5.8a).  Where cross-relaxation is 
occurring and CSA is having a large effect, some of these lines are much broader than the 
others (Figure 2.5.8b) and when they are averaged there will be a considerable reduction in 
peak height compared to the narrow intense peak.  Therefore, where this effect is very 
large, such as in the case of large molecules at high fields, it is best not to remove the 
splittings due to the heteronuclear couplings and retain the signal from the large narrow 
peak.  This is the basis of TROSY (238) and as a result, the spectra of larger proteins can be 
vastly improved using this technique. 
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Figure 2.5.8  Example of the TROSY effect in a 2D-
1H-
15N HSQC. 
Resonances are often decoupled in a 2D-
1H-
15N HSQC spectrum to produce one central 
peak (a: central grey peak).  Where cross-relaxation is occurring, the linewidths can vary 
between the four splittings and it is beneficial to maintain the narrow intense peak (b, top 
right peak). 
 
2.5.9  Rotational correlation time 
 
The rotational correlation time of Vt and mutants was measured in this thesis as a gauge of 
aggregation effects and/or oligomersation in solution.  The rotational correlation time (τc) 
of a protein in solution is defined as the average time for all molecules in a solution to 
achieve an orientation one radian away from the starting position (214).  For a protein of 
20kDa, a correlation time of around 10ns would be expected. 
 
τc is determined by the size, shape, and dynamics of the molecule (239).  As the correlation 
time is determined in part by the molecular weight, measuring τc can give clues to 
aggregation occurring in solution and oligomerisation states of proteins (240).  For protein   72 
less than 30kDa, τc is usually measured as a ratio of longitudinal and transverse relaxation 
rates (241-243) and by relating experimental values for τc to the solvent accessible area of a 
molecule, estimates of aggregation can be made as in Section 2.6.6 (239;240;244). 
 
As represented in Figure 2.5.9, small molecules have fast rotational tumbling and T1= T2.  
As the correlation time increases, T1 decreases to a minimum and then increases again 
while T2 continually decreases.  The linewidth is related to T2, such that as molecular 
weight increases, correlation time also increases and T2 gets smaller.  Therefore linewidths 
get larger as τc increases (215;217).  
 
 
Figure 2.5.9 Variation of T1 and T2 with correlation time 
As correlation time increases, T1 decreases to a minimum and then increases again while 
T2 decreases.  This decrease in T2 with increasing τc results in line broadening in NMR 
spectra. 
 
2.5.10  Partial deuteration and perdeuteration 
 
For proteins with large molecular weights, NMR spectra contain a large numbers of signals 
and increased overlap of the resonances.  Also due to the longer correlation time of larger 
molecules in solution, relaxation of the magnetisation on the spins is faster meaning that the   73 
signal lasts for a shorter time. As there is more efficient transverse T2 relaxation the 
linewidths of the resonances are increased which can compound the overlap problem and 
reduce the signal to noise of the experiment (245). 
 
As mentioned previously, dipolar relaxation is a dominant mechanism by which 
magnetisation is lost, this is especially due to 
1H-
1H (245) and 
13C-
1H spin pairs (246).  An 
effective way of making relaxation occur more slowly, thus allowing the signal to remain 
for a longer period, is by replacing protons attached to carbons with deuterons (
2H).  The 
substitution of deuterons for protons depletes the number of protons available for dipole-
dipole interactions, and as deuterons have approximately a 6-fold lower gyromagnetic ratio 
relative to protons (247), the transfer of magnetisation is much less efficient.   
 
Deuteration of proteins can be complete, where around 99% of all carbon-bound atoms are 
replaced (known as perdeuteration), or partial, where the percentage of deuteration is an 
average distribution throughout the molecule.  Deuteration can also be site-specific where 
2H is incorporated at known sites within a protein.  Protons are reintroduced into the amide 
NH positions to enable NMR detection, this is often from water buffers during the 
purification stage. 
 
Deuteration has been employed in this thesis to improve data acquired from triple 
resonance experiments (such as those in Section 2.6.4.1).  These experiments encounter 
problems as the molecular weight of proteins studied approaches 20-25kDa.  The long 
correlation times for these molecules causes efficient (and fast) relaxation of the spins 
involved.  These relaxation effects can lead to an absence of detectable Cβ resonances in 
the HNCACB experiment. As the HNCACB is an ‘out-and-back’ experiment, the success 
of the magnetisation transfer requires Cα T2 relaxation time long enough to establish the Cα 
to Cβ correlation (248).  Without the Cβ resonances, sequential assignment becomes very 
difficult as both the amino acid specific information and the sequential connectivity is lost. 
 
Deuteration is therefore useful for reducing the relaxation of magnetisation in larger 
molecules.  The result of this on the spectrum is an increase in sensitivity due to   74 
magnetisation surviving for longer and improved resolution (especially in carbon 
dimensions).  The lack of resolution is in part due to the short acquisition times required 
because of the normally rapid transverse relaxation rates (246). 
 
Deuteration also helps to suppress spin diffusion.  As stated earlier, the NOE acts to 
transfer magnetisation between hydrogen atoms through space.  This transfer may be more 
efficient through multiple short steps (e.g. through bonds) rather than a one-step transfer 
over the longer, direct distance (249).  During experiments such as the 
1H-
15N-NOESY-
HSQC spin diffusion can spread the signal over many protons so that the distance and 
connectivity information is lost. Proteins contain large networks of protons, and for 
proteins with a long correlation time, spin diffusion can cause problems if not accounted 
for.  Deuteration of the carbon bound protons prevents them from transferring 
magnetisation from the solvent and reduces spin diffusion. 
 
2.5.11  Selective labelling and unlabelling 
 
Selective labelling has been used in this thesis to enable the assignment of the protein 
backbone (for method see Section 2.2.4).  The procedure allows specific 
15N-labelled 
amino acids to be incorporated into proteins so that only the labelled amino acids are 
detectable using NMR.  When a 
1H-
15N-HSQC spectrum is recorded, only the amino acids 
with the 
15N label will be observed, hence the amino acid identity of these resonances is 
immediately known.  During assignment, this information can be used unambiguously to 
place connected residues from triple resonance experiments into the protein sequence. 
 
Conversely, selective unlabelling inserts a non-magnetic, amino acid specific 
14N in a 
protein that is labelled with 
15N at all other amino acid positions.  The selected amino acids 
are then missing from the 
1H-
15N-HSQC spectrum.  For method see Section 2.2.3. 
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2.5.12  Secondary structure from Cα and Cβ shifts 
 
Secondary structure can be identified in folded proteins from Cα and Cβ chemical shifts 
(250-252). The values for the carbon shifts for amino acids measured in urea (the random 
coil chemical shifts) can be subtracted from the experimental carbon shifts for the protein in 
question. This will produce a chemical shift deviation from the random coil value which is 
plotted against the residue number.  Large positive deviations for Cα are characteristic of α-
helices and negative deviations are seen for extended structures like β-sheets.  Conversely, 
Cβ shifts tend to be negative for α-helices and positive for extended structures. 
 
2.5.13  Chemical shift perturbation 
 
Solution NMR is a powerful tool for evaluating protein-ligand interactions.  It relies on the 
chemical shifts of the residues in the protein being sensitive to subtle changes in chemical 
environment (253).  It is especially useful as it can be used to detect weak interactions, with 
Kds in the millimolar range being detectable (254). 
 
The most widely used NMR method to determine binding interfaces is chemical shift 
mapping or chemical shift perturbation (254). 
 This is achieved by recording a 
1H-
15N-
HSQC spectrum of an isotopically labelled protein, and then monitoring the changes in the 
chemical shifts as a binding partner is titrated in.  These changes occur if the magnetic 
environment of the individual nuclei is changing. 
 
In this thesis, chemical shift perturbation has been used to explore protein interactions.  The 
manner in which the interaction occurs will be suggested by the exchange regime in the 
system. The NMR properties of the free and bound states are different.  These differences 
can be observed between the chemical shifts, relaxation rates and diffusion rates (253), and 
the differences are determined by the chemical exchange rate, Kex (255). When ligand is 
titrated into a protein solution, the chemical shift change, as well as the quality of the 
resulting spectra, is determined by the chemical exchange regime that the system is under 
(218).   76 
 
2.5.13.1  Exchange regimes 
 
Chemical exchange refers to any process where a nucleus exchanges between two or more 
environments which results in a change in its NMR parameters. Examples of factors 
resulting in chemical exchange include the making or breaking of chemical bonds, 
conformational changes within the molecule or pH changes within the sample.  NMR 
provides an excellent method for monitoring the exchange of a nucleus between different 
environments as long as they are magnetically distinct. 
 
The simplest manner in which a ligand will bind to a protein can be described as a second 
order exchange process, 
 
Equation 2.i 
 
 
where Kf is the forward (association ) rate constant and Kr is the reverse (dissociation) 
constant.  The chemical exchange regime for the system will depend on the relationship 
between the exchange rate (Kex) and the difference in chemical shifts between the free (P) 
and bound (PL) forms.  For the above system, if the exchange rate is greater than the 
difference in chemical shift between P and PL, then fast exchange will be observed.  If the 
exchange rate is less that the difference between the chemical shifts for the free and bound 
forms then slow exchange is occurring.  When the exchange rate approaches the same as 
the difference between the two states then the system is in the intermediate exchange 
regime (Equation 2.ii). 
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Equation 2.ii Chemical exchange regimes 
Fast Exchange:   Kex  >> δP-δPL 
Intermediate Exchange:   Kex   =  δP-δPL 
Slow Exchange:            Kex  << δP-δPL 
Kex is the exchange rate, δP is the chemical shift of the protein, δPL is the chemical shift of 
the protein-ligand complex 
 
The exchange regime will affect the appearance of the protein resonances in the spectrum.  
During fast exchange, when Kex  >> δP-δPL, one peak is observed which is an average signal 
from both the free and bound forms.  Slow exchange manifests as two peaks, one from the 
free form and one from the bound form due to the difference in chemical shift being larger 
than Kex.  Intermediate exchange causes severe line broadening and coalescence into one 
broad peak (Figure 2.5.10). 
 
During the course of a titration, several 
1H-
15N-HSQC spectra are recorded and overlaid.  If 
a nucleus is in fast exchange, as ligand is titrated in there will be a peak for the free protein 
which tracks to a new position as ligand concentration increases.  This peak will track until 
it reaches the final position for the fully bound protein.  This occurs because the peak is an 
average of the two different populations of free and bound forms.  It is easy to monitor this 
by following the assigned peak across the spectrum (Figure 2.5.11a).  If slow exchange is 
occurring then the position of a peak remains the same but it reduces in intensity as the 
population of free form changes into the bound form.  A new peak corresponding to the 
bound form will reappear at a new position in the spectrum (Figure 2.5.11b).  It is usually 
necessary to reassign the 
1H-
15N-HSQC spectrum of the bound form to determine the 
identity of the new peaks.  If the kex becomes the same as the chemical shift difference 
between states P and PL then the system in intermediate exchange.  When this occurs the 
two signals from the free and bound forms merge into one and severe line broadening can 
occur.  If this line broadening occurs too dramatically, then the resonances may disappear 
from the spectrum completely.   78 
 
Figure 2.5.10 Effects of chemical exchange  
In fast exchange, Kex is > the difference in chemical shifts between two resonance peaks 
and a single peak is observed.  In slow exchange, Kex < the difference between chemical 
shifts and two peaks are observed.  When the Kex is the same as the difference in chemical 
shifts, intermediate exchange is observed and line broadening occurs.  (Figure prepared 
using WINDNMR-Pro).   79 
 
 
 
 
Figure 2.5.11 Effect of fast and slow exchange on a 1H-15N-HSQC spectrum 
a: fast exchange manifests as one peak that tracks across the spectrum, starting from free 
protein (P) and ending at saturated protein-ligand complex (PL). b: slow exchange 
manifests as one peak that remains at the same chemical shift but loses intensity while a 
second new peak appears at a different chemical shift and increases in intensity 
 
Fast exchange is often observed for weaker interactions and slow exchange can be observed 
in stronger interactions where complex dissociation is slow (254).  For fast exchange, 
affinities can be obtained from plotting the chemical shift change vs. the ligand 
concentration, however slow exchange processes can be accompanied by line broadening 
effects and can make estimating affinities difficult (256).   
 
Resonances that show large chemical shift changes upon binding are assumed to be 
involved in the binding interface between the protein and the ligand, however, smaller 
changes can occur for residues close to the binding site, so some care needs to be taken 
when interpreting chemical shift perturbation data. 
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2.5.14  Hydrogen-deuterium exchange 
 
Main chain and side chain hydrogens in proteins are in constant exchange with the 
hydrogens in the solvent (257;258).  Exchangeable groups within proteins include the NH 
hydrogens and hydrogens in polar side chains attached to N, O and S atoms.  Hydrogens 
attached to carbon do not exchange easily (258).  The mechanism of hydrogen exchange in 
folded proteins is complex due to the different environments of core and surface hydrogens 
and factors such as steric inaccessibility to solvent, charge distributions in neighboring 
amino acids and hydrogen bonding that will all affect the rate of hydrogen exchange (259). 
 
Hydrogen exchange between the backbone NH groups and solvent occurs in a chemical 
reaction between the peptide group and an OH
- ion or H3O
+ ion.   Hydrogens that are more 
accessible will undergo this reaction more readily than stable hydrogens such as those in 
hydrogen bonds.  However, when left for long enough, even deeply buried hydrogens will 
exchange at a rate that can be measured (260).  
 
The rate of exchange between the molecule and the solvent is determined by the dynamic 
nature of protein molecules.  Several different exchange mechanisms have been proposed 
(see for example reference (259)), the two main models being the solvent penetration model 
and the unfolding model.  The solvent penetration model assumes that the ions can gain 
entrance to the protein core via transiently formed small pores and cavities.  These could 
appear due to rapid fluctuations of atoms in the interior or could arise due to 
rearrangements in hydrogen bonding.  The unfolding model proposes that hydrogens can 
only exchange when they are not in a hydrogen bonded form.  This can only occur in a 
small fraction of time where a high energy unfolding reaction occurs that transiently 
separates donor and acceptor molecules. This is a dynamic opening and closing reaction 
and can be a local unfolding where only a few residues unfold at a time, a global whole 
molecule unfolding or some intermediate subglobal form in between (257;261).   
 
Hydrogen exchange can be measured by looking at rates of exchange with deuterium oxide.  
A popular model for hydrogen exchange with deuterium is shown in Equation 2.iii.    81 
According to this model, an exchangeable hydrogen that is slow to exchange most often 
resides in the closed state where exchange cannot occur (NHcl).  Occasionally the molecule 
experiences a dynamic motion that causes it to open (NHop). Once an amide hydrogen 
reaches the open state, the balance between closing without exchange and moving forward 
with exchange dictates the two limits, EX1 and EX2 (262). 
 
Equation 2.iii 
 
 
The EX2 limit occurs when the return to the closed form is rapid compared to the exchange 
step and as a consequence the exchange is base catalysed.  This can give clues to 
thermodynamic behavior.  The EX1 limit occurs when return to the closed form is slow 
compared to the exchange step and is therefore not base catalysed.  EX1 provides 
information about kinetics and can monitor rates of unfolding or of local opening (263). 
 
In this thesis hydrogen-deuterium exchange has been used to study the protection of 
proteins to exchange when ligands are bound.  Ligand binding to a protein is predicted to 
protect the NH groups that are involved in the interaction by stabilising them so they do not 
exchange as readily. Using NMR, a protein can be dissolved in D2O, consecutive 
1H-
15N-
HSQC spectra can be recorded and the rate of exchange of individual NH groups measured.  
When used in this manner the deuterium atom cannot be detected.  Therefore any NH 
groups that are undergoing exchange with D2O will be missing from a 
1H-
15N-HSQC 
spectrum.  Protection and stabilisation of NH groups is observed as a decrease in the 
exchange rate, NH resonances would persist longer than in the free form.  Conversely, any 
destabilisation or change in dynamic nature of the protein upon ligand binding would be 
observed as an increase in exchange rate with D2O. 
 
Hydrogen-deuterium exchange can be a powerful method of confirming binding sites in 
proteins when used in concert with chemical shift perturbation experiments.  Hoellerer et   82 
al. (6) used chemical shift perturbation experiments to elucidate the binding sites for LD 
peptides on FAK and confirmed these by showing the same sites were protected in the 
presence of ligand, observed as increased protection from exchange with deuterium. This 
method has been employed in this thesis. 
 
2.6  NMR Methods 
2.6.1  Instrumentation 
 
Three different field strengths were used in this study.  600MHz data was acquired on the 
spectrometer in the School of Biological Sciences at the University of Southampton.  
800MHz data was acquired at the MRC Biomedical NMR Centre at the National Institute 
for Medical Research (NIMR), the experiments were conducted by Dr. Geoff Kelly.  
900MHz data was acquired at the Henry Wellcome Building for Biomolecular NMR 
Spectroscopy at the University of Birmingham.  Data was acquired with the assistance of 
Dr. Sara Whittaker.  Some 800MHz and 900MHz data was acquired with a cryoprobe. 
 
2.6.2  Sample preparation 
2.6.2.1 Vinculin tail 
 
Wild-type Vt and all mutant proteins were concentrated to approximately 1-2mg/mL in the 
high concentration NaCl buffer that the protein elutes from the cation exchange column, 
typically ~400mM NaCl.  Spin concentrators (Vivaspin) with either 15mL or 2mL volume 
were used to concentrate Vt (10,000 molecular weight cut-off with a regenerated cellulose 
membrane). The proteins were dialysed into the appropriate buffer using slide-a-lyser 
dialysis cassettes (Pierce) with a 10,000 molecular weight cut off.  Dialysis was carried out 
at 4ºC for at least 16 hours.  Typically 2 x 5L buffer was used to dialyse protein volumes 
from 0.5mL to 10mL.  Buffer choice was dependant on the desired experiment and can be 
found in relevant sections.  The concentration was measured post dialysis by absorbance at 
280nm and further concentration was carried out as required in new buffer.  A280nm   83 
readings were divided by the estimated absorbance at 1g/L to get a more accurate 
estimation of the concentration. 
 
Typically, 200µM Vt was used for 
1H-
15N-HSQC spectra at 600MHz. 
15N-relaxation 
experiments were carried out using 100µM Vt, and 500-600µM Vt was used for assignment 
experiments. 
 
The NMR sample was prepared in a volume of 520µl or 320µl.  For experiments at 
600MHz, 5% deuterium oxide and 0.5µl of 2M sodium azide was added.  The pH was 
checked and adjusted as necessary.  
 
For experiments on spectrometers with an attached cryoprobe, 10% deuterium oxide was 
added.  For samples at 900MHz that were not in a shigemi tube, 600µl sample volume was 
required to ensure good shimming. 
 
2.6.2.2 Paxillin His-LD1/LD2 
 
The purified paxillin protein was stored as a freeze-dried pellet at -20ºC prior to use.  
Known quantities of protein were dissolved into the necessary buffer to ensure the correct 
final protein concentration.  Remembering that paxillin His-LD1/LD2 cannot be 
concentrated in the normal manner using spin concentrators, it was important to calculate 
the correct volume of buffer to use, the protein pellet will make up some of the final 
volume so it was necessary to add the buffer in small amounts to make the correct final 
volume.  The sample was dissolved by pippetting up and down into the solution, care was 
needed to ensure there was no frothing of the viscous protein sample. The protein 
concentration was checked using an A280nm reading and corrected for the predicted 
absorbance at 1g/L. 
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2.6.3  Data acquisition and processing 
 
All experiments were carried out at a temperature of 25°C.   At 600MHz the proton carrier 
frequency was set to the water resonance (4.7791ppm).   
 
Gradient-enhanced 
1H-
15N-HSQC experiments (222) for Vt were typically acquired with 32 
scans and 84 increments, higher signal-to-noise was achieved when required with 128 scans 
and 128 increments.  At 600MHz the proton spectral width was 10006.3Hz and the proton 
acquisition time was 0.064s.  The nitrogen acquision time was 0.054s and 0.083s for ni=84 
and ni=128 respectively.  The 
15N spectral width was 1550Hz and the 
15N carrier was set to 
155.044ppm.  The decoupler offset frequency (dof2) for 
15N was 1580Hz. 
 
All 3D data was acquired using standard pulse sequences from the BioPack software 
(Varian).  600MHz 
1H-
15N-NOESY-HSQC data was acquired with a mixing time of 
120ms, 600MHz 
1H-
15N-TOCSY data was acquired with a 30ms mixing time, 800MHz 
1H-
15N-NOESY-HSQC data was acquired with a mixing time of 90ms and 900MHz 
1H-
15N 
TROSY-NOESY data was acquired using a mixing time of 100ms.
 
 
All processing was carried out in NMRpipe format (264). Phasing was corrected using 
NMRDraw (264) and spectra were visualised using NMRview5 (265). 
 
2.6.4  Methods for the assignment of Vt/I997S 
2.6.4.1 Data collection 
 
Table 2.6.1 shows all triple resonance and 
15N-edited data that was collected on Vt/I997S to 
enable assignment. 
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Table 2.6.1 Data collected for assignment of Vt/I997S 
Experiment  TROSY  Field 
MHz
(a) 
Buffer Conditions  Protein label 
& Concentration 
HNCACB  No  600  20mM Tris pH7, 300mM 
NaCl 
15N, 13C, 60-70% 
D2O, 0.5mM 
HNCA  No  600  20mM Tris pH7, 300mM 
NaCl 
15N, 13C, 60-70% 
D2O, 0.5mM 
HN(CO)CA  No  600  20mM Tris pH7, 300mM 
NaCl 
15N, 13C, 60-70% 
D2O, 0.5mM 
15N-TOCSY-HSQC  No  600  20mM Tris pH7, 300mM 
NaCl 
15N, 0.5mM 
15N-NOESY-HSQC  No  600  20mM Tris pH7, 300mM 
NaCl 
15N, 0.5mM 
HNCACB  Yes  800  20mM Tris pH7, 300mM 
NaCl 
15N, 
13C, 60-70% 
D2O, 0.5mM 
HNCA  Yes  800  20mM Tris pH7, 150mM 
NaCl, 50mM Arginine, 
50mM Glutamic acid 
15N, 13C, 60-70% 
D2O, 0.5mM 
HNCA  Yes  900  20mM Tris pH7, 300mM 
NaCl, 50mM Arginine, 
50mM Glutamic acid 
15N, 13C, 60-70% 
D2O, 0.5mM 
HN(CO)CA  Yes  900  20mM Tris pH7, 300mM 
NaCl, 50mM Arginine, 
50mM Glutamic acid 
15N, 13C, 60-70% 
D2O 
0.5mM 
HNCA  No  900  20mM Tris pH7, 150mM 
NaCl 
15N, 13C, 60-70% 
D2O, 0.55mM 
HNCACB  No  900  20mM Tris pH7, 150mM 
NaCl 
15N, 13C, 60-70% 
D2O, 0.55mM 
15N-NOESY-HSQC  No  800   20mM Tris pH7, 150mM 
NaCl, 50mM Arginine, 
50mM Glutamic acid 
15N, 0.6mM   86 
HNCACB  Yes  800 
Cryo 
20mM Tris pH7, 150mM 
NaCl, 50mM Arginine, 
50mM Glutamic acid 
15N, 13C, >95% 
D2O, 0.5mM 
HN(CO)CACB  Yes  800 
Cryo 
20mM Tris pH7, 150mM 
NaCl, 50mM Arginine, 
50mM Glutamic acid 
15N, 13C, >95% 
D2O, 0.5mM 
15N-TROSY-
NOESY 
Yes  900 
Cryo 
20mM Tris pH7, 150mM 
NaCl, 50mM Arginine, 
50mM Glutamic acid 
15N, 13C, >95% 
D2O, 0.5mM 
HN(CO)CA  Yes  800 
Cryo 
20mM Tris pH7, 150mM 
NaCl, 50mM Arginine, 
50mM Glutamic acid 
15N, 13C, >95% 
D2O, 0.4mM 
HNCO  Yes  800 
Cryo 
20mM Tris pH7, 150mM 
NaCl, 50mM Arginine, 
50mM Glutamic acid 
15N, 13C, >95% 
D2O, 0.4mM 
 
(a) Cryo: data acquired with cryoprobe 
 
2.6.4.2 Assignment procedure 
 
The method used to enable assignment of Vt/I997S began with initial NH connectivities 
being identified using amide NOE data from 
1H-
15N-NOESY-HSQC spectra.  When a set 
of NH resonances were linked, the triple resonance experiments were used to confirm the 
connectivities and to possibly extend them further.  Any amino acid specific information 
was noted from the triple resonance experiments and the carbon α and β chemical shift 
information submitted to the ‘type-prob’ and ‘seq-prob’ programs (266) that returns the 
most likely amino acid type and position in the sequence for these connected residues.  
These probabilities were confirmed and the correct position chosen using the known lysine 
and arginine residues from selective labelling and unlabelling.  A final check was carried 
out using the triple resonance data to ensure that all connectivties were correct. 
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The Cα and Cβ shifts were recorded and the deviation from random coil calculated using 
values from (252).  These were plotted against residue number to predict secondary 
structure and to verify that assignment was correct. 
 
2.6.4.3 TALOS 
 
The secondary chemical shift data was used to predict the φ and ϕ torsion angles using the 
program TALOS (Torsion Angle Likelihood Obtained from Shifts and sequence similarity) 
(267).  TALOS contains a database of 186 proteins whose x-ray crystal structures are 
known to 2.2Å, and searches the database to find the 10 best matches for a given amino 
acid triplet.  It uses the triplet to give data about the central residue.  If these matches have 
consistent values then their averages and standard deviations are used as an average for a 
prediction for the given data. 
 
The predictions for Vt/I997S were compared to the .PDB file for wild-type Vt (1QKR) to 
determine similarities and differences. 
 
2.6.5  Estimation of rotational correlation time  
 
Relaxation experiments were carried out using 100µM Vt in 20mM Tris pH7, 400mM 
NaCl.  
15N relaxation time constants were calculated from a series of one-dimensional 
15N 
T1 and T2 relaxation spectra recorded with relaxation delays of 0.02s, 0.08s, 0.16s, 0.32s, 
0.60s, 1.00s, 1.40s for T1 and 0.01s, 0.03s, 0.05s, 0.07s, 0.09s, 0.11s for T2. 
 
To extract the correlation time, the amide regions recorded for both T1 and T2 at each 
delay were integrated from 7.62ppm-12ppm, avoiding the NH2 peaks.  This provided the 
intensity as the area under the peaks.  The first integral value was normalised to 1 and the 
remaining values were measured compared to this.  These intensities (I/I0) were plotted 
against relaxation delay (s) using the xmgrace program.  The results of this plot were fitted 
using the non-linear curve fitting algorithm in xmgrace with the parameters in Equation 2.iv 
and the a1 value was extracted.   88 
 
Equation 2.iv    y=a0*exp(-a1*x). 
 
The y value corresponds to I/I0 and the a1 value corresponds to either 1/T1 or 1/T2.  T1/T2 
was calculated for each data set and was inputted into a program called ‘tmest’ which 
estimates correlation time based on the approach by Kay et.al (242). 
 
2.6.6  Hydrodynamic modelling 
 
The Vt sequence for wild-type and mutants 892-1061 was submitted to the hydrodynamic 
modelling program HYDRONMR (240;244). The residues 878-891 and 1062-1066 were 
removed as they are expected to be flexible as judged by the crystal structure.  Structure 
files containing monomeric protein and dimeric protein found in the asymmetric unit were 
submitted.  The suite of HYDRO programs models behavior of macromolecules by 
producing a shell model that creates the surface of the protein by using small beads.  This 
‘bead model’ can be used to predict correlation times for a macromolecule in solution.  By 
submitting a structure file of a monomer and dimer, correlation times for monomeric and 
dimeric protein can be predicted and from this it is possible to estimate the proportion of 
dimer in solution using Equation 2.v. This estimation of proportion of dimer assumes that 
the dimer found in the crystal interface is also occurring in solution. 
 
Equation 2.v  1/τm = (∝D/τdim) + (∝M/τmon) 
τm = measured correlation time 
∝D = proportion of dimer 
∝M = proportion of monomer 
τdim = predicted dimer correlation time 
τmon = predicted monomer correlation time 
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2.6.7  Chemical shift perturbation 
 
Chemical shift perturbation experiments have been carried out at 600MHz and 900MHz. 
 
Table 2.6.2 Chemical shift perturbation experiments that have been carried out 
   Field  [NaCl]/mM  50mM Arg,  
   (MHz)    50mM Glu 
LD1 peptide  600  400  None 
  600  150  None 
   600  50  Yes 
LD2 peptide  600  400  None 
  600  150  None 
   600  50  Yes 
LD4 peptide  600  400  None 
  600  150  None 
   600  50  Yes 
Paxillin His-  900  150  None 
 LD1/LD2  900  50  Yes 
 
 
2.6.7.1 Wild-type Vt plus paxillin peptides LD1, LD2 and LD4 
2.6.7.1.1 Sample preparation 
 
The peptides used for the titrations were synthesised by Peptide Protein Research Ltd.  
These 13mer peptides represent the paxillin LD motifs LD1 residues 1-13, LD2 residues 
141-153 and LD4 residues 262-274 (human numbering).  His-LD1/LD2 was expressed and 
purified in the lab.  Figure 2.6.1 shows the LD peptides and the longer His-LD1/LD2 
construct used. 
 
LD1: MDDLDALLADLES MM: 1420.537 
LD2: NLSELDRLLLELN MM: 1541.746 
LD4: ATRELDELMASLS MM: 1435.598   90 
 
Figure 2.6.1 LD constructs used in this thesis 
 
Wild-type Vt was at 200µM in one of the following buffers: 20mM Tris pH7, 400mM 
NaCl; 20mM Tris pH7, 150mM NaCl; or 20mM Tris pH7, 50mM NaCl, 50mM arginine, 
50mM glutamate. 
 
To carry out the titration, two protein samples were required at the same concentration and 
volume.  One contained Vt at the desired concentration (solution A), the other contained 
both Vt and one LD peptide at a molar excess of 20x (solution B).  Solution B was used to 
titrate into solution A which ensures that the concentration of Vt does not change 
throughout the experiment. 
 
In order to overcome large pH changes on addition of excess peptide to Vt, Vt and peptide 
were prepared at a concentration that is double the final desired concentration.  For 
example, to prepare 1mL of Vt at 200µM, 500µl at 400µM would be made in the 
appropriate buffer.  To prepare 500µl of LD peptide at 2mM, a 4mM solution of LD 
peptide would be made in 250µl of the identical buffer and the pH adjusted to 7. 
 
The 250µl of LD peptide was added carefully to 250µl of Vt solution producing a 200µM 
protein solution containing 2mM LD peptide.  To the remaining 250µl Vt, the same volume 
of buffer was added to make a 500µl Vt solution at 200µM.  The pH of both solutions was   91 
adjusted so that they are identical (pH7).  5% deuterium oxide and 0.5µl of 2M sodium 
azide was added to both samples.  
 
2.6.7.1.2 Experimental procedure 
 
A titration plan was made prior to conducting the experiments. A 
1H-
15N-HSQC spectrum 
was run on the free Vt (solution A) and on the Vt plus 20x molar excess LD peptide 
(solution B).  The titration was performed by removing a calculated volume from solution 
A and then replacing it with the identical volume of solution B. To calculate the amount of 
solution B to add, a titration planner created by Dr. Stuart Findlow (University of 
Southampton) was used.  This calculates the volumes by using Equation 2.vi. 
 
Equation 2.vi 
 
 
δ   = volume changed (amount to remove and add back into sample) 
[Lf]   = final ligand concentration in sample 
[Li]   = initial ligand concentration in sample 
vol   = total sample volume 
[L]   = concentration of stock ligand  
 
 
Molar ratios of Vt:LD peptide chosen for titration were 0, 0.25, 0.5, 0.75, 1.0, 2.0, 5.0, 
10.0.  For each point in the titration series, a 
1H-
15N-HSQC spectrum was acquired with 32 
scans and 84 increments.  Before each titration point the spectrometer was reshimmed. 
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2.6.7.2 Wild-type Vt plus paxillin His-LD1/LD2 
2.6.7.2.1 Sample preparation 
 
Paxillin His-LD1/LD2 was stored as a freeze-dried solid at -20ºC.  It cannot be 
concentrated using spin concentrators, so it needs to be dissolved into solutions to a known 
final concentration. 
 
For titration at 900MHz, 1.2mL of 
15N-wild-type Vt was prepared at 200µM in 20mM Tris 
pH7, 50mM NaCl, 50mM arginine, 50mM glutamate.  600µl was taken for the start point 
of the titration and 10% deuterium oxide and 0.5µl of 2M sodium azide was added.  The pH 
was checked and adjusted to 7 as necessary. The remaining 600µl was used to dissolve 
14N-
His-LD1/LD2 that has been freeze dried in known quantities into glass vials.  Vt was added 
into the vials and the solid was dissolved carefully so that bubbles were not created in the 
Vt solution.  His-LD1/LD2 was dissolved into Vt at a molar excess of 6x.   
 
2.6.7.2.2 Experimental procedure 
 
A titration plan was made prior to conducting the experiments as shown in section 
2.6.7.1.2.  A 
1H-
15N-TROSY spectrum was run on the free Vt (solution A) and then on the 
Vt plus 6x molar excess paxillin His-LD1/LD2 (solution B).  The titration series and 
method was conducted for titration points 0, 0.25, 0.5, 1, 2 and 4x molar excess.  TROSY 
experiments were acquired with 16 scans, 128 increments. 
 
2.6.8  Hydrogen-deuterium exchange experiments 
 
Hydrogen-deuterium exchange experiments were carried out on 500µL volumes of wild-
type Vt alone, wild-type Vt plus a 10-fold excess of paxillin peptides LD1, LD2 and LD4, 
and with a 4-fold excess of paxillin His-LD1/LD2. All Vt samples were at 200µM, 20mM 
Tris pH7, 50mM NaCl, 50mM arginine, 50mM glutamate and Vt plus ligand samples were 
prepared as in section 2.6.7.1.1.   93 
 
A 
1H-
15N-HSQC spectrum was recorded of 200µM wild-type Vt at pH7 with 32 scans and 
84 increments.  The precise volume of the solution was measured and then the entire 
sample was freeze-dried for 16 hours.  The structure of Vt is intact after freeze-drying.  
Immediately prior to running the second 
1H-
15N-HSQC experiment, the identical volume of 
deuterium oxide was added to re-dissolve the freeze-dried Vt.  The pH was checked to 
ensure it complied with pH = pD – 0.41 (208).  The second 
1H-
15N-HSQC experiment was 
run and the time between adding deuterium oxide and starting the experiment was 
measured (this time needs to be minimised).  In these experiments the time was 13 minutes.  
A series of consecutive 
1H-
15N-HSQC spectra were collected for the next 24 hours and a 
final spectrum was recorded 50 hours post D2O addition.  Each spectrum is acquired in a 
period of 2 hours.  
 
This was repeated for all Vt plus ligand samples, and the time between re-dissolving in D2O 
and beginning the series of HSQC experiments was maintained at 13 minutes.    
 
2.7  GST Pulldown and GST Catch-up experiments 
2.7.1  GST-pulldown assay 
 
For the paxillin-GST-LD1/LD2 only control: 500µl of cell lysate from paxillin-GST-
LD1/LD2 was bound to 200µl of glutathione 4B fastflow resin by incubating for 1hour at 
room temperature.  The resin was then spun down at 5000rpm in a microfuge and the 
supernatant removed.  The resin was washed once with 20mM Tris pH7, 150mM NaCl and 
the resin was spun down and the wash removed.  The paxillin GST-LD1/LD2 construct was 
next eluted using 10mM glutathione and the elution fraction run on an SDS-PAGE gel to 
visualise the protein.  For the paxillin-GST-LD1/LD2 plus wild-type Vt: 500µl of cell 
lysate from paxillin-GST-LD1/LD2 was incubated together with 1mL of purified wild-type 
Vt at 1mg/mL for 1 hour.  The method was followed as above, and the interaction was 
visualised on an SDS-PAGE gel. For the GST control: Purified GST was bound to 
glutathione 4B fastflow resin and then washed to a UV baseline.  Purified Vt at 1mg/mL 
was loaded onto the resin containing the GST fusion protein and washed to a UV baseline.   94 
The resin was eluted using 20mM reduced glutathione and interactions observed on an 
SDS-PAGE gel. 
 
2.7.2  Catch-up comparative chromatographic retention assay 
2.7.2.1 Principles 
 
A method developed by Charbonnier et al. (268) has been used in this study, the Holdup 
(or Catch-up) Comparative Chromatographic Retention Assay.  This assay is based on the 
principles of reversible binding of fusion proteins to affinity resins, but is distinct from a 
GST-pulldown experiment as no washing steps are included. 
 
GST-pulldown experiments are based on the fact that GST-fusion proteins will bind 
reversibly to an affinity matrix.  When bound, the fusion protein can be used to ‘fish’ for 
interaction partners.  Any protein that elutes with the GST-fusion protein is considered to 
be an interaction partner.  A major problem with GST-pulldown experiments is that 
washing steps are employed between binding of the partners and observing the final 
complex. This means that the detection of an interaction is dependent on its ability to 
survive these washing steps. In other words, strong interactions will survive, but weaker 
more elusive interactions may not be observed due to the complex being washed away 
(268). 
 
In this assay, the results obtained are observing interactions at equilibrium, and can be used 
both as an interaction detection tool and also has a way of evaluating Kd.  The authors 
describe two versions of the assay, the hold-up and catch-up experiments.  The difference is 
that hold-up experiments use affinity resin with ligand pre-bound to the beads, the catch-up 
experiment pre-incubates both ligands together before binding.  In this thesis, the catch-up 
version has been utilised. 
 
The principle of the experiment is shown in Figure 2.7.1.  Ligand fusion protein is mixed 
with resin and analyte protein in two equal reactions.  A competitor molecule is added to   95 
one of the reactions and the liquid phases of both reactions are extracted.  Comparing the 
two extracts reveals the proportion of free and bound analyte at equilibrium. Selective 
disappearance of the analyte in the competitor-free reaction indicates an interaction. 
 
2.7.2.2 Method 
 
20mL expression grows were carried out of GST-LD1/2 and calexcitin. Purified Vt was 
used at 1-2mg/mL concentration in 20mM Tris, pH7, 300mM NaCl.  The cell pastes were 
thawed and resuspended in 2.5mL of 20mM Tris pH7, 100mM NaCl and sonicated on ice 
using a XL-2020 sonicator at power 3 with a microprobe for 12 x 5sec on, 30sec off.  Care 
was taken to ensure no heating or frothing occurred in the sample to allow efficient 
sonication and prevent damage to the proteins.  Fusion protein cell lysate were mixed 
together and left on ice with gentle agitation for 1 hour according to Table 2.7.1. 
 
Table 2.7.1 Incubation reactions 
Reaction  45µl  15µl 
1  GST  Pure Vt (1-2mg/mL) 
2  GST-LD1/2  Pure Vt (1-2mg/mL) 
3  GST-LD1/2  Calexcitin (control) 
4  GST-LD1/2  Tris Buffer (control) 
 
Meanwhile, glutathione beads are prepared.  For each reaction, two microfuge tubes need to 
be prepared, one labelled plus (+) and one labelled minus (–). This will give rise to 8 x 
1.5mL microfuge tubes.  Into each tube, glutathione 4B beads are aliquotted to make 15µl 
of bed volume.  The beads are washed with 1mL of 20mM Tris pH7, 100mM NaCl and 
spun down at 2000 rpm in a benchtop microcentrifuge for 10mins to remove the 
supernatant. This is repeated twice with 200µl buffer.  When the 15µl bed volume is 
achieved in each tube, 15µl of 20mM Tris pH7, 100mM NaCl is added to each bed volume. 
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When the incubation time is complete, each reaction is split in half into the appropriate 
tubes, adding 30µl of reaction to each.  Each microfuge tube is vortexed for 1 minute each.  
The vortex should be set at a speed so that the beads form a gentle ‘swirl’ in the reaction 
mixture.  Beads should not be allowed to jump up the side of the tubes else they will be 
lost.  This vortex procedure is repeated three times.  The samples are next left for 30 
minutes on ice with gentle agitation. 
 
Two buffers are required; the ‘minus’ buffer (-) containing 20mM Tris pH7, 100mM NaCl; 
and the ‘plus’ buffer (+) containing 20mM Tris pH7, 100mM NaCl, 20mM reduced 
glutathione.  To all tubes with the (+) condition, 30µl of the ‘plus buffer’ is added.  To all 
tubes with the (–) condition, 30µl of the ‘minus buffer’ is added.  The vortex procedure is 
repeated twice and the reactions are left for 30minutes. 
 
Next, glass wool filters are prepared.  Label 8 x 1.5mL microfuge tubes to match the 
reaction tubes.  For each tube, take a 0.5mL microfuge tube and pierce a hole in the tip 
using a syringe needle.  Stuff the small tube with glass wool to form a filter.  The 
corresponding reaction mixture and beads is added to the 0.5mL tubes containing the filter.  
The small tubes are capped and placed into the 1.5mL microfuge tubes.  These are then 
spun down at 2000 rpm for 5 minutes.  The liquid phase will be filtered into the microfuge 
tube and will contain the proteins of interest.  
 
An SDS-PAGE gel is run of all reactions, the (+) and (-) for each reaction is run adjacent to 
one another.  To load the gel, take 20µl of sample, add 20µl of reducing sample buffer and 
boil for 5 minutes.  Load 20µl into the wells, ensuring that no sample spills into the next 
wells.  Stain and destain. 
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Figure 2.7.1.  Principle of the Catch-up assay 
The ligand fusion protein is shown in cyan and yellow (L) and the binding partner or  
analyte is shown in red (A). L & A are pre-incubated and then batch mixed with affinity 
resin. Half of the reaction is mixed with a buffer containing a competitor molecule for 
elution, and half is mixed with buffer containing no competitor.  The liquid phase is 
extracted and the resin and any associated proteins are ‘caught up’ on the resin. Analysis 
of the liquid phase from both the competitor fraction and non-competitor fraction will give 
an indication of binding affinity. Figure adapted from (268). 
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2.8  Preparation of figures 
 
All molecular visulisation has been completed using the program MOLMOL (269) with the 
exception of Figure 1.3.9 which was created by Dr. Stuart Findlow (University of 
Southampton) using the program Pymol (DeLano Scientific).  NMR spectra were created 
using NMRview5 (265).  All images were manipulated using CorelDRAW12 before 
importing into Microsoft Word. 
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3  Results 
3.1  Expression, Purification and Characterisation of wild-type Vt 
 
Wild-type vinculin tail (residues 879-1066) has been expressed and purified for use in this 
study.  The construct was provided in the pET-15b construct and contains an N-terminal 
histidine tag.  The plasmid was a kind gift from Professor D. Critchley (University of 
Leicester) and the sequence can be found in Appendix 5.1.   
 
3.1.1  Expression and purification 
 
Wild-type vinculin tail (Vt) was over-expressed in both Luria Broth and M9 minimal media 
to produce an induction band well above the E.coli background (Figure 3.1.1).  The 
expression band for Vt runs higher than expected for its molecular weight of 21586.8. 
Expression in LB takes four hours from induction at 30ºC and typically yields 8mg/L.  
Expression levels of wild-type Vt in M9 minimal media is comparable, although the length 
of expression is extended to 16 hours at 30°C. 
 
 
Figure 3.1.1 Polyacrylamide SDS-Page gel showing induction of wild-type Vt using LB 
medium after induction with 1mM IPTG for 4 hours.   
Lane 1: molecular weight standard-multimark, with molecular weights of products 
alongside (in kDa); lane 2: pre induction sample; lane 3: 4 hour post induction.  Induction 
bands can be seen higher than expected for a protein of 21kDa.   100 
The purification of wild-type Vt has been adapted from Bakolitsa et.al. (172) (see Section 
2.2.7). The first stage of purification is a Nickel-NTA affinity column, a typical 
chromatogram is shown in Figure 3.1.2.  The 100% elution fraction (250mM imidazole) is 
pooled and the 280nm absorbance measurement is recorded which enables determination of 
the amount of thrombin to add for histidine tag removal.  The total amount of Vt in this 
elution pool is inaccurate due to the presence of 250mM imidazole which also absorbs at 
280nm, however this value is sufficient for determining the concentration of thrombin 
required.  
 
Thrombin is added at 1 unit per 1-2mg of protein, depending on the amount of thrombin 
required and the time that is available for cleavage.  The rate at which thrombin cleaves the 
histidine tag from Vt can vary; generally 1 unit of thrombin per mg of protein,  plus the 
addition of 5mM CaCl2,   will remove >99% of the tag after 21 hours at 35°C. It is 
necessary to test the extent of cleavage on SDS-PAGE gel prior to loading onto the next 
column. Vt is very robust as thrombin appears to only cleave Vt at the cleavage site, so 
leaving the reaction longer than required is not detrimental to the sample. 
 
 
Figure 3.1.2 Wild-type Vt Ni-NTA loading and elution profile.   
The blue trace is the absorbance at 280nm and is used to monitor the concentration of 
protein.  The green trace shows the percentage of imidazole being used to elute, the first 
elution is 18% and the second is 100%.   Fractions are shown in red along the x-axis.   101 
A typical chromatogram from the cation column is shown in Figure 3.1.3.  Vt elutes 
between 400-600mM NaCl and is greater than 95% pure after this step. 
 
 
Figure 3.1.3 Wild-type Vt SP Sepharose (cationic) elution profile. 
The blue trace is the absorbance at 280nm and is used to monitor the protein.  The green 
trace shows the percentage of 1M NaCl being used to elute, the gradient is run from 0-
100%.  The brown line is a measure of the conductivity of the elution fractions.  Fractions 
are shown in red along the x-axis. 
 
Figure 3.1.4 shows an SDS-PAGE gel of 
15N labelled wild-type Vt as it progresses through 
the purification.  The 
15N-labelled protein has very little impurities remaining after the Ni-
NTA step in contrast to the 
14N-labelled preparation.  After thrombin cleavage, the cation 
exchange step is utilised to remove the histidine tag and the thrombin from the sample, 
although this is never detectable on SDS-PAGE gels.  
 
After purification, Vt is concentrated to 1mg/mL directly from the cation column for 
storage at -20
oC.  Vt benefits from being concentrated close to the desired final 
concentration in the high NaCl elution buffer or in a buffer with 50mM arginine and 50mM   102 
glutamate as additives before dialysis into lower NaCl buffers.  Section 3.3.5 discusses the 
buffer choice for Vt.  
 
 
Figure 3.1.4 Polyacrylamide SDS-Page gel showing wild-type Vt at various stages of 
the purification. 
Lane 1: molecular weight standard-multimark, with molecular weights of products 
alongside (in kDa); lane 2: sonicated homogenate-the major band is His-Vt; lane 3: 
insoluble material post sonication; lane 4: Ni-NTA load, His-Vt is the major band; lane 5: 
Ni-NTA flow-through showing that His-Vt has bound to the affinity column; lane 6: pooled 
His-Vt from Ni-NTA column, pre thrombin cleavage; lane 7: Vt post thrombin 
cleaved/cation load; lane 8: final wild-type Vt at 1mg/mL. 
 
Analysis of the different methods of storage show that freezing at -20ºC does not appear 
detrimental to the sample.  Figure 3.1.5 shows the amide region of a one-dimensional 
proton spectrum for wild-type Vt that has been stored by different methods.  It was 
interesting to note that leaving Vt at 4ºC for four days in solution leads to a reduction in 
intensity of signal.  This was important to realise as it means some urgency is required 
when handling these samples in NMR solution studies.  Freezing at -20ºC was deemed an 
acceptable method of storage as the intensity and appearance of the spectrum was good, 
and freeze-drying also appears non-detrimental to the sample but was not chosen as the 
preferred method. 
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Figure 3.1.5. The amide region of a one-dimensional proton spectrum of Wt-Vt 
measured at 600MHz. 
A: Storage at 4ºC; B: After freezing at -20ºC; C: After freeze-drying and resuspension in 
water. Vt was at 200µM in 20mM Tris pH7, 400mM NaCl. 
 
3.1.2  Characterisation of wild-type Vt 
3.1.2.1 Mass spectrometry 
 
The mass spectrum of 
15N-labelled wild-type Vt shows that the molecular weight obtained 
from the purified protein matches that which is expected from the amino acid sequence and 
shows high incorporation of 
15N (Figure 3.1.6 and Table 3.1.1 ). 
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Figure 3.1.6 Electrospray ionization mass spectrometry (ESI MS) of 
15N wild-type Vt 
Major peak at 21866 corresponds to wild-type Vt, peaks at 21889 (+23) and 21910 (+21) 
are likely to be sodium adducts 
 
Table 3.1.1 Predicted molecular weight of 
14N and 
15N Wt-Vt and the measured 
molecular weight by mass spectrometry 
 
14N-Wt-Vt 
15N-Wt-Vt 
Predicted molecular weight
(a)  21586.8  21866.8 
Measured molecular weight  Not done  21866.0 
 
(a) predicted using protparam (270) 
 
3.1.2.2 Analytical size exclusion chromatography   
 
Initial studies using analytical size exclusion chromatography suggests that wild-type Vt 
exists as a monomer (Figure 3.1.7).  The molecular weight calculated from the column   105 
calibration appears smaller than expected, with 17kDa being calculated from an expected 
21kDa.  
 
 
Figure 3.1.7 Analytical gel filtration (superdex-75) of Wt-Vt.   
The blue trace is the protein absorbance at 280nm. Column was calibrated and run using 
50mM Na2HPO4, 150M NaCl.  100µl of 1mg/ml Vt was injected. 
 
3.1.2.3 Secondary structure by circular dichroism  
 
The crystal structure of wild-type Vt shows it to be highly α-helical with no other 
secondary structure (588). Far UV circular dichroism has been carried out to determine 
whether the purified Vt protein assumes an α-helical conformation. 
 
Wild-type Vt gives rise to a far UV spectrum characteristic of α-helical proteins, with CD 
minima at 208nm and at 223nm (Figure 3.1.8). Submission of this data to an online server 
that predicts secondary structure (SOMCD (212)) predicts that 98.7% of the secondary 
structure is α-helical, 0.6% is due to β-turn and 0.7% is due to random/other structural 
elements.  None is β-sheet.  This prediction is a little higher than expected, but is consistent 
with a high α-helical content. 
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Figure 3.1.8 Far UV circular dichroism spectrum of wild-type Vt at 0.5µM in water. 
 
3.1.2.4 
1H-
15N-HSQC spectrum 
 
A typical 
1H-
15N-HSQC is shown for wild-type vinculin tail in Figure 3.1.9.  The spectrum 
shows well dispersed NH resonances between ~6.8ppm-10.7ppm in the proton dimension 
which is indicative of a folded protein.  The wild-type Vt construct contains 192 residues.  
Since the four prolines do not give rise to a signal in an 
1H-
15N-HSQC spectrum and the 
first residue is not usually seen because it exchanges too quickly with the solvent,  187 NH 
resonances are expected to be seen from the backbone amides. In addition 3 peaks are 
expected from the indole NH of the tryptophan side chains.  Also expected are 18 
resonances arising from the NH2 groups of asparagines and glutamines. These are easily 
identified as they have two distinct proton shifts corresponding to the same nitrogen shift.  
Discounting the signals arising from NH2 groups, an initial peak count in the spectrum 
produces 180 peaks from an expected 190. The difference could be due to resonance 
degeneracy of some residues or to the fact that some residues are in intermediate exchange 
leading to undetectable, broad peaks.   
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At 600 MHz, the resonances at the centre of the spectrum are not well dispersed and there 
is some overlap with other peaks where there are two (or more) peaks with the same 
chemical shift that appear as one large peak in the spectrum.   
 
 
 
Figure 3.1.9 
1H-
15N-HSQC spectrum of 
15N wild-type Vt 
Vt concentration 200µM in 20mM Tris pH7, 300mM NaCl.  Spectrum acquired for 12hrs at 
600MHz, spactral  folding results  in the indole peaks appearing at the top of the spectrum. 
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3.1.2.5 Rotational correlation time  
 
Rotational correlation times of proteins can be extracted from 
15N relaxation measurements 
and can be related to the molecular weight of a protein.  The overall correlation time for 
wild-type Vt has been determined from averaged 
15N-relaxation times.   
 
Figure 3.1.10 shows the first block from a 2D-
15N relaxation experiment for both T1 and T2 
together with the integrated intensities.  Intensities were plotted for increasing relaxation 
delay times and used to determine T1 and T2 values.  From the data in Figure 3.1.10, values 
for T1 and T2 relaxation time constants were 1.054 and 0.062 respectively.  These were 
used to calculate an experimentally measured correlation time (τm) of Vt in 20mM Tris 
pH7, 400mM NaCl at 100µM of 13.0ns.  
 
As the crystal structure of Vt contains two molecules in the asymmetric unit, the monomer 
and dimer can be used to estimate the correlation time using a hydrodynamic bead model 
(244).  For Vt residues 892-1061 the correlation time for a monomer was estimated to be 
8.2ns and for a dimer it was estimated to be 20ns.  Assuming a simple monomer-dimer 
equilibrium one can estimate the mole fraction of molecules that are in a monomeric state 
and that are in a dimeric state.  The calculation predicts that wild-type Vt at 100µM is 63% 
dimer.  This result gives an indication that Vt may exist as an oligomer or that aggregation 
may be occurring in solution between Vt molecules.   
 
As previously mentioned in Section 1.3.3.1, there is a crystallographic dimer interface 
centered at residues isoleucine I997 and methionine M1022 which is located on the most 
hydrophobic part of the Vt molecule.  It is possible that this interface is having an effect in 
solution.  Similarly, there is a potential interaction between the N-and C-termini of Vt 
molecules which could also be affecting the oligomerisation state of Vt in solution.   109 
 
Figure 3.1.10 Results of 
15N relaxation experiments on wild-type Vt 
A: amide region of the first relaxation delay for T1=0.020ms, B: amide region of the first 
relaxation delay for T2=0.010ms.  The integration curve that was used is shown as a black 
line.  C and D: graph used to determine T1 and T2 values, black line represents actual data 
and red line represents the curve fit. 
 
3.1.2.6 Wild-type Vt summary 
 
Recombinant wild-type Vt has been successfully expressed and purified and can be labelled 
with 
15N.  Far-UV circular dichroism studies confirm that the protein is α-helical, as 
predicted from the crystal structure. Whilst gel filtration suggests that Vt exists as a 
monomer, measurement of the correlation time suggest that there could be transient higher 
order oligomers in solution.   110 
3.2  Mutagenesis of Vt 
 
Site directed mutagenesis is a technique used to introduce specific mutations in DNA 
molecules at predetermined positions.  There are several methods of site directed 
mutagenesis available, the method chosen for this project is the Quikchange method from 
Stratagene, and while strictly speaking is a non-PCR method, does use PCR–type 
denaturation and annealing steps to introduce mutations. 
 
The polymerase chain reaction (PCR) was originally developed by Kary Mullis and co-
workers (271). The PCR method of site directed mutagenesis uses PCR to insert and 
amplify specific mutations into a template DNA. There are commonly three steps to PCR; 
the denaturation step where the DNA template and mutagenic primers are melted so that 
they separate from each other, the annealing step where the primers bind to the template 
DNA, and the extension step where a DNA polymerase extends the primers to make a new 
strand of DNA.  This is repeated for 20-30 cycles to amplify the mutated DNA. 
  
3.2.1  QuikChange site directed mutagenesis 
 
Mutagenesis of Vt has been carried out using the ‘Quikchange’ method from Stratagene.  
This method allows site-specific mutations to be incorporated into double-stranded 
plasmids, which removes the need for subcloning into M13 based vectors and for single 
stranded DNA rescue (272).  It does not require specialised vectors, restriction sites or 
multiple transformations which makes it a rapid method for introducing point mutations.  It 
can also be used to delete or insert multiple amino acids. It is considered to be a ‘non-PCR’ 
method of SDM as the primers are designed to only amplify the parental strand and not the 
mutated strand, thus is not strictly true PCR  
 
The primers used in this method are complementary to opposite strands of the vector. A 
high fidelity DNA polymerase replicates both strands of the plasmid without displacing the 
mutant primers.  The primers are extended to produce a mutated plasmid.  After the PCR, 
DpnI endonuclease is used to digest methylated and hemimethylated parent DNA, thus   111 
selecting the unmethylated mutated plasmids.  Precise details of this can be found in section 
2.3.4. 
 
There are a few variations to the method as proposed in the Quikchange manual.  Pfu 
polymerase was used in the place of pfu turbo.  This polymerase has the same fidelity as pfu 
turbo but needs a longer extension time. Also, it was found that the mutated DNA could be 
transformed directly into E.coli BL21 (DE3) cells that had been made calcium competent, 
meaning that a transformation step into XL1-blue cells was not required. 
 
3.2.2  Rationale for mutations 
 
A number of Vt mutants have been created during this study, a list can be seen in Table 
3.2.1.  Single point mutants have been made in an attempt to improve the solution behavior 
of Vt by disrupting a putative self-association interface.  The double mutant was produced 
in the hope it would maximise this effect.  A Vt deletion mutant with the final 21 residues 
removed has also been produced that removes some of the second putative self-association 
interface. 
 
Table 3.2.1 Mutants created for use in this study 
Mutant name  Mutation  Vt residues
(a) 
Vt/I997S  Ile997 to Ser  879-1066 
Vt/M1022S  Met1022 to Ser  879-1066 
Vt/I997S/M1022S  Ile997 to Ser 
Met1022 to Ser 
879-1066 
Vt/∆C  C-terminus removed  879-1045 
 
(a) all constructs have an additional four residues,  GSHM,  at the beginning of the 
sequence from the thrombin cleavage site. 
 
The rationale for the point mutations comes from the crystal structure of Vt (172).  As 
stated previously (Section 1.3.3.1), the second half of helix four of Vt is the most   112 
hydrophobic region, and that residues within this region are involved in a crystallographic 
dimer interface.  The residues that this interface is centered around are residues I997 and 
M1022 (Figure 3.2.1).  The measured rotational correlation time for wild-type Vt suggests 
that wild-type Vt may exist in solution as an oligomer (Section 3.1.2.5), so by making this 
region less hydrophobic Vt monomer formation may be promoted.  This would in turn 
reduce the correlation time and improve signals obtained in NMR experiments.  Isoleucine 
997 and methionine 1022 have been mutated to serine residues to introduce a hydrophilic 
charged residue that should disrupt the proposed dimer interface.   
 
The Vt/∆C mutation is based on a similar mutant from Bakolitsa et al. (172). This mutation 
deletes the C-terminal hairpin which could be a second self-association site for Vt, but has 
been implicated in binding to acidic phospholipids.  It is designed to retain the 5 helix 
topology but lack self-association properties and acidic phospholipid binding propensity. 
 
 
Figure 3.2.1 Wild-type Vt face 3-4 and face 4-5 showing sites of the point mutations. 
The Vt crystal structure is coloured magenta, I997 is coloured cyan and M1022 is coloured 
yellow.   113 
3.2.3  Results of mutagenesis 
 
The first step in the mutagenesis method is a ‘PCR-style’ step where the mutagenic primers 
are annealed to the template DNA to create new DNA containing the desired mutation.  For 
single point mutations, wild-type double stranded miniprep DNA was used as the template, 
for double mutants the mutated Vt/I997S DNA was used as the template and the M1022S 
primer was used to insert the second mutation.  Figure 3.2.2 shows the mutagenic primers 
used.  
 
Vt/I997S For:   5’-CC  ATC  AGC  ACG  CAG  CTC  AAA  AGC  CTT  TCC  ACA 
GTG AAA GCT ACC-3’ 
 
Vt/I997S Rev:   5’-GGT AGC TTT CAC TGT GGA AAG GCT TTT GAG CTG 
CGT GCT GAT GG-3’ 
 
Vt/M1022S For:   5’-CA  GAA  CAG  GCA  ACT  GAG  AGC  TTG  GTT  CAT  AAC 
GCC CAG AAC C-3’ 
 
Vt/M1022S Rev:  5’-G GTT CTG GGC GTT ATG AAC CAA GCT CTC AGT TGC 
CTG TTC TG-3’ 
 
Vt/∆C For:   5’-G AGA GAA GCT GAA GCA GCA TCC TAG AAG ATA AGA 
ACA GAT GCC GG-3’ 
 
Vt/∆C Rev:   5’-CC  GGC  ATC  TGT  TCT  TAT  CTT  CTA  GGA  TGC  TGC 
TTC AGC TTC TCT C-3’ 
 
Figure 3.2.2 Mutagenic primers for wild-type Vt.  
Forward and reverse primers are designated ‘For’ and ‘Rev’ respectively. The mutated 
codons are shown in bold. 
 
After the PCR, an agarose gel was run to ensure that the DNA was amplified.  The results 
in Figure 3.2.3 show a clear single band that represents the amplified DNA.  At this point 
both mutant and template DNA will be present. 
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Figure 3.2.3 Ethidium bromide-stained 1% agarose gel showing the results of the PCR 
to make mutant Vt/I997S. 
Lane 1: wild-type Vt miniprep used as a marker; lane 2 & 3: PCR products of wild-type Vt 
plus I997S mutagenic primers. 
 
The template DNA was next digested by DpnI endonuclease and the mutated DNA is 
transformed into E.coli BL21 (DE3) cells.  These are grown on LB-agar plates with 
ampicillin for selection and then colonies are picked and the DNA extracted and sent for 
sequencing.  All mutants have been sequenced and are correct, and example of a 
sequencing reaction for Vt/I997S is shown in Figure 3.2.4. 
 
Figure 3.2.4 Segment of DNA sequencing profile received from MWG-biotech. 
Black box confirms incorporation of the AGC codon to make the Vt/I997S mutant. The 
coloured peaks correspond to the base and the wide green bar represents the good quality 
>30, which means the probability of a wrong base is greater than 1 in 1000. 
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3.3  Characterisation of Vt mutants 
 
All of the Vt mutants can be over-expressed in LB and M9 media (Figure 3.3.1). They have 
been purified using the same method for wild-type Vt, and all proteins behaved similarly to 
the wild-type throughout the purification. The exception was Vt/M1022S which behaved 
differently during the final concentration step where 65% of the material was lost.  This 
suggests that the Vt/M1022S mutation alters the properties more than the I997S mutation. 
 
 
 
Figure 3.3.1 Composite polyacrylamide SDS-PAGE gel showing expression of Wt Vt 
and mutants in LB.  
All cells were induced using 1mM IPTG and expression was at 30°C for 5 hours. Lane 1: 
molecular weight standard with molecular weights of products alongside (in kDa); lane 2: 
Wt Vt pre-induction; lane 3: Wt Vt post induction showing expression band; lane 4: 
Vt/I997S pre-induction; lane 5: Vt/I997S post induction; lane 6: Vt/M1022S pre-induction; 
lane 7: Vt/M1022S post induction; lane 8: Vt/I997S/M1022S pre-induction; lane 9: 
Vt/I997S/M1022S  post induction; lane 10: Vt/∆C pre induction; lane 11: Vt/∆C post 
induction. 
 
The calculated molecular weights for each Vt mutant are shown in Table 3.3.1. Mass 
spectra for the 
15N-labeled proteins reveal a high percentage of 
15N incorporation. The 
yields of wild-type Vt, Vt/I997S and Vt/I997S/M1022S are comparable, the Vt/M1022S 
mutant has a yield 50% less than wild-type Vt. By comparison, the Vt/∆C yield is low.   116 
 
Table 3.3.1 Average yields, calculated and measured molecular weights of 
15N labeled 
Vt constructs 
Construct  Yield mg/L  Calculated 
15N 
Molecular 
weight/Da
(a)  
Measured 
15N 
Molecular 
weight/Da
(b) 
Difference/Da 
Wt  8.0  21867  21866  1 
Vt/I997S  8.2  21841  21839  2 
Vt/M1022S  4.7  21823  21819  4 
Vt/I997S/M1022S  7.9  21797  21792  5 
Vt/∆C  2.1  19214  19210  4 
 
(a) Molecular weight calculated using the protparam tool (270). (b) measured by ESI-MS 
 
3.3.1  Analytical size exclusion chromatography  
 
Size exclusion chromatography was carried out on the mutants to judge whether the 
proteins were monomeric.  Figure 3.3.2 shows that Vt/I997S and Vt/M1022S elute as 
monomers in a volume that suggests a molecular weight lower than expected but not 
dissimilar to the wild-type protein. 
 
Figure 3.3.3 shows the elution profile for Vt/I997S/M1022S and Vt/∆C.  The absorbance 
trace at 280nm does not yield a single peak as expected.  On inspection of the SDS-PAGE 
gel, there is no protein present in the early peak at 8.1 and 8.2mL.  It is not clear what this 
is attributed to but is at the limit of the void volume for this column.  Vt/I997S/M1022S is 
present in the later peak and predicts a molecular weight of 20kDa which suggests a 
monomeric protein. The Vt/∆C SDS-PAGE gel shows that the peak at 22kDa corresponds 
to the mutant protein but there is degradation in the sample.  It suggests that the Vt/∆C is 
less stable at room temperature than the wild-type protein. 
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Figure 3.3.2 Analytical size exclusion chromatography (superdex-75) of Vt/I997S (top) 
and Vt/M1022S (bottom) 
The blue trace is the protein absorbance at 280nm. Column was calibrated and run using 
50mM Na2HPO4, 150M NaCl.  100µl of 1mg/ml Vt mutant was injected. 
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Figure 3.3.3 Analytical gel filtration (superdex-75) of Vt/I997S/M1022S and 
corresponding SDS-PAGE gel(top) and Vt/∆C and corresponding SDS-PAGE gel 
(bottom). 
The  blue  trace  is  the  protein  absorbance  at  280nm.  Polyacrylamide  gel  for 
Vt/I997S/M1022; lane1: molecular weight marker showing weights in kDa; lane 2: 8.1mL 
fraction;  lane  3:  12.3mL  fraction  showing  protein  of  interest.  Polyacrylamide  gel  for 
Vt/∆C; lane1: molecular weight marker showing weights in kDa; lane 2: 8.2mL fraction; 
lane 3: 11.7mL fraction showing protein of interest. Column was calibrated and run using 
50mM Na2HPO4, 150M NaCl.  100µl of 1mg/ml Vt mutant was injected.   119 
3.3.2  Secondary structure by circular dichroism  
 
Far UV circular dichroism spectroscopy has been used to determine whether the mutations 
introduced into wild-type Vt have altered the native secondary structure.   
 
While the CD minima for all mutants are similar suggesting a high content of α-helical 
structure, the magnitude of the CD signal is different between the mutants.  Some 
explanation for this could be down to slight differences in protein concentrations or due to 
variations in the lengths of the α-helices (211).  Visual inspection of the spectra suggest a 
high helical content and that this is supported by a more quantitative analysis using a CD 
prediction program (212). All spectra are similar to the wild-type Vt, which suggests that 
any structural differences are too subtle to be detected by CD measurements.  Vt/M1022S 
is the most different from the wild-type, this may be a reflection of the observed protein 
losses during concentration.  It may be that the helices are affected by this mutation more 
than the I997S mutation. The Vt/∆C spectrum shows that the C-terminal 21 residues are not 
required for the formation of Vt helices. 
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Figure 3.3.4 Far UV circular dichroism spectrum of all mutant Vt proteins compared 
to wild-type Vt 
All proteins at 0.5µM in water. The dark blue trace in all spectra is Wt-Vt, red is Vt/I997S, 
blue is Vt/M1022S, green is Vt/I997S/M1022S, magenta is Vt/∆C. 
 
3.3.3 
1H-
15N-HSQC spectrum of mutant Vt 
 
1H-
15N-HSQC spectra have been recorded for all mutants and can be seen in Figure 3.3.5-8.  
Globally, the spectra for the point mutants show good dispersion in the proton and nitrogen 
dimension which suggests that they are folded.  The Vt/∆C mutant shows evidence of   121 
degradation and the dispersion is poorer. All spectra were recorded using identical 
acquisition parameters and processed identically on a sample of 200µM protein 
concentration.  Overall the spectra for the point mutants are similar but there are subtle 
differences in many of the chemical shifts. 
 
The intensity of the Vt/I997S spectrum (Figure 3.3.5) is increased compared to the wild-
type Vt spectrum.  The Vt/I997S peaks appear more rounded and better dispersed in the 
central region.  An initial peak count produces 160 peaks suggesting that 20 are missing 
compared to the wild-type (the wild-type initial peak count produced 180 peaks).  This does 
not take into account peak degeneracy, there may be multiple peaks in the same place in the 
spectrum. 
 
The Vt/M1022S spectrum (Figure 3.3.6) also has well rounded peaks with a well dispersed 
central region, however it gives a markedly less intense spectrum than wild-type Vt. There 
are 176 peaks in this spectrum.  As stated previously, concentrating this mutant protein 
resulted in a loss of 65% of the material, the HSQC provides further evidence that the 
Vt/M1022S mutation is adversely affecting the solution properties of Vt. 
 
The double mutant, Vt/I997S/M1022S (Figure 3.3.7) spectrum has 175 well rounded peaks, 
but similarly to the Vt/M1022S single mutant, the spectrum is much weaker in intensity 
compared to wild-type Vt.  
 
The 
1H-
15N-HSQC spectrum for the Vt/∆C mutant in Figure 3.3.8 has been acquired for 2 
hours and shows a marked difference to wild-type Vt. The resonances in the proton 
dimension are less well dispersed and the quality of the spectrum looks lower than wild-
type Vt, as judged by the small sharp peaks in the region of 8.3-7.7ppm. The quality of the 
12 hour data was poor-there were many more sharp peaks in the 8.3-7.7ppm region and the 
peaks overlapped greatly.  It seems that the Vt/∆C mutant is unstable and degrades rapidly 
at 25ºC.  This would agree with observations in the size exclusion chromatography where 
the SDS-PAGE gel showed other bands apart from the desired protein (Figure 3.3.3).  
Comparing this data to the CD spectroscopy shows that while the C-terminal 21 residues   122 
are not required for formation of Vt helices, they do play a role in stability of the Vt 
structure over time. 
 
 
Figure 3.3.5 
1H-
15N-HSQC spectra of Vt/I997S 
Top: 
1H-
15N HSQC spectrum for Wt Vt (left) and Vt/I997S (right).  Bottom: Overlay of the 
two spectra, Wt Vt in black and V/I997S in red. All spectra acquired for 12 hours in 20mM 
Tris pH7, 400mM NaCl.   123 
 
 
Figure 3.3.6 
1H-
15N-HSQC spectra of Vt/M1022S 
Top: 
1H-
15N HSQC spectrum for Wt Vt (left) and Vt/M1022S (right).  Bottom: Overlay of 
the two spectra, Wt Vt in black and Vt/M1022S in blue. All spectra acquired for 12 hours in 
20mM Tris pH7, 400mM NaCl. 
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Figure 3.3.7 
1H-
15N-HSQC spectra of Vt/I997S/M1022S 
Top: 
1H-
15N HSQC spectrum for Wt Vt (left) and Vt/I997S/M1022S (right).  Bottom: 
Overlay of the two spectra, Wt Vt in black and Vt/I997S/M1022S in green. All spectra 
acquired for 12 hours in 20mM Tris pH7, 400mM NaCl. 
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Figure 3.3.8 
1H-
15N-HSQC spectra of Vt/∆C 
Top: 
1H-
15N HSQC spectrum for Wt Vt (left) and Vt/∆C (right).  Bottom: Overlay of the two 
spectra, Wt Vt in black and Vt/∆C in magenta.  
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3.3.4  Rotational correlation times for Vt mutants 
 
Rotational correlation times have been measured for Vt/I997S and Vt/M1022S to determine 
whether the mutations have promoted monomer formation.  Wild-type Vt had a τm of 
13.0ns and the hope was that the mutants would have a lower τm.  Figure 3.3.9 shows an 
example of the amide regions that were integrated and the data plots that were used to 
estimate the τm.  The fitted data gave T1 and T2 values of 1.465 and 0.090 respectively for 
Vt/I997S and 1.36 and 0.104 for Vt/M1022S. The calculated correlation times were 12.6ns 
for Vt/I997S and 11.3ns for Vt/M1022S.  The proportion of dimer in solution was 
estimated as described in Section 2.5.9.  The comparison with the wild-type protein can be 
seen in Table 3.3.2.  Both mutants have reduced the correlation time and the apparent 
percentage of dimer as judged by hydrodynamic modelling.  The reduction is not as marked 
as was expected, it may be that the rate at which this association is occurring has been 
affected which would account for the improved lineshapes in the HSQC spectra, but the 
association is still present.  It is also possible that both of the self association interfaces as 
shown in Figure 1.3.8 and Figure 1.3.9 are both occurring, and these point mutations are 
only reducing the self association of one of these interfaces. 
 
 
Table 3.3.2 Measured rotational correlation times for mutant proteins and proportion 
of dimer predicted in solution 
 
Vt mutant  Correlation time/ns  % dimer estimated 
Wt  13.0  63 
Vt/I997S  12.6  59 
Vt/M1022S  11.3  47 
Vt/I997S/M1022S  Not determined  Not determined 
Vt/∆C  Not determined  Not determined 
 
   127 
 
Figure 3.3.9 Results of 
15N relaxation experiments on Vt/I997S and Vt/M1022S 
Left: amide region of the first relaxation delay, for T1=0.020ms, for T2=0.010ms.  The 
integration curve that was used is shown as a black line.  Right: graph used to determine 
T1 and T2 values, black line represents actual data and red line represents the curve fit.   128 
3.3.5  Wild-type Vt and Vt/I997S buffer choice 
 
The inherent low sensitivity of NMR experiments generally requires high protein 
concentrations typically in the order of hundreds of µM.  The signal to noise of NMR 
experiments is also degraded by high sample conductivity, for example brought about by 
the addition of salt to the sample, an issue that is particularly significant when using 
cryogenic probes.  
 
Attempts to concentrate both wild-type Vt and Vt/I997S to above 500µM resulted in 
precipitation of the protein in buffers containing 20mM Tris pH7 with 400mM NaCl.  If the 
salt concentration is lowered to 150mM NaCl this precipitation seems to occur at lower 
concentrations, although this has not been measured quantitatively.  An additional 
observation is that Vt/I997S at 500µM suffers from degradation over 2-3 days which causes 
problems in data collection for assignments as the experiments typically last for several 
days. 
 
It was therefore necessary to optimise the buffer conditions to balance the salt 
concentration, protein concentration and stability.  The solubility and stability of Vt in 
400mM NaCl is better than in 150mM NaCl, yet 150mM NaCl is better for NMR studies 
and closer to physiological conditions.  50mM NaCl ultimately produced the best chemical 
shift perturbation data (see Section 3.6.3).   
 
In order to achieve this reduction in salt without compromising on stability and solubility, 
50mM arginine and 50mM glutamate was added to buffer solutions.  Adding these amino 
acids to a 50mM NaCl buffer maintains the ionic strength to that of a 150mM NaCl 
solution, yet the mobility of these ions are reduced compared to NaCl.  Since signal-to-
noise (S/N) in an NMR experiment is determined in part by ionic strength and ion mobility, 
the reduction in mobility produces a better S/N for a given experiment without 
compromising on ionic strength.  Therefore Vt is still as stable as in a buffer containing 
150mM NaCl, but produces a better NMR spectrum.  Adding 50mM arginine and 50mM 
glutamate to buffers has also been shown to protect proteins against degradation thus aid in   129 
long term stability, both beneficial for NMR.  This is why they were also added to 150mM 
NaCl containing buffers.  Fortunately, the amino acids do not adversely affect any protein-
protein or protein-nucleic acid interactions (273). 
 
When Vt is dialysed into 20mM Tris pH7, 150mM NaCl, 50mM arginine, 50mM glutamate 
it can be concentrated to a higher concentration than without (800µM has been achieved 
without significant aggregation). Qualitatively, the 50mM arginine/50mM glutamate buffer 
is preserving the protein for longer at high Vt concentrations, as judged by 
1H-
15N-HSQC 
spectra, but ultimately does not prevent degradation of the spectral quality.  At Vt 
concentrations of 200µM in 150mM NaCl this buffer is not always necessary as the 
spectral quality is consistent over the time course of the experiments.  Experiments carried 
out at 50mM NaCl also contained 50mM arginine and 50mM glutamate to ensure that Vt is 
stable. 
 
3.3.6  Choice of mutant and isotopic labelling of Vt/I997S 
 
To enable further studies on Vt it was necessary to assign the 
1H-
15N-HSQC spectrum.  
There were concerns that the wild-type Vt spectrum was not of sufficient quality to produce 
useful data to achieve full assignment.  Consequently, Vt/I997S was chosen to use for 
assignment purposes on the basis that the protein yield is the same as for the wild-type 
protein yet the resonances in the 
1H-
15N-HSQC spectrum are sharper and more resolved. 
 
Assignment of the Vt/I997S 
1H-
15N-HSQC spectrum is described in Chapter 3.4.  Vt/I997S 
has been isotopically labelled with 
15N, 
13C and deuterium.  Initially, deuterium labelling 
was carried out with the aim of 60-70% incorporation; however, only perdeuteration 
improved the acquired NMR data sufficiently to obtain good quality spectra for backbone 
assignment.  Mass spectrometry of the perdeuterated protein shows that incorporation of 
deuterium into Vt/I997S was efficient, with greater than 99% incorporation (Figure 3.3.10). 
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Figure 3.3.10 ESI-Mass spectrometry results for perdeuterated Vt/I997S 
Measured mass is 23879, expected results 23911.7.  This suggests deuterium incorporation 
is greater than 99%.   131 
 
3.4  Sequential Resonance Assignment of the Vt/I997S backbone  
 
For any detailed studies on proteins using NMR, it is necessary to identify the chemical 
shift of nuclei along the backbone which will then act as an ‘atomic signature’ that 
identifies each site in the protein (274).  Assignment of the Vt/I997S backbone has been 
carried out so that chemical shift perturbation experiments can be interpreted.  To date there 
is no published backbone resonance assignments for wild-type Vt or the mutant Vt/I997S. 
 
The Vt/I997S protein used in this study has a molecular weight of 21587 Da and contains 
192 amino acids.  Backbone assignment using state-of-the-art NMR technology should be 
feasible for a protein of this size.  However, for several reasons Vt assignment has been a 
challenge and has required the use of 
15N, 
13C and 
2H labelling together with TROSY 
spectroscopy at high fields. Lack of solubility, the need for high ionic strength buffers and 
limited chemical shift dispersion due to the α-helical nature of Vt have caused problems 
with quality of data collected, and the degenerate amino acid sequence has made it difficult 
to identify where in the sequence a series of connected resonances should lie.  
 
As previously stated in Section 3.3.6, the Vt/I997S protein has been used for assignment 
purposes as the quality of the 
1H-
15N-HSQC spectrum shows improved dispersion and 
lineshapes compared to the wild-type protein. Several approaches have been taken to 
enable assignment.  Heteronuclear triple resonance experiments on partially and fully 
deuterated protein, as well as 
15N-edited NOESY experiments were used with optional 
relaxation optimisation using TROSY spectroscopy.  Additionally, amino acid selective 
labeling and unlabelling have all been employed.  A list of experiments can be found in 
Chapter 2.6.4.1.  
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3.4.1  Assigned Vt/I997S 
1H-
15N-TROSY spectrum 
 
The NH resonance assignments determined to date are shown in Figure 3.4.1 and Figure 
3.4.2.  Of the 192 residues in Vt/I997S, four are proline residues which will not be present 
in a 
1H-
15N-HSQC spectrum so cannot be assigned.  This leaves 188 potential backbone 
NH resonances that are available for assignment. Of these, 147 backbone resonances have 
been assigned (78%).  Within helices the proportion of assigned residues is higher (Table 
3.4.1) and overall 88% of the α-helical regions are assigned.  The crystal structure of wild-
type Vt is shown in Figure 3.4.3 with the Vt/I997S assignments mapped onto it to show the 
distribution of assignments.  Of the 147 backbone NH resonances assigned, all of the 
corresponding Cα shifts have been assigned, and for residues other than glycine, there are 9 
residues that have no Cβ shift assigned to them, many of which are serine and threonine 
residues.  There are also 109 initial CO assignments.  An assignment table can be seen in 
Appendix 5.5. 
 
 
Table 3.4.1 Proportion of assigned residues in the helical regions of Vt/I997S 
 
Helix 
number 
Number of 
assigned residues 
Number of 
residues in helix 
Percentage 
assigned 
1  12  15  80 
2  18  18  100 
3  28  28  100 
  4
(a)  21  27  78 
5  27  32  84 
 
(a) In helix four there is one proline residue that cannot be assigned 
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Figure 3.4.1 
1H-
15N-TROSY spectrum of 
15N, 
13C, 
2H uniformly labelled Vt/I997S 
showing assigned NH resonances. 
Spectrum acquired at 800MHz.  Vt/I997S was at 500µM, perdeuterated, 
15N and 
13C 
labelled in 20mM Tris pH7, 150mM NaCl, 50mM arginine, 50mM glutamate. Full 
spectrum showing the assignments.  Resonances  marked with ‘*’ are degenerate. The 
resonance labelled R987 (marked with †) corresponds to one residue in Vt/I997S but may 
correspond to two residues in wild type protein, and ‡ is a resonance that is only seen at 
low contour levels. . The assignment of the central region between 8.8-7.4 ppm and 116-
124ppm in the proton and nitrogen dimension respectively are shown in Figure 3.4.2.  
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Figure 3.4.2 Expansion of central region of the 
1H-
15N-TROSY spectrum of 
15N, 
13C, 
2H uniformly labelled Vt/I997S showing assigned NH resonances. 
Spectrum  acquired  at  800MHz.    Vt/I997S  was  at  500µM,  perdeuterated, 
15N  and 
13C 
labelled in 20mM Tris pH7, 150mM NaCl, 50mM arginine, 50mM glutamate. Close up of 
the central region showing assignments.  Residues marked with ‘*’ are degenerate. R987 
(marked with †) is one residue in Vt/I997S but may be two residues in wild type protein. 
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Figure 3.4.3 Assigned residues from Vt/I997S mapped onto the crystal structure of 
Wild-type Vt. 
Grey residues are unassigned, magenta residues are assigned in the Vt/I997S spectrum. 
 
3.4.2  Assignment strategy 
 
The assignment of Vt/I997S has been approached from a variety of angles.  Triple 
resonance experiments that correlate 
1H
N, 
15N, 
13Cα and 
13Cβ have been used to provide 
sequential connectivities between amino acids.  The HNCA, HNCACB, HN(CO)CA and 
HN(CO)CACB experiments have been conducted on partial and fully deuterated Vt/I997S. 
The data gathered from triple resonance experiments alone was not sufficient to complete 
the assignment.  Therefore, in addition to the triple resonance experiments, 
15N-edited 
NOESY-HSQC and the equivalent TROSY experiment have been carried out to exploit the 
NOEs that arise between the amide groups of amino acids in an α-helix.  Finally, in order to 
enable the identification of stretches of connected spin systems within the Vt/I997S 
sequence, amino acid selective labelling and unlabelling was conducted.   
 
3.4.3  Triple resonance experiments 
 
Several sets of triple resonance experiments have been recorded on 
15N, 
13C , 60-70% 
2H 
Vt/I997S as well as on 
15N, 
13C, 99% 
2H Vt/I997S.  Using 
1H-
15N-TROSY versions of 
these experiments has improved the signal-to-noise of the acquired data.    136 
 
The primary triple resonance experiments that have been used to assign the backbone are 
TROSY-HNCACB and TROSY-HN(CO)CACB on 
15N, 
13C, 99% 
2H Vt/I997S, measured 
at 800MHz with a cryoprobe.  Figure 3.4.4 shows sequentially assigned 
1H-
13C sections at 
defined 
15N resonances from the TROSY-HNCACB spectrum.  These represent the best 
quality data recorded of Vt/I997S.  There are clear carbon resonances from both the α and β 
carbons for the amino acid at position i and for the preceding amino acid at position i-1. 
 
Figure 3.4.4 
1H-
13C sections at defined 
15N resonances from TROSY-HNCACB 
spectrum recorded at 800MHz with a cryoprobe.  
Vt/I997S was at 500µM in 20mM Tris pH7, 150mM NaCl, 50mM arginine, 50mM 
glutamate.  In this spectrum Cα resonances are shown in black and Cβ resonances in red 
because their signals are 180º out of phase leading to positive and negative intensities.  
Sequential connectivities are shown as black lines and corresponding assignments shown 
across the top. 
 
However, for the majority of carbon resonances, both the HNCACB and the 
HN(CO)CACB were required to confirm the presence of the resonances to the preceding 
amino acid.  Figure 3.4.5 shows 
1H-
13C sections taken from the TROSY- HNCACB and the   137 
TROSY- HN(CO)CACB and illustrates that for many sections, the i-1 peak was not visible 
in the HNCACB, and was connected using the HN(CO)CACB, for example the sections 
containing A1041, E1042 and I1046 are missing the i-1 information in the HNCACB. 
 
 
Figure 3.4.5 
1H-
13C sections at defined 
15N resonances from a TROSY-HNCACB 
spectrum (left) and TROSY-HN(CO)CACB spectrum (right) recorded at 800MHz 
with a cryoprobe. 
Vt/I997S was at 500µM in 20mM Tris pH7, 150mM NaCl, 50mM arginine, 50mM 
glutamate.  In this spectrum Cα resonances are shown in black and Cβ resonances in red 
because their signals are 180º out of phase leading to positive and negative intensities.  
Sequential connectivities are shown as black lines and corresponding assignments shown 
across the top. The strips on the right were required to determine the connectivities, the 
circles represent resonances missing in the TROSY-HNCACB spectrum. 
 
Whilst these two triple resonance experiments were successfully used in most cases, 
sometimes it was necessary to refer to an HNCA to verify either the presence of a Cα 
resonance of the preceding amino acid (i-1) or to decide which of the two Cα resonances 
had the strongest intensity (to decide which resonance corresponded to the Cα residue itself   138 
(i)).  The HNCA experiment used has a TROSY sequence element applied and was carried 
out on 
15N, 
13C , 60-70% 
2H Vt/I997S at 800MHz without a cryoprobe.  The HNCA has 
improved sensitivity compared to the HNCACB due to the magnetisation transfer only 
having to go as far as the Cα atoms.  Figure 3.4.6 is a good example of how it has been 
used to complement the other experiments.  The 
1H-
13C section for M933 from the 
TROSY-HNCACB spectrum shows a very weak peak at 58.6ppm that could be a Cα i-1 
peak, and this can be verified by inspecting the same section at 58.6ppm in the TROSY-
HNCA.  S934 had two Cα resonances at 60.3ppm and 61.7ppm but it was unclear which 
was the Cα i and which was the Cα i-1.  The HNCA confirms that the resonance at 
61.7ppm which is of lesser intensity in the HNCACB corresponds to the Cα i. 
 
 
 
Figure 3.4.6 
1H-
13C sections at defined 
15N resonances from a TROSY-HNCACB 
spectrum (left) and a TROSY-HNCA spectrum (right). 
Vt/I997S was at 500µM in 20mM Tris pH7, 150mM NaCl, 50mM arginine, 50mM 
glutamate.  In this spectrum Cα resonances are shown in black and Cβ resonances in red 
because their signals are 180º out of phase leading to positive and negative intensities.     139 
 
3.4.4 
1H-
15N NOESY-HSQC experiments 
 
The triple resonance experiments alone were not sufficient to assign the backbone. The 
most significant problem was that the number of spin systems that were linked together 
representing a stretch of amino acids was insufficient and the chemical shifts not diverse 
enough to unambiguously place them in the sequence.  In order to overcome this, the α-
helical nature of Vt was exploited.  In an α-helix the 
1H
N-
1H
N distance (dNN) is such that 
sequential NOEs can be detected between the amides of neighboring amino acids (215).  
The data collected on Vt/I997S only enables NOEs between residues i, i-1 and i+1 to be 
detected with certainty, NOEs to i+2 have occasionally been detected and are probably due 
to spin diffusion effects. 
 
Initially a 
1H-
15N-NOESY-HSQC spectrum was acquired at 600MHz on 
15N, 
13C , 
1H 
Vt/I997S, connectivities were improved by acquiring at 800MHz.  A 
1H-
15N-TROSY-
NOESY was run 
15N, 
13C , 99% 
2H Vt/I997S at 900MHz to visualise only the NH and to 
see transfer to more distant amino acids in the helix, only in some cases was an NOE to an 
amino acid 2 residues away seen.  A 
1H-
15N-TOCSY-HSQC to complement the above did 
not produce sufficient data to use in the assignment. 
 
For the majority of the assignments, the connections were first formed using the 
15N-edited 
NOESY experiments and were then confirmed by inspecting the connections in the 
HNCACB and HN(CO)CACB.  Figure 3.4.7 shows an example of this.  The NOESY is 
shown at the top where the connections through the helices have been made, and the 
corresponding strips from the TROSY-HNCACB and TROSY-HN(CO)CACB are shown 
below with the connectivities confirmed. 
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Figure 3.4.7 
1H-
13C sections at defined 
15N resonances from a 
1H-
15N-NOESY-HSQC 
spectrum (top) showing NH connectivities through the helices.  Bottom: TROSY-
HNCACB & TROSY-HN(CO)CACB confirming the connectivities. All spectra 
recorded at 800MHz 
Vt/I997S at 500µM in 20mM Tris pH7, 150mM NaCl, 50mM arginine, 50mM glutamate. 
Sequential connectivities are shown as black lines and corresponding assignments shown. 
Top: the 
1H-
15N-NOESY-HSQC was carried out on 
15N, 
13C , 
1H Vt/I997S, black peaks 
correspond to intra- and inter-residual NOEs between protons.  Bottom: the triple 
resonance spectra are from 
15N, 
13C, 99%
2H Vt/I997S.  In this spectrum Cα resonances are 
shown in black and Cβ resonances in red. 
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Once stretches of sequential resonances were determined, the amino acid specific 
information contained in the Cα and Cβ shifts should enable them to be placed into the Vt 
sequence.  However, the Vt sequence was found to be degenerate and most assigned 
stretches could not be placed.  Therefore it was necessary to find some ‘anchor residues,’-
residues whose identity could be determined so that connected resonances could be placed 
with confidence.  This was facilitated by amino-acid selective labelling techniques. 
 
3.4.5  Amino acid selective labelling and unlabelling  
 
Amino acid selective 
15N labeling has been carried out on Vt/I997S for the amino acids 
lysine, valine, isoleucine and leucine, and selective ‘unlabelling’ of arginines has been 
completed (Section 2.2.3 and 2.2.4).  
 
Selective labeling of lysine produced a 
1H-
15N-HSQC spectrum showing 14 NH resonances 
from an expected 16.  Figure 3.4.8 shows this spectrum and an overlay showing which 
resonances are lysines.  There are no chemical shift differences between the position of the 
peaks in the 
15N-labelled and the lysine labelled spectrum but resonance degeneracy has 
been exposed where a green resonance can be seen slightly to one side of a larger black 
resonance corresponding to a degenerate peak that contains resonances from at least two 
amino acids. 
 
The remaining two lysine residues were believed to be missing from the spectrum, but on 
closer inspection, two potential lysine residues can be identified at very low contour levels 
in the 
1H-
15N-HSQC spectrum.  The position on these are at 6.9ppm, 118.5ppm and 
8.9ppm, 128ppm in the proton and nitrogen dimension respectively (Figure 3.4.10 and 
Figure 3.4.8).  There are 11 residues that have been assigned as lysines from the data, the 
remaining five resonances must arise from unassigned residues K881, K911, K975, K1035 
and K1047.   
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Figure 3.4.8 1H-15N-HSQC spectrum of Vt/I997S selectively labelled with 15N 
labelled lysine. 
Left: recorded NH resonances shown in green with subsequent assignments shown. Black 
circles represent the two potential lysines that can be observed at low contour levels.  
Right: overlay of fully labelled 
15N Vt/I997S (black) and 
15N labelled lysine (green).  
Spectra acquired at 600MHz on 200µM Vt/I997S in 20mM Tris pH7, 300mM NaCl. 
 
Selective unlabelling of arginine residues was also carried out.  In this experiment, 
14N 
arginine is added in excess to an expression grow containing 
15N-labeled ammonium 
chloride.  Resonances that originate from arginine will be missing from the 
1H-
15N-HSQC 
spectrum.  From 15 expected missing peaks, 13 are clearly missing from the spectrum. 
Figure 3.4.9 shows the results of the selective unlabelling of arginines.  Of the 13 
resonances identified as arginines, 11 are assigned and two are unknown.  This leaves two 
resonances missing from the spectrum.  One of these, R903 did not initially appear due to 
the fact it was overlapped with another residue (E1014) so was not clearly identified.  This 
was assigned independently of the selective labelling.  The remaining peak cannot be 
found, the reason for this is unknown.  R910, R976 and R1039 remain unassigned  
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Figure 3.4.9 Overlay of 
1H-
15N-HSQC spectra for Vt/I997S selectively unlabelled with 
arginine. 
Black is the fully 
15N-labelled protein, red is the same protein with arginines selectively 
unlabeled. Missing arginine resonances are represented as black peaks where there is no 
red peak on top of it. Spectra acquired at 600MHz on 200µM Vt/I997S in 20mM Tris pH7, 
300mM NaCl. 
 
As a consequence of these two experiments, the amino acid type of the resonances coming 
from 14 arginines and 14 (possibly 16) lysines is determined.  This information was vital to 
facilitate the triple resonance based assignments as they helped to overcome uncertainty 
when attempting to place sequentially connected resonances into the Vt/I997S sequence.  
Without this information, the assignment of the Vt/I997S 
1H-
15N-HSQC spectrum would 
not have been possible. 
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Figure 3.4.10 shows all of the lysine and arginine resonances that have now been assigned.  
There are three arginine resonances and five lysine resonances that remain unassigned. 
 
 
Figure 3.4.10 
1H-
15N-TROSY spectrum of Vt/I997S showing assigned lysine (green) 
and arginine (red) NH resonances.  Spectrum acquired at 800MHz 
Lysines found at low contour levels are shown in pale green and unassigned arginines are 
shown in orange.  Pink denotes R903 that was not identified by selective unlabelling 
experiments. 
 
Unlike the lysine selective labelling experiments, selective labelling of valine, leucine and 
isoleucine did not produce a discrete set of peaks corresponding to the expected number of 
amino acids.  Figure 3.4.11 shows the results of the valine selective labelling experiment. In 
this spectrum, 110 peaks can be identified at differing intensities (at the contour level   145 
shown in Figure 3.4.11 there are 60).  There are 9 valine residues in Vt/I997S so there are 
many more resonances in the spectrum than expected.   
 
 
Figure 3.4.11 
1H-
15N-HSQC spectrum of Vt/I997S selectively labelled with 
15N labelled 
valine. 
 
The relative intensity of all resonances in the valine, isoleucine and leucine spectra were 
compared to fully 
15N-labelled protein and a plot was made to see if a set of intense peaks 
could be identified that would correspond to the expected amino acids (Figure 3.4.13).  
While there are some resonances that are much more intense than others, this data was not 
used for the purpose of assignment for fear of it being misleading. 
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In retrospect, this information has been checked to see whether it corresponds to the 
assignments that have now been completed.  Valine and isoleucine resonances that had a 
relative intensity (relative to the 
15N fully labeled sample) greater than 1.5 and leucine 
resonances greater than 1 and 0.5 were picked and cross checked to see whether these 
corresponded to the appropriate residue. 
 
Eleven resonances for valine met the above criteria (Figure 3.4.12).  Of these, six had been 
identified as valines in the assignment.  Four were unassigned and one was assigned as 
I991.  This isoleucine also met the criteria in the isoleucine experiments. 
 
 
Figure 3.4.12 
1H-
15N-HSQC spectrum of Vt/I997S selectively labelled with 
15N labelled 
valine showing eleven residues with the greatest relative intensity 
Blue peaks are all of the resonances that appeared in the spectrum, the most intense are 
marked with a circle. * represent unassigned resonances.   147 
 
While this data was not specific enough to aid in the assignment, it was used to verify the 
assignments of the valine residues in Vt/I997S.  The isoleucine resonances also 
corresponded with many of the already assigned amino acids, although there were more 
resonances picked that were not isoleucine compared to the valine experiment.  Many of 
these wrongly picked residues have been assigned as leucines.  The leucine selective 
labelling was the least specific with many picked peaks coming from isoleucine and in 
some cases alanine.  There were many peaks that did however correspond with assigned 
leucines. 
 
It appears that isotope scrambling has occurred between valine, isoleucine and leucine.  
This is likely due to the action of transaminases (275).  Future experiments of this sort 
might benefit from shorter induction times and addition of transaminase inhibitors such as 
α-aminooxyacetic acid (276) or β-chloro-L-alanine (277). 
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Figure 3.4.13 Relative intensity of resonances originating from valine (green), leucine (blue) and isoleucine (red) selective 
labelling experiments 
Upper limits were set at relative intensity >1.5 for valine and isoleucine, >1 and >0.5 for leucine.  149 
3.4.6  Secondary structure of Vt/I997S 
 
The secondary 
13C chemical shift values for Vt/I997S in solution have been used to 
investigate the secondary structure of the mutant.   Figure 3.4.14 shows the chemical shift 
deviation from random coil for the assigned Cα and Cβ resonances.  Helical elements of the 
wild-type Vt protein from the crystal structure have been indicated as a comparison.  
 
Circular dichroism has already been used to show the α-helical nature on Vt/I997S (Section 
3.3.2), chemical shift deviations should give information on the helical nature of individual 
residues.  Globally, the Cα chemical shift deviations suggest that there are 5 helices in 
Vt/I997S and these correlate with the helical regions found in the wild-type structure.  Gaps 
in the data are due to missing assignments.  The Cβ data is less informative, the helical 
regions from the wild-type correspond with the Cβ chemical shift deviations for Vt/I997S, 
yet there are not clear breaks in the helices as for the Cα data. 
 
As there appear to be some subtle differences between Vt/I997S and the wild-type, the 
secondary chemical shift data was used to predict the backbone φ− (phi) and  ϕ− (psi) 
torsion angles using TALOS (Torsion Angle Likelihood Obtained from Shifts and sequence 
similarity) (267).  These predictions were then compared to the known crystal data for the 
wild-type protein (for methods see Section 2.6.4.3).  For most of the Vt/I997S residues, the 
TALOS-predicted dihedral angles were close to that of the crystal structure.  Some of the 
predictions from the Vt/I997S data were ambiguous in the fact that they did not all fall in 
the same regions in the Ramachandran plot, and some were also different from the crystal 
structure.  These regions have been represented in Figure 3.4.15 in yellow.  There were also 
some regions where the helicity seemed to extend past that of the expected crystal data, 
these have been represented in red.  One of these residues R987 is a residue whose NH 
resonance appears as one in the Vt/I997S 
1H-
15N-HSQC spectrum but as two in the wild-
type spectrum.  Further evaluation of the significance of these differences between wild-
type and Vt/I997S will require relaxation data and residual dipolar couplings to be 
measured to obtain dynamic and structural data. 
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Figure 3.4.14 Chemical shift deviations for assigned residues in Vt/I997S 
Black: Vt/I997S Cα chemical shift deviations from random coil peptides in urea. Red: 
Vt/I997S Cβ chemical shift deviations.  Helical regions from the crystal structure of wild-
type Vt are shown as blue lines. 
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Figure 3.4.15 Regions in Vt where the φ φ φ φ- and ϕ− ϕ− ϕ− ϕ− angles differ between the measured 
crystal structure and predicted torsion angles in solution  
Red regions are where the helicity extends past what is expected from the crystal structure; 
yellow regions are where predictions are not good and/or differ from the crystal structure. 
 
The region around the I997S mutation gives predictions in the α-helical region and are all 
similar to the isoleucine in the crystal structure, and the predictions for residues that have 
been implicated in a crystallographic dimer interface between asymmetric units (Figure 
1.3.8 and Figure 1.3.9) all agree with the crystal structure.  The only unassigned residue in 
this region is V1001.   
3.4.7  Exchange effects on Vt/I997S 
 
Several residues in Vt/I997S are exchanging on an NMR timescale in the 
1H-
15N-HSQC 
spectrum.  These were identified with the help of Dr. Stuart Findlow, and were identified as 
different NH chemical shifts possessing identical 
13C chemical shift patterns. 
 
Three of these residues include D1051, A1052 and G1053.  On inspection of the crystal 
structure of wild-type Vt (172) these residues are involved in the self-association crystal 
interface between the N-and C-terminus of two Vt molecules, distinct from the   152 
hydrophobic interface centred around I997 and M1022.  This occurs within the asymmetric 
unit between the C-terminus of one Vt molecule and the N-terminus and helix 2 in another 
(Figure 3.4.16).  D1052 can make a salt bridge to R935, and it can also hydrogen bond to 
G1053 (Figure 3.4.17).  It is possible that this interface between two Vt molecules could 
occur in solution and would create an equilibrium between Vt dimers and monomers.   
 
 
 
Figure 3.4.16 Two wild-type Vt molecules packing in the asymmetric unit  
The C-terminal domain of one Vt molecule (blue) interfaces with helix 2 of a second 
molecule (green).  A salt bridge can form between D1051 and R935, and D1051 can 
hydrogen bond to G1053. The hydrophobic interface residues I997 and M1022 are shown 
for reference.   153 
 
 
Figure 3.4.17 Close up of the region involved in the crystal interface between two Vt 
molecules 
D1051 can form a salt bridge to R935 (distances 2.72Å and 2.95Å) and can hydrogen bond 
to G1053 (1.80Å). 
 
Therefore, two potential interaction sites between wild-type Vt molecules could be acting 
in solution, the first between the hydrophobic regions centred at I997 and M1022, and the 
second between the C-terminus and helix 2.  This may in part explain the larger than 
expected correlation time of 13.0ns for wild-type Vt, and may also explain why the single 
point mutations at I997S only reduced the τm to 12.6ns.  Even with one self-association 
interface mutated, the second may still be having an effect in the Vt/I997S mutant. 
 
 
3.4.8  Transferring Vt/I997S assignments to the wild-type 
1H-
15N-HSQC 
and TROSY spectrum 
 
The assignments from Vt/I997S were transferred from the 
1H-
15N-TROSY spectrum 
measured at 800MHz onto a 600MHz 
1H-
15N-HSQC spectrum and a 900MHz 
1H-
15N-
TROSY spectrum of wild-type Vt so that subsequent experiments using wild-type protein 
can be easily interpreted.  The resonances have been transferred to the 900MHz spectrum   154 
as well as the 600MHz as there is more resolution in the former so that individual peaks can 
be observed where at 600MHz they are overlapped. 
 
While many of the NH resonances in the Vt/I997S spectrum coincide with the resonances 
in the wild-type spectra, there are some that cannot be transferred with complete 
confidence.  A confidence level was assigned arbitrarily, resonances that occurred in an 
identical chemical shift in both spectra was assigned a value of  ‘5’ and the resonances that 
could not be identified with confidence were assigned the value ‘1’.  When the assignments 
were being transferred there were certain regions with the same number of peaks but the 
patterns were different.  These can be seen in Appendix 5.6, and show how confidence of 1 
does not mean that they should be disregarded, just that care should be taken when 
interpreting data from these assignments. 
 
In total, 138 of the possible 147 assignments from Vt/I997S were transferred to the wild-
type spectrum.  Of these, 82 were assigned with a confidence of 5, 27 with a confidence of 
4, 13 with a confidence of 3, 5 with a confidence of 2 and 9 with a confidence of 1.   The 
eleven residues assigned in Vt/I997S that could not be transferred are M889, H906, L928, 
K956, T993, S997, S999, K1002, I1011, Q1018 and A1019 (S997 is the mutated residue). 
The assigned 600MHz spectrum can be seen in Figure 3.4.18 and Figure 3.4.19, and the 
900MHz spectrum in Figure 3.4.20 and Figure 3.4.21.  The crystal structure of wild-type Vt 
with the corresponding Vt/I997S assignments and confidence levels is shown in Figure 
3.4.22. 
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Figure 3.4.18 
1H-
15N-HSQC spectrum of wild-type Vt showing transferred NH 
resonance assignments from Vt/I997S spectrum 
Spectrum acquired at 600MHz.  Wild-type Vt was at 200µM and labelled with 
15N in 20mM 
Tris pH7, 400mM NaCl. Full spectrum showing the assignments and confidence level, 
5(black) meaning high confidence and 1(pink) meaning poor.  Confidence scale s shown in 
bottom left hand corner of spectrum.  Resonances marked with ‘*’ are degenerate. R987 
(marked with †) is one residue in Vt/I997S but may be two residues in wild type protein, 
and ‡ is a resonance that is only seen at low contour levels.  Red circles are resonances 
that are present in the wild-type spectrum but not in the Vt/I997S spectrum. 
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Figure 3.4.19 Expanded section of the 
1H-
15N-HSQC spectrum of wild-type Vt 
showing transferred NH resonance assignments from Vt/I997S spectrum 
Confidence level, 5(black) meaning high confidence and 1(pink) meaning poor.  
Confidence scale is shown in bottom left hand corner of spectrum..  Resonances marked 
with ‘*’ are degenerate.  Red circles are resonances that are present in the wild-type 
spectrum but not in the Vt/I997S spectrum 
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Figure 3.4.20 
1H-
15N-TROSY spectrum of wild-type Vt showing transferred NH 
resonance assignments from Vt/I997S spectrum 
Spectrum acquired at 900MHz with attached cryoprobe.  Wild-type Vt was at 200µM and 
labelled with 
15N  in 20mM Tris pH7, 150mM NaCl, 50mM arginine, 50mM glutamate.. 
Full spectrum showing the assignments and confidence level, 5(black) meaning high 
confidence and 1(pink) meaning poor.  Confidence scale shown in bottom left hand corner 
of spectrum.  Red circles are resonances that are present in the wild-type spectrum but not 
in the Vt/I997S spectrum 
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Figure 3.4.21 Expanded section of the 
1H-
15N-TROSY spectrum of wild-type Vt 
showing transferred NH resonance assignments from Vt/I997S spectrum 
Confidence levels, 5(black) meaning high confidence and 1(pink) meaning poor.  Red 
circles are resonances that are present in the wild-type spectrum but not in the Vt/I997S 
spectrum 
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Figure 3.4.22 Wild-type Vt crystal structure shown at 90º rotations with assigned 
Vt/I997S NH resonances mapped on 
Coloured residues correspond to the confidence of assignment.  Black 5-good, blue 4, 
green 3, red 2 and pink 1-poor.  Grey residues are either unassigned or not transferred to 
wild-type. 
 
3.4.9  Summary 
 
Assignment of the Vt/I997S backbone NH resonances has been challenging and using 
multiple NMR experimental data, 76% of the residues in Vt/I997S have been assigned.  
The secondary structure of Vt/I997S in solution appears very similar to the wild-type 
protein as judged by secondary Cα chemical shift deviations and from torsion angle 
predictions.  There may be some subtle structural but further data is required to determine 
the significance of these differences. 
 
The Vt/I997S NH assignments have been mapped onto the wild-type Vt 
1H-
15N-HSQC 
spectrum; of the 147 Vt/I997S NH assignments, 138 have been transferred to the wild-type 
spectrum.  Using these wild-type Vt assignments, it will now be possible to interpret 
chemical shift perturbation data between Vt and paxillin LD motifs. 
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3.5  Characterisation of Paxillin  
 
In order to study the interaction between Vt and paxillin, different paxillin regions have 
been utilised.  Small 13mer peptides containing paxillin LD motifs LD1, LD2 and LD4 
have been synthesised and longer paxillin constructs have been recombinantly expressed 
(Figure 2.6.1).  Paxillin constructs containing paxillin LD1 and LD2 in pGEX-LD1/LD2 
and pET-15B-LD1/LD2 were obtained from Professor D. Critchley (University of 
Leicester) and have been purified for use in interaction experiments.  Paxillin constructs 
containing paxillin GST-LD3/LD4 and GST-LD4/LD5 (also obtained from Professor D. 
Critchley, University of Leicester) have been expressed but at low levels so purification has 
not been possible. 
 
3.5.1  Secondary structure of paxillin LD1, LD2 and LD4 peptides 
 
The paxillin 13mer peptides have been synthesised for use in chemical shift perturbation 
studies using NMR.  The sequences of LD1, LD2 and LD4 can be found in Chapter 2.6.7.1. 
As there is some debate in the literature about the secondary structure of LD motifs, far UV 
circular dichroism was used in an attempt to discover clues about the secondary structure 
present in these short motifs. Figure 3.5.1 shows the results of the far UV CD on peptides 
LD1, LD2 and LD4 and a table showing typical values from known secondary structure. 
 
All of the LD peptides have a negative signal at 202nm, LD1 and LD4 have a stronger 
signal than LD2.  They also have a weak negative signal at 225nm.  Using the table in 
Figure 3.5.1, it can be seen that these peptides are not consistent with one singular type of 
secondary structure.  The negative value at 202nm is often seen for random coil while a 
weak negative value at 225 would be consistent with β-turn structure.  CD spectra for 
oligopeptides notoriously encounter difficulties (211) and it is evident that there is not 
enough structural information here to predict with confidence the secondary structure of the 
LD peptides.  More structural information will be required to determine the nature of the 
secondary structure of these peptides.    161 
 
Figure 3.5.1 Far UV spectra for peptides LD1 (orange) LD2 (green) and LD4 (blue) 
All of the peptides have a minima at 202nm and a weak negative signal at 225nm. Peptides 
at 50µM in water. Typical values are from Rodger and Nordén (211). 
 
3.5.2  Expression and purification of paxillin containing LD1 and LD2 
 
Paxillin GST-LD1/LD2 and His-LD1/LD2 were over-expressed in LB media.  The GST 
construct produces an induction band above the E.coli background when expression is 
carried out at 16°C for 16 hours. (Figure 3.5.2), induction at 30°C does not produce an 
induction band.  Paxillin His-LD1/LD2 was expressed in LB media and in M9 minimal 
media at 16°C for 16 hours, however an induction band cannot be observed on an SDS-
PAGE gel. Induction can only be confirmed after capture on a Ni-NTA affinity column.  
 
Attempts to purify GST-LD1/LD2 were made but the protein degrades when the GST tag is 
removed by thrombin cleavage.  This construct was used for binding studies from the crude 
lysate (see 3.6.1 and 3.6.1). Initial attempts at purification of His-LD1/LD2 were hampered 
by large protein losses as monitored by SDS-PAGE gel.  Attempts to remove the histidine 
tag also resulted in rapid protein loss. 
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Figure 3.5.2 Composite polyacrylamide SDS-PAGE gel showing induction of paxillin 
GST-LD1/LD2 using LB medium after induction with 1mM IPTG for 16 hours at 
16ºC. 
Lane 1: molecular weight standard-multimark, with molecular weights of products 
alongside (in kDa); lane 2: pre induction sample; lane 3: 16 hour post induction.  
Induction bands can be seen corresponding to the molecular weight of 45kDa. 
 
The N-terminus of paxillin is suggested to be natively unstructured (206) hence expression 
of N-terminal fragments may be plagued by unspecific proteolysis.  Successful purification 
of the His-tagged LD1/LD2 paxillin construct has been enabled using 6M urea for cell lysis 
and affinity capture.  The details of the purification are outlined in Chapter 2.2.8. The E.coli 
cell pellet is resuspended in a tris buffer containing 6M urea.  Sonication is performed in 
this buffer, the cell lysate is clarified and the soluble fraction loaded onto a Ni-NTA 
column.  The eluent does not contain urea, so the protein is buffer exchanged on the 
column.  Treating the protein in this harsh manner results in strong protein band on an 
SDS-PAGE gel and also increases the integrity of the construct throughout purification.  
The chromatogram from this column is shown in Figure 3.5.3.  The 100% fraction is 
pooled and continues through purification. 
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Figure 3.5.3 Paxillin His-LD1/LD2: Ni-NTA loading and elution profile. 
The blue trace is the absorbance at 280nm and is used to monitor the proteins.  The green 
trace shows the percentage of imidazole being used to elute, the first elution is 10% and the 
second is 100%.  The brown trace monitors the conductivity. Fractions are shown in red 
along the x-axis. 
 
Attempts at removal of the histidine tag have resulted in loss of the protein throughout the 
duration of the purification, after thrombin cleavage a singular band can be observed by 
SDS-PAGE, but the protein subsequently disappears.  Due to the small size of the tag (6x 
histidines) it has not been removed from the paxillin construct in this study. 
 
The second column is an anion exchange column, however the construct does not bind to 
the column, it is collected in the unbound flow-through fraction. Figure 3.5.4 shows the 
elution profile.  Rather than attempting to bind his-LD1/LD2 to a cation column, it was 
collected as the unbound sample as it resulted in a low concentration of salt in the sample 
which would help during later desalting steps. 
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Figure 3.5.4 Paxillin His-LD1/LD2: Q-Sepharose (anionic) elution profile. 
The blue trace is the absorbance at 280nm and is used to monitor the protein.  The green 
trace shows the percentage of 1M NaCl being used to elute, the gradient is run from 0-
100%.  The brown line is a measure of the conductivity of the elution fractions.  Fractions 
are shown in red along the x-axis. 
 
The protein is lost through the membrane of spin concentrators with a 5,000 molecular 
weight cut-off, despite the molecular weight of paxillin his-LD1/LD2 being 19769 Da.  For 
NMR studies, it is necessary that the protein concentration can be adjusted for different 
experiments, so the protein is next buffer exchanged into water and then freeze dried.  
Dialysis was not attempted due to worries that it may be lost through the membrane, 
instead the protein is run over a sephadex G25 column to desalt into water.  The desalting 
profile is shown in Figure 3.5.5.  The absorbance at 280nm is recorded and then the protein 
is then freeze dried in known quantities for 2-4 days. 
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Figure 3.5.5 Paxillin His-LD1/LD2: Sephadex G25 elution profile. 
The blue trace is the absorbance at 280nm and is used to monitor the protein.  The brown 
line is a measure of the conductivity of the elution fractions.  Fractions are shown in red 
along the x-axis. 
 
 
Figure 3.5.6 shows a gel of the construct as it is purified.  The final product is >95% pure 
and the yield is approximately 7mg/L. 
 
It became apparent that care needs to be taken with the desalting step, as NMR data 
acquired at 900MHz showed presence of both urea and imidazole in a batch of His-
LD1/LD2.  Figure 3.5.7 shows how the imidazole peaks can interfere with the resonances 
in a 
1H-
15N-TROSY spectrum.  Future protein preparations should be desalted several times 
to ensure complete removal of these contaminants from the sample. 
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Figure 3.5.6 Composite polyacrylamide SDS-PAGE gel showing paxillin his-LD1/LD2 
at various stages of the purification. 
Lane 1: molecular weight standard-multimark, with molecular weights of products 
alongside (in kDa); lane 2: Ni-NTA load, paxillin cannot be observed; lane 3: Ni-NTA 
flow-through showing that no major band can be seen corresponding to paxillin; lane 4: 
pooled paxillin his-LD1/LD2 from Ni-NTA column ready to be loaded onto the anion 
column; lane 5:pooled unbound fraction from ion exchange ready for loading onto the 
desalting column; lane 6: Paxillin his-LD1/LD2 post desalt & post freeze-dry, resuspended 
in 20mM Tris pH7, 150mM NaCl. 
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Figure 3.5.7 
1H-
15N-TROSY spectra of wild-type Vt (200µM) plus an excess of paxillin 
(A); and paxillin His-LD1/LD2 at 100µM (B) at 900MHz with a cryoprobe showing 
that urea and imidazole have contaminated the sample 
 
3.5.3  Mass spectrometry 
 
The mass spectra of unlabelled 
14N and labelled 
15N-paxillin His-LD1/LD2 have been 
carried out (Figure 3.5.8 and Table 3.5.1).  The mass spectrum results show that the 
construct is slightly smaller than expected.  The difference in mass could be due to Met 
being removed from the N-terminus (see sequence in Appendix 5.4), inputting the sequence 
minus the first methionine into a molecular weight prediction program(270) returns the 
predicted molecular weight 19639 which is identical to the data obtained.  Removal of this 
methionine would not interfere with the binding motifs. 
 
Table 3.5.1 Results of mass spectrometry for 
14N and 
15N labelled His-LD1/LD2 
 
 
14N-His-LD1/LD2 
15N- His-LD1/LD2 
Predicted molecular weight  19769  20013 
Measured molecular weight  19639  19876 
Difference  130  137 
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Figure 3.5.8 Electrospray ionization mass spectrometry of 
14N and 
15N His-LD1/LD2 
Major peaks at 19639Da (
14N) and 19876Da (
15N) correspond to paxillin His-LD1/LD2 
with ~130Da missing.  
14N: peaks at 19656 (+17), 19676 (+20), 19698 (+22) and 19734 
(+36)  are likely to be NH4
+, Na
+ and Cl
- adducts respectively. 
15N: peaks at 19895 (+19), 
19915 (+20) and 19938 (+23) are likely to be NH4
+ and Na
+ adducts.   169 
 
3.5.4  Analytical size exclusion chromatography 
 
Size exclusion chromatography was carried out on paxillin His-LD1/LD2 to assess the 
oligomeric state of the protein.  The results show a major peak at 42kDa and suggest that 
His-LD1/LD2 may exist as a dimer in solution. 
 
 
Figure 3.5.9 Analytical gel filtration (superdex-75) of paxillin His-LD1/LD2 in 20mM 
Tris pH7, 150mM NaCl and polyacrylamide gel of fractions.  
The blue trace is the protein absorbance at 280nm.  Lane 1: molecular weight marker 
showing weights in kDa; lane 2: protein peak from fraction A9 (8ml); lane 3: peak from 
fraction A10; lane 4: fraction A11 (10.7ml); lane 5: fraction A12 (12.2ml). 
 
3.5.5  Secondary structure of paxillin His-LD1/LD2 using circular 
dichroism 
 
The far-UV circular dichroism spectrum of paxillin His-LD1/LD2 in water is shown in 
Figure 3.5.10.  The spectrum appears to lack the usual indicators of protein secondary 
structure, there is a weak negative at 230nm and there is a positive maxima at 200nm.  For 
a random coil a net CD value of a strong negative just below 200nm, a positive band at   170 
218nm and a weak negative band at 235nm is expected (211).  While it is unclear exactly 
what the nature of the secondary structure is, there does appear to be elements of random 
coil. 
 
 
Figure 3.5.10 Far UV circular dichroism spectrum of paxillin His-LD1/LD2 at 0.5µM 
in water 
 
3.5.6 
1H-
15N-HSQC spectrum 
 
A 
1H-
15N-HSQC spectrum for paxillin His-LD1/LD2 is shown in Figure 3.5.11. The 
observed NH resonances appear between 7.7-8.9ppm and are not well dispersed which is 
indicative of unstructured protein.  There are 184 amino acids in His-LD1/LD2 of which 21 
are prolines thus 163 resonances are expected.  A peak count estimate shows that there are 
159 resonances arising from NH groups.  There is one tryptophan in the protein, the indole 
NH can clearly be seen at N129.5ppm, H
N10.1ppm, and there are 11 glycines, they may be 
the cluster of peaks between 113-109ppm.  The 900MHz spectrum in Figure 3.5.12 shows   171 
the same number of peaks but the overlap is reduced.  It may be possible to assign some of 
this spectrum at 900MHz. 
 
 
 
 
Figure 3.5.11 
1H-
15N-HSQC spectrum of 
15N paxillin His-LD1/LD2 at 600MHz 
Paxillin concentration 100µM in 20mM Tris pH7, 150mM NaCl, 50mM arginine, 50mM 
glutamate.  Spectrum acquired for 2hrs at 600MHz. 
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Figure 3.5.12 
1H-
15N-HSQC spectrum of 
15N paxillin His-LD1/LD2 at 900MHz 
Paxillin concentration 100µM in 20mM Tris pH7, 150mM NaCl, 50mM arginine, 50mM 
glutamate.  Spectrum acquired for 1hr at 900MHz using a cryoprobe.   173 
 
3.6  Vt- Paxillin Interaction Studies 
 
The interaction between vinculin and paxillin was first identified in 1990 by Turner and 
colleagues (67). In this study the authors determined that paxillin interacted with the tail 
domain of vinculin.  Further experiments (86)
 using truncated GST-vinculin polypeptides 
revealed that the region of Vt that is required to bind paxillin as Vt 978-1028.  
 
In order to confirm that the Vt construct used in this study will interact with paxillin, two in 
vitro binding experiments were carried out, the GST-pull-down experiment and the catch-
up comparative retention assay (268).  These have been carried out using wild-type Vt and 
paxillin GST-LD1/LD2.  
 
3.6.1  GST-pulldown experiments with Vt and paxillin 
 
Initial attempts to observe an interaction between Vt and a synthetic paxillin peptide 
containing the LD1 motif did not show apparent chemical shifts of wild-type Vt in an NMR 
titration experiment (data not shown).  Thus a GST-pulldown interaction assay was 
performed on larger paxillin constructs and wild-type Vt.   
 
GST-pulldown experiments take advantage of the selective binding of gluthathione-S-
transferase affinity tag to glutathione resins.  A protein of interest which contains a GST-
affinity tag is bound to a glutathione resin.  Proteins can be passed over this resin and then 
washed off, any interacting proteins would remain bound to the GST-protein.  This method 
only preserves interacting partners that survive multiple washing steps, so tends to select 
strong binding events where the exchange rate is slow or irreversible. 
 
Figure 3.6.1 shows that when paxillin GST-LD1/LD2 and wild-type Vt are incubated 
together, they elute together from glutathione resin after washing steps to remove any other 
proteins.  This can be seen from the extra band corresponding to Vt in lane 3 which is   174 
missing from lane 2.  The control experiment in Figure 3.6.2 show that Vt does not interact 
with GST, and Vt does not bind non-specifically to glutathione resin (data not shown). 
 
 
Figure 3.6.1 Composite polyacrylamide gel showing the results of the pulldown 
experiment.  
Lane 1: molecular weight marker showing weights in kDa; lane 2: Paxillin GST-LD1/LD2 
cell lysate bound, washed and eluted from glutathione beads not in presence of Vt; lane 3 
Paxillin GST-LD1/LD2 cell lysate in presence of Vt that has been bound, washed and 
eluted  from glutathione beads. 
 
 
Figure 3.6.2 Polyacrylamide gel showing results of the GST control pulldown 
experiment.  
Lane 1: molecular weight marker showing weights in kDa; lane 2 & 3: GST loaded onto 
the column, 5µl and 10µl loads; lane 4 & 5: Vt loaded onto the column, 5µl and 10µl 
loads; lanes 6, 7 & 8: washing unbound Vt from column; lane 9 & 10: GST eluted from the 
column-no Vt is present.    175 
 
3.6.2  Catch-up comparative retention assay 
 
The Catch-up Comparative Chromatographic Retention Assay is a new assay developed by 
Charbonnier et al. (268) and is based on the principles of reversible binding of fusion 
proteins to affinity resins. It is distinct from a GST-pull-down experiment as no washing 
steps are included and is therefore better suited to detect transient or fast exchanging 
interactions. 
 
An example of results obtained from a catch-up experiment is shown in Figure 3.6.3.  
During the experiment, interaction partners are incubated together for 1 hour and then 
incubated with an affinity resin such as glutathione beads.  One interaction partner contains 
an affinity tag, in this case GST.  The mixtures are split in half and are treated with either a 
buffer containing 20mM reduced glutathione (the (+) condition) or a buffer containing no 
glutathione (the (-) condition).  GST-containing proteins will be eluted from the resin when 
reduced glutathione is added but will remain on the resin when a buffer minus glutathione 
is used.   
 
If the other interaction partner binds to the GST-containing protein, then both proteins will 
be observed on a reducing SDS-PAGE gel when the resin is treated with reduced 
glutathione.  In the (-) glutathione condition, the GST-containing protein will remain on the 
resin and will not be seen on an SDS-PAGE gel.  The interaction partner will be observed 
at a level that is determined by the strength of binding to the GST-protein and is judged by 
comparison to the (+) condition.  No binding would be seen as a band on the (-) condition 
gel at the same intensity as on the (+) condition, the difference being that the GST-protein 
would not be observed (Figure 3.6.3(3).  Strong binding would appear as no band on the gel 
compared to the (+) condition (Figure 3.6.3(1).  Weak or transiently interacting proteins 
would appear at a level that was related to the binding equilibrium (Figure 3.6.3(1). 
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Figure 3.6.3.  Example results from the catch-up assay.  
Examples of a strong interaction (1), a weak interaction (2) and no interaction (3).  Blue 
bands represent proteins on a polyacrylamide gel stained with coomassie blue. 
 
This assay was carried out using the recombinant paxillin LD construct, GST-LD1/LD2.  
Figure 3.6.4 shows the results of the experiment. Lanes 1 and 2 show a control where a 
non-interacting partner, calexcitin, is added.  Calexcitin does not interact with GST-
LD1/LD2 as calexcitin can be seen at the same level in both lanes.  Lanes 3 and 4 are 
controls to ensure that the assay is working as GST-LD1/LD2 can be seen in lane 3 but not 
in lane 4.  Lane 5 and 6 show that Vt is interacting with GST-LD1/LD2 as Vt is present at a 
much lower level  in lane 6 than in lane 5.  The results are clarified in Figure 3.6.5.  Control 
experiments to establish that the interaction was not GST-mediated were hampered by poor 
resolution on SDS-PAGE between Vt and GST, and experimental problems when using an 
unrelated GST-fusion protein.  Observations suggested that the GST-fusion control protein 
was not binding to the resin making the results of the control inconclusive. 
 
The catch-up experiment suggests an interaction between Vt and GST-LD1/LD2 that is of 
high affinity as very little Vt is in the liquid phase of the minus condition.  Since the 
concentration of the GST-LD1/LD2 is unknown the strength of the interaction cannot be 
quantified.  
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Figure 3.6.4  Composite polyacrylamide SDS-PAGE gel showing the results of the 
catch-up assay between GST-LD1/LD2 and wild-type Vt.   
Three sets of experiments are shown.  The plus (+) condition contains 20mM reduced 
glutathione for elution, the minus (-) condition does not contain 20mM reduced 
glutathione. Lanes 1&2: GST-LD1/LD2 plus calexcitin (control), both cell lysates.  Lanes 
3&4: GST-LD1/LD22 only (control).  Lanes 5&6: GST-LD1/LD2 cell lysate plus purified 
Vt.   
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Figure 3.6.5 Results from Figure 3.6.4 with gel patterns clarified   
Blocks shown are representative of protein bands on a gel. Red blocks are the bands of 
interest, grey blocks are placed there for reference only and come from the results gel.  The 
plus condition contains 20mM reduced glutathione for elution, the minus condition does 
not contain 20mM reduced glutathione.   
 
These results suggest an interaction between GST-LD1/LD2 and wild-type Vt, and agrees 
with the interaction previously observed (5;67;80;86).
  Catch-up experiments between Vt 
and GST-LD3/LD4 and GST-LD4/LD5 have been hampered by poor expression of the LD 
constructs.    179 
 
3.6.3  Interaction studies of Vt and paxillin by NMR  
 
An important aim of this thesis is to investigate the nature of the interaction between Vt and 
paxillin.  Elucidating the location of the interaction site for paxillin on Vt, the specificity of 
LD motifs for Vt and strength of the interaction is important to enable the understanding of 
how the two molecules interact within FAs. 
 
Solution NMR is a powerful tool for evaluating protein-ligand interactions.  It relies on the 
chemical shifts of the residues in the protein being sensitive to subtle changes in chemical 
environment (253). It is especially useful as it can be used to detect weak interactions, with 
Kds in the millimolar range being detectable (254). 
 
The most widely used NMR method to determine binding interfaces is chemical shift 
perturbation (254).  This can be achieved by recording a 
1H-
15N-correlation spectrum of an 
isotopically labelled protein, and then monitoring the changes in the chemical shifts as a 
binding partner is titrated in. 
 
3.6.3.1 Chemical shift perturbation experiments 
 
Titration series were carried out using wild-type Vt at 200µM protein concentration.  Table 
2.6.2 lists the titration experiments that have been carried out in this study. At 600MHz, 
1H-
15N-HSQC spectra were recorded for each titration point.  At 900MHz, TROSY spectra 
were recorded. Ligands used for the titration were either synthesised paxillin 13mer 
peptides LD1, LD2 or LD4; or a longer purified paxillin construct His-LD1/LD2.  The 
sequences of the peptides can be found in Chapter 2.6.7.1, and the sequence of paxillin His-
LD1/LD2 can be found in Appendix 5.4. 
 
Overall, chemical shift perturbations were small and did not produced a simple, discrete set 
of affected residues that formed a continuous interaction surface.  However, intensity 
changes as a function of ligand concentration were notable, in some cases leading to   180 
disappearance of resonances. As this may be indicative of intermediate exchange (Section 
2.5.13.1), intensity changes were included in the analysis.  Accordingly the analysis of the 
data has been approached in the following manner.  For each assigned residue, three 
parameters were analysed and the results represented as block diagrams as a function of 
sequence.  The first is the intensity change between the first and the last titration point 
(corresponding to equivalent molar ratios for all peptides except for the His-LD1/DL2 
construct).  This has been measured as a percentage intensity decrease, so the results are the 
percentage of the signal that remains at a 10-fold excess of ligand (4-fold for His-
LD1/LD2).  This manifests on a graph as a positive value for intensity decreases and a 
negative value for intensity increases.  The more positive the bar then the more signal has 
been lost.  The second and third parameters are the chemical shift differences between the 
first and last titration points in the proton and nitrogen dimension respectively. 
 
3.6.3.2 Interaction of wild-type Vt with LD1, LD2, LD4 and His-LD1/LD2 
 
All of the data analysis in this section was carried out using the titration data measured in 
20mM Tris pH7, 50mM NaCl with 50mM arginine, 50mM glutamate buffer.  Great care 
was taken to maintain the pH and buffer composition and the concentration of Vt 
throughout the titrations (see methods, Section 2.6.7.1).  Criteria were set to distinguish 
whether a perturbation was a result of direct interaction with a ligand.  Percentage intensity 
decreases were set to ≥50%, chemical shift differences in the proton and nitrogen 
dimension were set as 0.03ppm and 0.2ppm respectively.  This criteria was judged to be 
acceptable, a more stringent cut-off of 60% intensity decrease and higher chemical shift 
differences resulted in most effects being lost.   The following descriptions are summarised 
in Table 3.6.1. 
 
LD1 plus wild-type Vt (Figure 3.6.6) 
When a 10-fold excess of LD1 peptide is added to wild-type Vt there is a global intensity 
drop for most chemical shifts that are assigned along the backbone.  There does not appear 
to be any distinct regions where the intensity loss is more localised.  Of the assigned   181 
residues, 64 have an intensity decrease larger than 50%. The average intensity decrease 
across all assigned chemical shifts is 44.0% 
 
The largest proton chemical shift changes are contained in helices 1, 3 and 5.  There are 15 
residues that have chemical shift changes of greater than 0.03ppm in the proton dimension. 
The largest chemical shift changes in the nitrogen dimension are contained in helices 3, 4 
and 5, and there are some changes in the linker region between helices 4 and 5.  There are 
10 residues that shift greater than 0.2ppm.  Combining both proton and nitrogen chemical 
shift changes gives a total of 21 residues affected. 
 
Figure 3.6.7 shows these affected residues mapped onto the crystal structure of Vt.  The 
intensity decreases are spread throughout the molecule, although helix 3 seems to be 
affected more than other helices.  The chemical shift changes appear to be less global, with 
face 3-4 and 4-5 being affected more than the other two faces.  Helix 3 appears to be most 
affected.  
 
LD2 plus wild-type Vt (Figure 3.6.8) 
When a 10-fold excess of LD2 peptide is titrated into wild-type Vt there is a global 
intensity drop, the average decrease across all of the assigned chemical shifts is 45.7%.  
There are 54 residues that have an intensity decrease of greater than 50%.   
 
The largest proton chemical shift changes are contained in helices 1 and 5, with some large 
shifts in helices 2 and 3 also.  There are 11 chemical shifts that titrate more than 0.03ppm in 
the proton dimension.  The largest chemical shift changes in the nitrogen dimension are in 
helices 1, 3, 4 and 5. There are 7 that are greater than 0.2ppm.  Combining both proton and 
nitrogen shifts gives a total of 14 residues affected. 
 
Figure 3.6.9 shows these affected residues mapped onto the crystal structure of Vt.  The 
intensity decreases are spread throughout the molecule, with clusters of affected residues on 
helix 3, face 4-5 and face 5-2. The chemical shift changes appear to be less global, with   182 
most of the shifts found near the top of the helical bundle.  Faces 3-4, 4-5 and 5-2 have 
small clusters of affected residues. 
 
LD4 plus wild-type Vt (Figure 3.6.10) 
When a 10-fold excess of LD4 is titrated into Vt, the average chemical shift intensity 
decrease is 22.2%.  There are only two chemical shifts that decrease in intensity more than 
50% (C950 and M1005), and there is one residue that shifts in the proton dimension greater 
than 0.03ppm (A1044).  No chemical shift changes are seen in the nitrogen dimension 
greater than and 0.2ppm. 
 
Figure 3.6.11 shows these affected residues mapped onto the crystal structure of Vt. There 
are only three residues affected and they are on helix 3, on the linker between helix 4 and 5, 
and at the end of helix 5.  There are no global affects or discrete regions that are being 
affected. 
 
His-LD1/LD2 plus wild-type Vt (Figure 3.6.12) 
For these experiments a 4-fold excess of paxillin His-LD1/LD2 was added to wild-type Vt,  
this excess causes a global reduction in intensity and an average intensity decrease for all 
assigned chemical shifts of 51.9% There are 85 chemical shifts that decrease in intensity 
more than 50%.   
 
There are three chemical shifts that change in the proton dimension greater than 0.03ppm 
and only one that shifts in the nitrogen dimension greater than 0.2ppm.  These are in helices 
1 and 5. 
 
Figure 3.6.13 shows these affected residues mapped onto the crystal structure of Vt.  The 
intensity decreases are spread throughout the molecule, with affected residues clustering on 
all faces with helix 3 being affected the most.  The chemical shift changes are found on 
helix 1 and 5 but do not seem to be clustered. 
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Table 3.6.1 Summary table of Vt perturbation upon LD titration 
 
  Molar 
excess 
of 
ligand 
Average 
decrease 
(%) 
No. residues 
that decrease ≥ 
50% 
∆H 
≥0.03 
∆N 
≥0.2 
Total 
residues 
affected 
∆H and 
∆N 
No. of 
residues 
affected 
in total 
LD1  10  44.0  64  15  10  23  70 
LD2  10  45.7  54  11  7  14  56 
LD4  10  22.2  2  1  0  1  3 
His-
LD1/LD2 
4  51.9  85  3  1  4  86   184 
 
Figure 3.6.6 Wt-Vt plus LD1.  Bar charts showing percentage intensity decrease (A), 
proton chemical shift difference (B) and nitrogen chemical shift difference (C).  185 
 
 
Figure 3.6.7 Chemical shift perturbations caused by LD1 peptide mapped onto the crystal structure of Wt-Vt.  Perturbed NH 
resonances shown in orange, unperturbed NH resonances shown in grey. Criteria: intensity decrease ≥ ≥ ≥ ≥ 50% or ∆ ∆ ∆ ∆H ≥ ≥ ≥ ≥0.03ppm 
or ∆ ∆ ∆ ∆N ≥ ≥ ≥ ≥0.2ppm.  186 
 
 
Figure 3.6.8 Wt-Vt plus LD2. Bar charts showing percentage intensity decrease (A), 
proton chemical shift difference (B) and nitrogen chemical shift difference (C).  187 
 
 
Figure 3.6.9 Chemical shift perturbations caused by LD2 peptide mapped onto the crystal structure of Wt-Vt.  Perturbed NH 
resonances shown in green, unperturbed NH resonances shown in grey. Criteria: intensity decrease ≥ ≥ ≥ ≥ 50% or ∆ ∆ ∆ ∆H ≥ ≥ ≥ ≥0.03ppm or 
∆ ∆ ∆ ∆N ≥ ≥ ≥ ≥0.2ppm.   188 
 
 
Figure 3.6.10 Wt-Vt plus LD4. Bar charts showing percentage intensity decrease (A), 
proton chemical shift difference (B) and nitrogen chemical shift difference (C).  189 
 
 
Figure 3.6.11 Chemical shift perturbations caused by LD4 peptide mapped onto the crystal structure of Wt-Vt.  Perturbed NH 
resonances shown in blue, unperturbed NH resonances shown in grey. Criteria: intensity decrease ≥ ≥ ≥ ≥ 50% or ∆ ∆ ∆ ∆H ≥ ≥ ≥ ≥0.03ppm or 
∆ ∆ ∆ ∆N ≥ ≥ ≥ ≥0.2ppm.   190 
 
Figure 3.6.12 Wt-Vt plus His-LD1/LD2. Bar charts showing percentage intensity 
decrease (A), proton chemical shift difference (B) and nitrogen chemical shift 
difference (C).   191 
 
Figure 3.6.13 Chemical shift perturbations caused by His-LD1/LD2 mapped onto the crystal structure of Wt-Vt.  Perturbed 
NH resonances shown in brown, unperturbed NH resonances shown in grey. Criteria: intensity decrease ≥ ≥ ≥ ≥ 50% or ∆ ∆ ∆ ∆H 
≥ ≥ ≥ ≥0.03ppm or ∆ ∆ ∆ ∆N ≥ ≥ ≥ ≥0.2ppm.   192 
3.6.3.3 Comparison of LD1, LD2, LD4 and His-LD1/LD2 data 
 
A list of all the perturbed residues for LD1, LD2 and His-LD1/LD2 that meet the above 
criteria with an ‘or’ condition can be found in Appendix 5.7.  All of the titration 
experiments at 600MHz were carried out under identical conditions so can be directly 
compared to one another, the His-LD1/LD2 titration carried out at 900MHz may be 
affected by different exchange regimes but is still comparable as the buffer conditions were 
the same. 
 
The global reduction in intensity for the chemical shifts when titrating with LD1 and LD2 
suggests that the system is experiencing intermediate exchange processes.  Figure 3.6.14A 
and B shows all Vt residues that are perturbed when LD1 and LD2 are titrated in.  As the 
figure shows, many of these are the same for LD1 peptide as for LD2.  In contrast, the LD4 
peptide only perturbs 3 residues (see Figure 3.6.11).  The average global reduction in 
intensity is very similar for LD1 and LD2 (44.0% and 45.7%), while the average intensity 
decrease for the LD4 peptide is half, only 22.2%. LD4 is not perturbing residues in Vt in 
the same manner as the LD1 and LD2 peptides.  
 
There are differences between the perturbations of the chemical shifts when titrating with 
LD1 and LD2.  The list in Appendix 5.7 highlights the residues that are affected 
specifically by LD1 compared to LD2 and vice versa.   
 
For LD1, the perturbed shifts that are titrating in the proton and nitrogen dimension and 
broadening are being affected on a fast-to-intermediate timescale.  There are more 
perturbations affected in this manner with LD1 than for LD2.  In the LD2 titration, there are 
residues in fast-to-intermediate exchange, but some of the perturbations seem to remain in 
the same position in the spectrum but reduce in intensity.  This situation is ambiguous as it 
could suggest intermediate exchange where the free and bound complex shifts coincide, or 
in slow exchange.  To identify slow exchange the chemical shifts of the saturated complex 
would need to be assigned.   
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Examples of the different types of perturbations can be seen in Figure 3.6.15.  Threonine 
T990 is undergoing a fast-to-intermediate exchange process for both LD1 and LD2.  The 
NH resonance shifts in the proton and nitrogen dimension whilst the intensity is 
simultaneously decreasing (Figure 3.6.15a & b).  In contrast, the same resonance with LD4 
does not move or decrease in intensity (c).  Arginine R963 and glutamate E960 are 
examples of fast-to-intermediate exchange with LD1 peptide (d, g) and slow or 
intermediate exchange for LD2 (e, h).  In both cases the resonances do track in the proton 
and nitrogen dimensions with LD2, but this is below the threshold for an affected peak, the 
resonance is perturbed dominantly by an intensity drop.  In both cases LD4 peptide is not 
perturbing the resonance. 
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Figure 3.6.14 Residues that are affected by both slow and fast exchange in wild-type Vt.   
A: when LD1 is added to a 10-fold excess, B: when LD2 is added to at 10-fold excess, C: when His-LD1/LD2 is added to a 4-fold 
excess.  195 
 
 
Figure 3.6.15.  Examples of perturbed NH resonances when LD peptides are titrated 
into wild-type Vt.   
Each picture is an overlay of several spectra with increasing molar ratios of peptide added.  
Molar ratio of peptide: 0 (black), 0.25 (red), 0.75 (green), 1.0 (blue), 2.0 (magenta), 10.0 
(cyan).  Arrows show direction and distance of fast exchanging peaks, bold arrows 
represent shifts greater than the criteria, unbold arrows show shifts that are below the 
criteria. 
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The His-LD1/LD2 titrations were carried out under identical conditions at 900MHz.  
Perturbed residues are also being affected by intermediate exchange processes during this 
titration.  As Figure 3.6.14C shows, many of the resonances perturbed by LD1 and LD2 are 
also perturbed by His-LD1/LD2.  However there are more resonances perturbed by His-
LD1/LD2 (86 residues) compared to LD1 (70) and LD2 (56).  Of the perturbed resonances, 
there are 20 that are specific to His-LD1/LD2 compared to the LD1 and LD2 
independently. There are very few resonances that are exchanging on a fast-to-intermediate 
timescale with His-LD1/LD2, most are in an intermediate or slow exchange regime. 
 
More chemical shifts with His-LD1/LD2 are in intermediate or slow exchange in the His-
LD1/LD2 titration compared to the individual peptides.  Figure 3.6.16 shows how the NH 
resonances from threonine T990, arginine R963 and glutamate E960 are being affected on a 
slower timescale (as suggested by the intensity decreases) compared to the individual LD1 
and LD2 peptides 
 
 
 
 
Figure 3.6.16 Examples of resonances that are affected on a slower timescale when 
His-LD1/LD2 is added to wild-type Vt compared to the individual LD1 and LD2 
peptides. 
Each picture is an overlay of several spectra with increasing molar ratios of His-LD1/LD2 
added.  Molar ratios: 0 (black), 0.25 (red), 1.0 (blue), 2.0 (magenta), 4.0 (cyan).  Arrows 
show direction and distance of fast exchanging peaks, bold arrows represent shifts greater 
than the criteria, unbold arrows show shifts that are below the criteria. 
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3.6.3.4 Effect of salt on the interaction of Vt with LD peptides 
 
The titrations with Vt and LD peptides have been conducted at various salt concentrations.  
Initially, 400mM NaCl was used as it was known that Vt has a stability problem at lower 
NaCl concentrations.  In this initial study it was difficult to observe many fast exchanging 
resonances and there were global intensity drops and degradation of 
1H-
15N-HSQC spectral 
quality.  The salt was subsequently dropped to 150mM which improved the quality of 
spectra obtained and also appeared to show more fast exchanging peaks.  Finally it was 
dropped to 50mM with the addition of 50mM arginine and 50mM glutamate which has 
ultimately produced the best quality data. 
 
In order to check that the salt concentration was not affecting the perturbations in a 
different manner between experiments, the LD1 titrations at different salt concentrations 
were subject to the same analysis as above.   For NaCl concentrations of 400mM, 150mM 
and 50mM, the average intensity decrease across all assigned residues is 48.8%, 45.1% and 
44.0% respectively.    
 
Figure 3.6.17 presents chemical shift data for residues in fast-to-intermediate exchange 
with LD1, conducted at different NaCl concentrations.  The major effect of lowering NaCl 
concentration has been to increase the size of the chemical shift changes undergoing fast-
to-intermediate exchange.  The effect is particularly marked for the shifts in the nitrogen 
dimension.  The total number of chemical shift changes identified at 400mM NaCl was 15, 
at 150mM was 20 and at 50mM was 23.  The 50mM NaCl has the advantage over the 
150mM because it increases the observed shift perturbations so that the results can be 
analysed with more confidence.   
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Figure 3.6.17 Bar graphs showing proton and nitrogen chemical shift differences at 
varying NaCl concentrations. 
Line shows cut-off used in the analysis of 50mM NaCl titrations 
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3.6.3.5 Hydrogen-deuterium exchange for wild-type Vt in the presence of 
paxillin 
 
Hydrogen-deuterium exchange experiments have been carried out to determine whether 
addition of LD peptides to wild-type Vt altered the protection of NH groups to exchange 
with D2O.  Previous studies with the FAT domain of FAK used this method to verify the 
proposed binding sites by observing that the residues suggested for the binding interface 
were also protected from exchange (6). 
 
A 
1H-
15N-HSQC spectrum was recorded of wild-type Vt in 20mM Tris pH7, 50mM NaCl, 
50mM arginine, 50mM glutamate, dissolved in water.  This spectrum was acquired in 2 
hours, which is the minimum time to get an adequate signal from a 200µM sample of Vt.  It 
was then freeze-dried and re-dissolved in an identical volume of deuterium oxide.  
Immediately, a second identical 
1H-
15N-HSQC spectrum was recorded and then spectra 
were recorded consecutively with 2 hour intervals for 24 hours. 
 
This method was repeated for wild-type Vt that had been prepared to contain a 10-fold 
excess of either LD1, LD2 or LD4. 
 
3.6.3.6 Description of the data for wild-type Vt plus LD1, LD2, LD4 and 
His-LD1/LD2 
 
Figure 3.6.19 shows the deuterium exchange data.  When Vt is measured in water there are 
164 resonances in this 
1H-
15N-HSQC spectrum that come from backbone NH atoms.  After 
freeze-drying and re-dissolving in D2O, 87 resonances remain (53%), these have resisted 
exchange with D2O after 2 hours.  The NH resonances that have been unambiguously 
assigned and which can be distinguished in the spectrum have been mapped onto the Vt 
crystal structure, the NH atoms have been represented (Figure 3.6.18).  Most of the NH 
resonances that remain lie within the centre of the helices.  This suggests that they may be 
involved in hydrogen bonding in the α-helix thus are protected from D2O exchange.  Helix 
3 appears well protected against exchange, but there are NH resonances in all helices that   200 
are protected.  There is one NH that appears to be protected in the loop section near the top 
of the helix bundle, this is surprising and the reason for this is unknown. 
 
When LD1 is added to Vt at a 10-fold molar excess, this 
1H-
15N-HSQC spectrum has 168 
resonances when measured in water and 17 remain (10%) when measured in D2O after 2 
hours, a dramatic decrease.  For LD2, there are 168 resonances when measured in water 
and 13 remain (8%) and for LD4, there are 164 resonances when measured in water and 43 
remain (26%) when measured in D2O.  It is not possible to precisely identify the resonances 
that remain in the Vt plus LD peptide experiments.  These results show that there is a 
decrease in the amount of protection to deuterium exchange when LD peptides are added to 
Vt compared to Vt alone. 
 
 
 
 
Figure 3.6.18 NH resonances in wild-type Vt that are protected from exchange with 
deuterium   
Purple spheres represent NH groups that remain after 2 hours in D2O 
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Figure 3.6.19 Results of the deuterium exchange experiments on wild-type Vt with 
different LD peptides added. 
Spectra in column A are measured in water, spectra in column B are measured in D2O. 
Peptide excess was 10-fold. The data were deliberately plotted at similar noise levels to 
allow a more accurate visual representation of the differences in the spectra. 
   202 
Deuterium exchange experiments were carried out using Vt with His-LD1/LD2 and a 4-
fold excess (Figure 3.6.20).  There are 190 Vt resonances in this spectrum when measured 
in water, after freeze-drying and re-dissolving in D2O, 37 resonances remained (19%). 
 
 
Figure 3.6.20 Results of the deuterium exchange experiments on wild-type Vt with 
His-LD1/LD2 added. 
Spectrum on left is measured in water, spectrum on right is measured in D2O. Ligand 
excess was 4-fold. 
 
Table 3.6.2 Summary of results from the deuterium exchange experiments 
  % resonances remaining 
after 2 hours 
Wt Vt  53 
Wt Vt + LD1  10 
Wt Vt + LD2  8 
Wt Vt + LD4  26 
Wt Vt + His-LD1/LD2  19 
 
The hydrogen-deuterium exchange data suggest that LD peptides are changing a global 
property of Vt.  Table 3.6.2 summarises these results.  From the data it can be seen that 
addition of LD1 and LD2 to Vt causes the amide groups to become more susceptible to 
exchange with D2O.  When LD4 is added the exchange is greater than for Vt alone, but not 
as drastic a change as for the other peptides.  His-LD1/LD2 is an intermediary between the 
two. Care needs to be taken in interpreting the His-LD1/LD2 data as it is a large protein so 
may be having other effects on the spectrum.   203 
 
3.6.3.7 Discussion  
 
The titration data are complex to analyse and hydrogen-deuterium exchange results are not 
typical of this type of experiment.  The chemical shift perturbations have not provided a 
discrete set of residues that could constitute an unambiguous binding face, and the 
deuterium exchange has shown that exchange is faster when paxillin is added to Vt.  The 
following sections attempt to summarise the observations without over-interpreting the data 
that has been obtained. 
 
Comparison of the three peptides LD1, LD2 and LD4 suggest that LD1 and LD2 will 
perturb the chemical shifts in the Vt spectrum whilst LD4 does not.  Paxillin His-LD1/LD2 
also perturbs similar residues to the individual LD1 and LD2 peptides. 
 
Globally, there is a reduction in intensity of the chemical shifts as the LD1, LD2 and His-
LD1/LD2 are titrated in to Vt.  This is not due to changes in Vt concentration in the sample 
as this was carefully maintained.  This intensity decrease was much less for LD4, and this is 
taken as evidence that the global intensity drop is caused by adding either LD1, LD2 or 
His-LD1/LD2.  There are several reasons that could contribute to a global intensity 
decrease. 
1.  Increasing linewidth due to slower tumbling caused by increasing size 
2.  Contribution to line shape by intermediate exchange  
3.  Changing the folding state/affecting secondary structure of Vt   
 
Vt could be interacting with the paxillin constructs which would increase the size of the 
whole molecule.  This would increase the correlation time causing faster relaxation rates 
which would lead to line broadening and loss of signal-to-noise.  Alternatively, Vt could be 
induced to interact with itself.  There is evidence to show that Vt can dimerise 
(41;172;204), and it is possible that paxillin is promoting oligomerisation of Vt producing a 
molecule with a slower tumbling time. 
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Related to this is the possibility that adding paxillin puts the Vt chemical shifts into 
intermediate exchange leading to line broadening.  This would apply to a paxillin-Vt 
interaction or Vt oligomerisaion. 
 
Finally, if paxillin was affecting the structure of Vt then this could affect the spectrum.  It is 
possible that Vt could become more loosely packed or slightly unfolded, this could affect 
the shape of the molecule and may also affect the correlation time. 
 
Assuming for the moment that it is the paxillin interacting with Vt the following 
observations can be made.  Both LD1 and LD2 peptides perturb the chemical shifts on a 
fast-to-intermediate exchange rate and an intermediate or slow exchange rate.  LD1 affects 
more resonances in a fast-to-intermediate exchange manner than LD2.  His-LD1/LD2 is 
mainly in intermediate or slow exchange with Vt.  Interestingly, the His-LD1/LD2 data 
does not indicate a dramatically higher affinity than for the individual peptides.  In other 
words paxillin His-LD1/LD2 does not appear to use aviditiy effects of two binding sites.  
The LD4 data suggests little interaction. 
 
Paxillin LD motifs have been shown to bind to the solvent accessible surfaces of FAK (6-
9), GIT1 (10) and actopaxin (α-parvin) (11).  With this in mind, the data from the 
perturbation experiments was used to identify residues that appear on the solvent accessible 
surfaces of the molecule.  This was judged by visual inspection, all perturbed residues that 
were on an accessible surface are potential candidates for binding.  Table 3.6.3 shows all 
assigned residues that meet the criteria for an affected resonance that are also on the 
external surfaces of the α-helices of Vt.  They were chosen by mapping all affected residues 
onto the crystal structure of Vt and picking the surface accessible residues.  Residues that 
are affected in the core of the protein have not been picked and have been assumed to be 
non-specific effects. 
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Table 3.6.3.  Potential candidates for binding interfaces on wild-type Vt 
LD1                      
Face 2-3     Face 3-4     Face 4-5     Face 5-2    
Ala  946  Arg  945  Gln  994  Ala  923 
Cys  950  Ile  948  Thr  990  Lys  924 
Asp  953  Gln  949  Arg  987  Ser  934 
Ala  957  Ala  955  Glu  1014  Arg  938 
Glu  960  Asp  959  Glu  1015  Asp  1013 
Leu  964  Thr  962  His  1025  Glu  1017 
Glu  967  Arg  963  Asn  1029     
Val  968  Lys  966  Ser  1033     
Gln  971  Lys  970  Glu  1040     
    Leu  982         
    Glu  986         
    Ser  992         
    Lys  996         
    Thr  1000         
LD2                      
Face 2-3     Face 3-4     Face 4-5     Face 5-2    
Ala  946  Arg  945  Gln  994  Asp  1013 
Cys  950  Ile  948  Thr  990  Glu  1017 
Glu  967  Gln  949  Glu  1014     
Val  968  Lys  952  Glu  1015     
      Asp  959  His  1025       
      Arg  963  Asn   1026       
    Lys  966  Ser  1033       
      Lys  970           
      Leu  982           
      Thr  1000           
His-LD1/LD2                      
Face 2-3     Face 3-4     Face 4-5     Face 5-2    
Asp  918  Arg  945  Arg  987  Ile  920 
Ala  921  Ile  948  Thr  990  Ala  923 
Ala  922  Gln  949  Gln  994  Lys  924 
Glu  932  Lys  952  Glu  1014  Ala  927 
Gln  949  Ala  955  Glu  1015  Ser  934 
Cys  950  Asp  959  Asn  1026  Arg  935 
Asp  953  Arg  963  Gln  1032  Arg  938 
Ala  957  Lys  966  Ser  1033  Asp  1013 
Glu  960  Lys  970      Thr  1020 
Glu  967  Arg  978      Val  1024 
Gln  971  Thr  979      Gln  1032 
    Leu  982      Glu  1042 
    Ser  992         
    Lys  996         
    Thr  1000           
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From this it can be seen that the highest number of perturbed residues are on Vt face 3-4 
with many of these being on helix 3.  Mapping these residues onto the crystal structure of 
Vt presents a potential interaction site on face 3-4 that covers most of helix 3 and part of 
helix 4 (Figure 3.6.21).  This region is similar when LD1, LD2 and His-LD1/LD2 is titrated 
into Vt suggesting that both LD1 and LD2 would interact at the same site on face 3-4, but 
there may be subtle differences between how LD1 or LD2 binds. 
 
 
Figure 3.6.21 Perturbed surface residues of Vt face 3-4 (purple) 
 
The affected residues on the face of helices 2-3 and 4-5 are shown in Figure 3.6.22.  For 
face 2-3, LD1 and LD2 perturb residues on helix 3, His-LD1/LD2 perturbs some on helix 2 
also.  For face 4-5 there are few perturbations but they are the same for all three paxillin 
constructs. 
 
Figure 3.6.23 shows the perturbed surface residues on face 5-2, plus all affected residues in 
the first helix, helix1.  These residues can be found in Appendix 5.7.  LD1 is perturbing a 
few residues on this face, LD2 perturbs less.  In contrast there are a 12 residues perturbed 
by His-LD1/LD2. 
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Figure 3.6.22 Perturbed residues on Vt face 2-3 (top-cyan) and 4-5 (bottom-yellow)  
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Figure 3.6.23 Potential interaction site of LD motifs with face 5-2 of Wt-Vt. 
Dark pink are perturbed residues on face 5-2, light pink are all perturbed residues on 
helix1 
 
The above figures present the perturbed residues that are on the exterior surfaces of the α-
helices of Vt.  Assuming that the interaction is a simple ‘face-to-face’ binding where the 
surface of one helix contacts the helix face of the ligand, these could be potential 
interaction sites.  Interesting possibilities arise from these pictures, for instance there 
appears to be an attractive interface on face 3-4 (Figure 3.6.21) where subtle differences 
between the specific residues could be involved in determining whether LD1 or LD2 binds. 
   
A second interesting observation is the perturbation of face 5-2 with His-LD1/LD2 
compared to the individual LD peptides.  LD2 peptides perturb only 2 residues on this face, 
LD1 perturbs 5, yet the longer construct containing both LD1 and LD2 perturbs 12 residues 
on face 5-2.  This could suggest that His-LD1/LD2 may gain access to this face where the 
peptides cannot.  This could occur if His-LD1/LD2 exhibits a higher affinity than the two 
motifs separately by having increased avidity, although the perturbation data does not fully 
support this.  However, the GST-pulldown and catch-up data argue for an interaction with 
higher affinity between Vt and His-LD1/LD2 than suggested by the NMR data alone.  One   209 
limitation of the NMR data for the paxillin construct is that a molar ratio of 1:10 was not 
achieved, if this molar ratio is achieved then increased affinity and avidity effects may be 
observed. The structure of Vt suggests that face 5-2 could be occluded by helix1, His-
LD1/LD2 may have a property that will enable access to this site. 
 
It was hoped that hydrogen-deuterium exchange would shed light on the proposed binding 
interfaces by showing areas of increased protection in the regions of ligand interaction.  
Contrary to expectation, the data suggests that exchange is actually increased when Vt is in 
the presence of paxillin.  There are several interesting possibilities for this result.  If the NH 
groups are now more accessible to exchange it could suggest that the Vt molecule has been 
destabilised.  It is also possible that Vt in solution is in a self-association equilibrium and 
that paxillin shifts the equilibrium to a more solvent accessible state.  Either way it seems 
that addition of paxillin is affecting the dynamic properties of Vt by increasing its 
susceptibility to exchange with deuterium.    
 
This deuterium data gives rise to the possibility that LD peptides are changing a global 
property of Vt and that the interaction between paxillin and Vt may be more complex than a 
simple ‘face-face’ helix interaction.  There are large scale global changes occurring, and it 
is difficult to imagine how a 13mer peptide would induce all of these by binding to one 
small region on Vt.  Residues are being affected in the same molecule by different rates of 
chemical exchange which could suggest that both a binding and unfurling/destabilising 
event is occurring simultaneously. 
 
Because the hydrogen-deuterium exchange data show global perturbations, the background 
changes in the chemical shift perturbation data is perhaps unsurprising, so by setting a 
criteria that searches for a small number of the most perturbed chemical shifts and 
intensities it is hoped to identify a subset of residues that are reporting primarily on residues 
that bind LD peptides directly. 
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3.6.3.8 Summary of results 
 
The data suggest that the Vt-LD interaction has a global and a local aspect, consequently 
LD binding is more complex than a face-to-face binding with preformed interaction 
surfaces.  Dissection of these effects is difficult but the following observations seem to be 
possible 
 
The data are consistent with a specificity between LD motifs; LD1 and LD2 both perturb 
residues in wild-type Vt, LD4 does not.  The affinity can be estimated by looking at 
whether Vt residues undergo fast or slow exchange with LD peptides, using this rationale, 
LD2 would have a slightly higher affinity than LD1.  His-LD1/LD2 would have a higher 
affinity than the individual LD peptides. 
 
Both peptides LD1 and LD2 cause chemical shift perturbations that have been grouped into 
regions based on residues that are accessible on the helix faces of Vt.  This data may be 
interpreted as potential interaction sites, the most attractive site being face 3-4 for LD1, 
LD2 and His-LD1/LD2.  Face 5-2 may be a second site accessible to His-LD1/LD2, with 
LD1 interacting weakly and LD2 not interacting at all.  Face 2-3 and 4-5 would be the least 
attractive interaction sites.   
 
The deuterium exchange data shows that the global properties of Vt is altered when paxillin 
is added and suggests that the interaction between the two may be more complex than 
previously thought. 
 
3.6.3.9 How do the current experiments compare to previous studies of 
Vt-LD interactions? 
 
As the ligand binding data are not a clear-cut case producing a well defined binding site, 
there is merit in evaluating the previously published results in the light of this new data.  It 
has previously been shown that Vt will bind to LD1, LD2 and LD4 (5;80) with LD2 being 
the strongest interaction and LD4 binding only weakly in GST pulldown studies.    211 
 
Prior to this, the two regions of Vt suggested to be paxillin binding subdomain (PBS) were 
defined as PBS1 and PBS2.  PBS1 was suggested due to sequence similarity to FAK as Vt 
residues 952-971 (110), and PBS2 was determined through truncation mutagenesis and 
pulldown studies to include Vt residues 978-1000 (86). PBS1 lies on helix 3 and PBS 2 lies 
on helix 4 of Vt (Figure 3.6.24). 
 
 
Figure 3.6.24 Paxillin binding subdomains 1 (PBS1:red) and 2 (PBS2:blue) (86;110) 
 
These PBSs had also been predicted for the FAT of FAK (residing on helix 1 and helix 4).  
A study by Hoellerer et al. (6) determined that the binding interface overlapped partially 
with this PBS, in addition they determined the specific residues that LD2 and LD4 would 
interact with on FAT helices 1-4 and 2-3.  The residues involved in the interface can be 
found in Table 3.6.4.   
Based on these findings, Hoellerer et al. (6) predicted two new structure based interaction 
sites on Vt on opposite faces of Vt (Table 3.6.4).  The Vt domain adopts a fold similar to 
the FAT domain, but FAT was found to interact with LD2 and LD4 (5-9) while Vt can 
interact with LD1, LD2 and LD4 (5;80).  Hoellerer et. al (6) speculated that the residues 
involved in FAT-LD binding can be superimposed onto Vt to create two predicted binding 
sites for LD motifs (Figure 3.6.25).  The two proposed sites make up face 3-4 and face 5-2   212 
on Vt, the specific residues can be found in Table 3.6.4 and in the introduction, Figure 
1.5.4.  The authors state that Vt face 5-2 has the pre-requisites for binding LD motifs (based 
on their findings with the FAT domain), namely a hydrophobic patch between two helices 
surrounded by basic residues that can interact with negative charges in the peptide.  
However, Vt face 5-2 is occluded by helix 1 and may require displacement of helix 1 to 
enable binding.   
 
 
 
 
Figure 3.6.25 Predicted binding sites in Vt based on the FAT domain of FAK. 
Pale green residues make up binding interface Vt 3-4 (FAK 2-3) and pale blue make up 
face Vt 5-2 (FAK 1-4). 
 
With this knowledge a comparison can be made with the data presented in this thesis. The 
attractive binding face 3-4 on Vt is compared to the PBS (86;110) and the new predicted 
two-face binding sites (6) in Figure 3.6.26A-C.  There are similarities between the 
experimentally derived data for Vt and both PBS1 and PBS2 (B) and the predicted two-site 
model (C). 
 
The second potential site on Vt face 5-2 is compared in Figure 3.6.26D-E. While the region 
is similar between the two there are more residues affected by His-LD1/LD2 than 
predicted.  This is likely a consequence of the extra amino acids in the His-LD1/LD2 
protein compared to 13mer peptide.   213 
 
 
 
 
 
Figure 3.6.26 Comparison of proposed binding interface on Vt with previous 
predictions 
A: Proposed binding interface 3-4 from the titration data (purple); B: PBS1 (blue) and 
PBS2 (red); C: Predicted binding interface 3-4 from FAK data; D: Proposed binding 
interface 5-2 from the titration data (pink); D: Predicted binding interface 5-2 from FAK 
data (light blue). 
 
A list of the residues in FAT affected by LD2 and LD4 and the predicted residues in Vt are 
shown in Table 3.6.4.  A comparison has been made to determine which paxillin LD motifs 
perturbed these predicted residues in the titration experiments.  Because the assignment of 
Vt was conducted using Vt/I997S, some assignments could not be transferred to the wild-  214 
type spectrum as peaks were ambiguous in their position or they were missing.  This means 
that some are missing from the analysis, these are labeled accordingly in the table.  As a 
result there are 10 out of 15 residues that can be analysed on face 3-4, and 9 out of 13 that 
can be analysed on face 5-2.   
 
For the residues predicted by Hoellerer et al. (6) to be on the Vt face 3-4 interaction site, 
chemical shift perturbations above the criteria set for analysis were seen for nine residues 
by LD1, LD2 caused perturbations to five residues, and His-LD1/LD2 perturbed eight.  On 
Vt face 5-2, LD1 perturbed three residues but LD2 did not perturb any of the predicted 
residues.  His-LD1/LD2 perturbed six.   
 
In addition, for face 3-4 there were and extra five, five and seven residues in Vt perturbed 
by LD1, LD2 and His-LD1/LD2 respectively that were not identified in the FAK binding 
study.  For face 5-2 there are and extra three perturbed residues with LD1, two residues for 
LD2 and six residues for His-LD1/LD2. 
 
This comparison is summarised in Table 3.6.5. for Vt and FAK Assuming that these sites 
do represent an interaction site in Vt, the data suggests that both LD1 and LD2 bind to Vt 
face 3-4, and in addition LD1 possibly may interact with Vt face 5-2 while this does not 
appear to be the case for LD2.  The data is consistent with no interaction for either site with 
LD4.   
 
It cannot be ruled out that LD2 and LD4 could interact with Vt face 5-2 as the affinity for 
this site may be too low to overcome potential steric hindrance from helix1. 
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Table 3.6.4 Comparison of the residues determined experimentally for FAK, the two 
site prediction for Vt and the experimental data from this thesis 
Experimental 
data
(a) 
Predicted 
residues
(b) 
Vt residues 
affected
(c)    
FAK  face 2_3  Vt  face 3_4  LD1  LD2  LD1/LD2 
Val  951  Ile  948  +  +  + 
Val  954  Ala  951  -  -  - 
Lys  955  Lys  952  -  +  + 
Gly  958  Ala  955  +  -  + 
Leu  959  Lys  956  -  -  - 
Arg  962  Asp  959  +  +  + 
Leu  965  Thr  962  +  -  - 
Asp  969  Lys  966  +  +  + 
Lys  988  Glu  986  +  -  - 
Asn  991  Pro  989  -  -  - 
Leu  994  Ser  992  +  -  + 
Gly  995  Thr  993  -  -  - 
Thr  998  Lys  996  +  -  + 
Met  1001  Ser  999  -  -  - 
Lys  1002  Thr  1000  +  +  + 
 
Experimental 
data
(a) 
Predicted 
residues
(b) 
Vt residues 
affected
(c)    
FAK  face 1_4  Vt  face 5_2  LD1  LD2  LD1/LD2 
Arg  919              
Tyr  925  Ile  920  -  -  + 
Val  928  Ala  923  +  -  + 
Thr  929  Lys  924  +  -  + 
Val  932  Ala  927  -  -  + 
Lys  933  Leu  928  -  -  - 
Val  935  Met  930  -  -  - 
Ile  936  Ala  931  -  -  - 
Ser  939  Ser  934  +  -  + 
His  1025  Gln  1028  -  -  - 
Ala  1028  Met   1031  -  -  - 
Val  1029  Gln  1032  -  -  + 
Lys  1032  Lys  1035  -  -  - 
Leu  1035  Val  1038  -  -  - 
 
(a) experimentally determined binding residues for LD2 and LD4 (6).  (b) predicted residues based on FAK 
data (6).  (c) experimentally determined chemical shift perturbations from this study.  ‘+’ means perturbation 
observed above the criteria set in the analysis, ‘-‘ means perturbation not observed above the criteria 
Residues in blue are unassigned, residues in red cannot be unambiguously determined in the wild-type Vt 
spectrum when transferring assignments from Vt/I997S to wild-type 
1H-
15N-HSQC spectra.   216 
 
Table 3.6.5 Comparison of the Vt data with FAK data from Hoellerer et al. (6) 
  LD1    LD2    LD4    His-LD1/LD2   
  FAK  Vt  FAK  Vt  FAK  Vt  FAK  Vt 
Face 3-4  -  +  +  +  +  -  nd  + 
Face 5-2  -    +
(a)   +  -  +  -  nd  + 
 
Plus signs represent an interaction, minus represents no interaction.  nd=not done. (a) 
possible interaction, few residues affected. 
 
Deuterium exchange experiments carried out on the FAT domain of FAK showed that the 
same regions that were affected by chemical shift perturbations were also protected from 
exchange with D2O, confirming that the LD peptides were interacting and giving those 
regions more stability.  In contrast, D2O exchange experiments with Vt do not show regions 
of increased protection when Vt and LD peptides are added together, in fact it suggests that 
Vt is becoming more susceptible to exchange in the presence of LD1 or LD2.  This 
suggests that a global mechanism may be operating at the same time as local binding of LD 
peptides.  What is clear is that the mechanism of interaction of Vt and paxillin is distinct 
from that of FAK and paxillin and it may not be a simple ‘face-face’ interaction between 
the helices. 
 
The chemical shift perturbation data suggests that the Vt residues perturbed by LD peptides 
are subtly different to that of LD peptides with FAK.  LD2 and LD4 were initially shown to 
be promiscuous recognition sequences when interacting with FAK (6), now there is some 
evidence that there may be site specificity (7;207).  The data presented here would be 
consistent with site specificity of LD peptides for Vt.  LD4 does not perturb Vt face 3-4 
whilst LD1 and LD2 do.  LD1 can affect residues on the occluded Vt face 5-2, whereas 
LD2 and LD4 cannot.  And even though LD2 and LD4 perturbations to this face cannot be 
completely excluded, there is a difference between them and LD1 in affecting this face.  
His-LD1/LD2 possesses properties that will allow perturbations to Vt face 5-2 which under 
the conditions used here the individual peptides do not.   217 
 
With the observations of global mechanisms causing increased hydrogen-deuterium 
exchange properties of Vt, thermal melting experiments have been carried out to observe 
the effects of LD peptides on the stability of Vt (Section 3.6.5).  
 
3.6.4  The His-LD1/LD2
 1H-
15N-HSQC spectrum in the presence of 
excess wild-type Vt 
 
Since paxillin His-LD1/LD2 can be recombinantly expressed and isotope labelled it was 
possible to observe the perturbations on paxillin His-LD1/LD2 when titrated with unlabeled 
Vt.  The 
1H-
15N-HSQC of paxillin at 900MHz with and without Vt at 4-fold excess is 
shown in Figure 3.6.27.  Paxillin assignments were not yet available, so the perturbations 
cannot be assigned to specific amino acids, but the overlay shows that there are a number of 
resonances that are missing from the spectrum and there are some new peaks that have 
appeared. 
 
In the spectrum, 3 peaks are new and there are 18 resonances that have completely 
disappeared.  This suggests that only a small number of residues in paxillin are involved in 
the interaction with Vt.  Tantalisingly, the number of residues contained in the LD1 and 
LD2 motif is 16; corresponding well to the number of resonances lost in the His-LD1/LD2 
spectrum.  A titration carried out at 600MHz under the same buffer conditions suggest that 
there are fast-to-intermediate and slow exchange effects occurring (data not shown).  
Attempts to identify whether one set of resonances may be affected before another 
(corresponding to one LD motif binding before another) was not possible to determine from 
the data.  Clearly identification of the interacting residues must await assignment. 
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Figure 3.6.27 Overlay 
1H-
15N-HSQC spectrum of paxillin with excess Vt 
Measured at 900MHz with a cryoprobe.  Paxillin alone shown in black, paxillin with 4-fold 
excess of Vt is shown in red. Paxillin His-LD1/LD2 at 100µM in 20mM Tris pH7, 50mM 
NaCl, 50mM arginine, 50mM glutamate. Vt was made to 600µM and added to 4-fold excess 
in the same buffer. 
 
An interesting observation was noted when an excess of Vt was added to paxillin.  On 
addition of a 4-fold excess of Vt to the solution of paxillin (at 100µM), the sample is clear. 
After leaving the sample overnight a massive precipitation event occurs.  Figure 3.6.28 
shows the contents of various samples from this experiment.  In the initial mixture of 4-fold 
excess Vt with paxillin (lane 3), a large band can be seen which coincides with the control 
Vt band.  Interestingly, a band corresponding to His-LD1/LD2 cannot be observed, despite 
being detected in a 
1H-
15N-HSQC spectrum.  There is also a protein band at 80kDa whose   219 
identity is unknown.  Mass spectrometry of this sample produces a peak of molecular mass 
matching that of Vt (data not shown).  The sample is pelleted after 12 hours to remove the 
precipitate, lane 4 shows the remaining soluble fraction.  Mass spectrometry of this sample 
also produces a peak corresponding to Vt, and the 80kDa band is still present.  Lane 2 
shows the precipitate.  A mass spectrum of this sample was unsuccessful, but the major gel 
band would be consistent with the molecular weight of Vt.  
 
 
Figure 3.6.28 Composite polyacrylamide gel showing different fractions from a His-
LD1/LD2 sample containing excess Vt 
A 4-fold excess of 
14N-Vt was added to 
15N-His-LD1/LD2 (100µM).  After 12 hours a 
precipitation event is observed.  The contents of the precipitate is shown in lane 2 (ppt).  
Lane 3 shows the initial mixture of Vt and His-LD1/LD2 (mix), and lane 4 shows the 
remaining soluble fraction after removal of the precipitate.  Lane 5 is Vt at 600µM that was 
left at room temperature for twelve hours, and lane 6 is a sample of His-LD1/LD2.  
 
A comparison of paxillin resonance intensity from 
1H-
15N-HSQC spectra before and after a 
precipitation event showed that paxillin can still be seen in solution at a similar intensity, 
looking at the relative intensities of resonances that remain from a sample that has been 
spun down to remove precipitate show a decrease in intensity by an average of 20 %.  This 
has been taken as evidence that paxillin is remaining in solution and that Vt may be 
precipitating out of solution.  The small loss of paxillin intensity may infer that the 
precipitate was made predominantly from Vt.  It is intriguing to speculate that paxillin may 
act as a catalyst for Vt aggregation or unfolding.   220 
 
3.6.5  Conformation of Vt in the presence of paxillin and thermal 
denaturation of Vt 
 
An idea that arose from the titration data is that the integrity of the structure of Vt could be 
affected by paxillin peptides LD1 and LD2 and the longer construct His-LD1/LD2.  
Hydrogen-deuterium exchange experiments show dramatically increased exchange rates 
with solvent in the presence of LD1, LD2 and His-LD1/LD2.  With this in mind, far-UV 
CD spectra were acquired on Vt in the presence of paxillin to observe any conformational 
differences and the stability of Vt was measured in the presence of paxillin by thermal 
denaturation monitored by circular dichroism.  The CD data was reported as ellipticity as 
the binding constant for the interaction is not known.  For His-LD1/LD2, ratios of 1:1 and 
1:4 have been used, 1:4 being the ratio used in the chemical shift perturbation experiments.  
For the LD peptides is was not possible to achieve the excess used for chemical shift 
perturbation, so LD peptides at 50µM were used.  If one assumes that the Kd was in the 
region of 10
-6M for LD peptides, when Vt is at 0.5µM and LD is at 50µM the expected 
proportion bound is 33%.   
 
3.6.5.1 Wild-type Vt 
 
Figure 3.6.29a shows the circular dichroism spectrum of wild-type Vt at 25ºC and 85ºC.  At 
25ºC the protein has a typical spectrum for an α-helix.  At 85ºC it is evident that the degree 
of helicity has reduced.  Figure 3.6.29b shows the thermal denaturation curve for wild-type 
Vt.  The melting temperature (Tm) can be calculated from the midpoint of the transition.  
This is found by finding the first derivative of this curve and finding the maximum value 
(see Methods Figure 2.3.2b-c). The results of this experiment suggest that wild-type Vt has 
a Tm of 74.9ºC ± 0.19.  This melting curve is not ideal as it is lacking a baseline at the end 
of the experiment, this was unexpected and is in part due to the high Tm for Vt. 
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3.6.5.2 Wild-type Vt plus LD peptides 
 
The difference spectra from the wavelength scans for wild-type Vt plus LD peptides are 
shown in Figure 3.6.30a.  The addition of all LD peptides at 25ºC appears to reduce the 
helicity by a small amount, with the reduction by LD2 and LD4 being the same and LD1 
being reduced the most.  At 85ºC the reduction in helicity is marked and does appear to be 
greater than when Vt is alone.  Figure 3.6.30b shows the melting profile for Vt plus LD 
peptides.  The melting temperatures for wild-type Vt plus LD1, LD2 or LD4 is 69.8ºC ± 
0.30, 78.4ºC ± 0.46 and 75.0ºC ± 0.44 respectively.  Together this data suggests that LD1 
peptide reduces the helicity of Vt and lowers the Tm by 5ºC, LD2 lowers the helicity of Vt 
but increases the Tm by 3ºC and LD4 lowers the helicity but does not affect the Tm. 
 
3.6.5.3 Wild-type Vt plus His-LD1/LD2 
 
The difference spectra from the wavelength scans for wild-type Vt plus paxillin His-
LD1/LD2 is shown in Figure 3.6.31a. The addition of paxillin at a 1:1 and 1:4 ratio at 25ºC 
appears to reduce the helicity of Vt by a small amount.  At 85ºC the reduction in helicity is 
marked and is greater than when Vt is alone. The 1:4 ratio has a very large change in the 
CD spectrum which is greater than the 1:1. 
 
Figure 3.6.31b shows the melting profile for Vt plus His-LD1/LD2 at 1:1 and 1:4 ratio.  
The melting temperature for the 1:1 and 1:4 ratios is 72.8ºC ± 0.28 and 72.3ºC ± 0.38 
respectively.  Together this data suggests that His-LD1/LD2 reduces the helicity of Vt with 
the 1:4 ratio being more efficient at this than the 1:1.  His-LD1/LD2 at 1:1 lowers the Tm 
by 2ºC, and at 1:4 lowers the Tm by 3ºC. 
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Figure 3.6.29 Far UV difference wavelength scan at 25ºC and 85ºC and thermal 
denaturation curve for wild-type Vt at 0.5µM   223 
 
Figure 3.6.30 Far UV difference wavelength scans at 25ºC and 85ºC and thermal 
denaturation curve for wild-type Vt plus LD peptides 
Vt was at 0.5µM, LD peptides at 50µM.  A: LD1 plus Vt at 25ºC (dark orange) and 85ºC 
(light orange); LD2 plus Vt at 25ºC (light green) and 85ºC (dark green);  LD4 plus Vt  at 
25ºC (dark blue) and 85ºC (light blue; Vt alone at 25ºC (purple circle) and 85ºC (pink 
circle). B: melting curves for Vt plus LD1 (orange), LD2 (green), LD4 (blue) and Vt only 
(purple). 
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Figure 3.6.31 Far UV difference wavelength scans at 25ºC and 85ºC and thermal 
denaturation curve for wild-type Vt plus His-LD1/LD2 
Vt was at 0.5µM.  A: 1:1Vt:His-LD1/LD2 at 25ºC (red) and 85ºC (orange); 1:4 Vt:His-
LD1/LD2 at 25ºC (brown) and 85ºC (khaki); Vt alone at 25ºC (purple circle) and 85ºC 
(pink circle). B: melting curves for 1:1 Vt:His-LD1/LD2 (red), 1:4 Vt:His-LD1/LD2 
(brown) and Vt only (purple). 
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Table 3.6.6 Melting temperatures for all experiments 
 
  Tm  % resonances remain 
after 2hours in D2O 
Wt Vt  74.9 ± 0.19  53 
Wt Vt + LD1  69.8 ± 0.30  10 
Wt Vt + LD2  78.4 ± 0.46  8 
Wt Vt + LD4  75.0 ± 0.44  26 
     
Wt Vt + His-LD1/LD2 1:1  72.8 ± 0.28  nd 
Wt Vt + His-LD1/LD2 1:4  72.3 ± 0.38  19 
 
The results for the Tm for all experiments are shown in Table 3.6.6. The high melting 
temperature for Vt was unexpected.  Two other instances of Tm for Vt have been cited in 
the literature and these are conflicting.  Saunders et al. (137) calculated the Tm for Vt using 
DSC and found the Tm to be 63.3ºC.  In contrast, Bakolitsa et al. (152) show that the Tm is 
greater than 70ºC.  This high melting temperature could reflect the fact that helices are 
more stable than the overall structure, or it could reflect aggregation of Vt at higher 
temperatures (278). 
 
Unfortunately these results have not unambiguously answered the question of whether the 
Vt structural integrity is affected by LD peptides.  Table 3.6.6 presents the Tm and 
deuterium exchange results together.  LD4 peptide has the least effect on the D2O exchange 
and appears to affect the helicity of Vt to a small degree but does not affect the Tm.  LD1 
leads to the loss of virtually all resonances in the D2O spectrum and CD shows that the 2º 
structure is affected and the Tm is lowered, LD2 also leads to loss of most resonances in the 
D2O exchange and the CD results show effects on the 2º structure while the Tm is 
increased.  These results would be consistent with higher order aggregates occurring when 
paxillin is added to Vt and would also agree with the observation that excess Vt will 
precipitate when added to paxillin.  These data would benefit from being carried out at 
higher LD peptide excesses. 
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4  Discussion 
 
The nature of the interaction between Vt and paxillin has been under debate for some time. 
Vt was shown in vitro to interact with paxillin LD1, LD2 and LD4 (5;80).  The region on 
Vt proposed to bind to paxillin was shown by truncation mutagenesis and sequence 
alignment to reside on helix 3 and 4 of Vt (see Section 1.5, Figure 1.5.2); this region was 
called the paxillin binding subdomain and consists of two regions, PBS1 and PBS2 
(86;110).  An alternative prediction for the binding region on Vt was made by Hoellerer et 
al. (6) which comprised of two binding sites on opposite faces on Vt (see Section 1.5, 
Figure 1.5.5) 
 
This thesis set out to describe the molecular basis of the interaction between Vt and paxillin 
LD motifs.  The original aims were to locate the binding site for paxillin LD motifs on Vt 
and to understand the specificity, stoichiometry and affinity of this interaction.  A 
comparison of this data would then be completed using data from the interaction between 
the FAT domain of FAK with paxillin (6) in an attempt to further understand the molecular 
recognition involved when LD motifs interact with a target sequence, and also to 
understand how FAK and vinculin might compete for binding of paxillin (4).  Since this 
original aim, the structures of two more paxillin binding partners, Git1 (10) and actopaxin 
(α-parvin) (11) in complex with LD motifs have been solved and have been included in this 
comparison. 
 
The interaction between Vt and LD motifs has proven more complex than originally 
anticipated, but the body of data presented in this thesis has provided several new avenues 
of investigation which can now be explored.  
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4.1  Vinculin tail and paxillin can be purified for use in NMR 
studies 
 
In this study, recombinant wild-type and mutant Vt proteins have been purified from E.coli 
expression to a purity >95% (Section 3.1.1 and 3.3).  All purified proteins adopt a similar 
highly α-helical fold as judged by far-UV circular dichroism measurements and produce 
monomeric proteins when analysed by size exclusion chromatography (Section 3.1.2. and 
3.3). Wild-type Vt and Vt/I997S have subsequently been used throughout this thesis.  
Buffers containing 50mM arginine and 50mM glutamate aided in the solubility and 
stability of Vt in solution at high concentrations (Section 3.3.5). 
 
A recombinant paxillin construct, pET-15B-LD1/LD2 , containing LD motifs LD1 and 
LD2 has also been purified to >95% purity, called His-LD1/LD2.  This purification is 
challenging and is still being refined to produce the best quality protein possible (Section 
3.5).  At present, the oligomeric state of His-LD1/LD2 is unclear; size exclusion 
chromatography suggests that it may exist in multiple forms.  Circular dichroism suggests 
that it is predominantly unstructured and this is in agreement with the poor dispersion of 
proton signals in the 
1H-
15N-HSQC spectra. 
 
4.2  The Vt/I997S backbone amides have been assigned and the 
assignments transferred to wild-type Vt 
 
78% of the amino acids in Vt/I997S have been assigned in the 
1H-
15N-HSQC spectrum.  
88% of the α-helical regions have been assigned, many of the missing regions are in 
extended loops at the N-and C-terminus.  It was an especially challenging assignment 
problem, and was enabled using a multi-faceted approach involving 3D-heteronuclear 
editing techniques, amino acid selective labelling and triple resonance experiments in 
conjunction with high levels of perdeuteration.  There is evidence in the 
1H-
15N-HSQC 
spectrum that Vt has multiple conformations for some backbone amides, as judged by slow 
exchange effects for some resonances in the spectrum (Section 3.4.7). 
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Of the Vt/I997S NH assignments, 93% could be transferred to the wild-type spectrum, 78% 
of these were transferred with a high level of confidence.  There are still some unknown 
resonances that are unique to the wild-type spectrum, and some that have been transferred 
at a lower confidence level that need to be confirmed by recording triple resonance 
experiments on wild-type Vt.   
 
4.3  Elucidating the nature of the interaction between Vt and 
paxillin has proven difficult 
4.3.1  Catch-up experiments show an interaction but chemical shift 
perturbation data is more complex than anticipated 
 
It has been previously observed that Vt and paxillin interact in vitro (5;67;79;80;86).  GST-
pulldowns and catch-up experiments carried out in this thesis confirm this interaction and 
show that GST-LD1/LD2 will interact with Vt in a manner that is not mediated by 
unspecific GST binding (Section 3.6.1 and 3.6.2). Based on the catch-up experiment, the 
interaction between the two appears to be tight, although it was not possible to estimate a 
dissociation constant. 
 
Chemical shift perturbation studies using NMR have focused on specific LD motifs and the 
effect that they have on Vt (Section 3.6.3).  When peptide mimics of LD1 and LD2 are 
added to Vt, chemical shift perturbations occurred throughout the entire Vt molecule rather 
than at discrete sites.  These perturbations manifest themselves as intensity decreases as 
well as positional changes which may suggest that these interactions are in the fast-to-
intermediate exchange regime.  Due to this fact, adaption of the analysis methodology was 
required to combine the information from chemical shift changes and intensity changes.  
The wide distribution of perturbations suggest that there may be a global process affecting 
Vt in addition to LD binding.  In an attempt to separate global and local changes, a 
threshold was set for chemical shift changes and intensity decreases.  Resonances below 
this threshold were not considered significant for the determination of a LD binding site.  
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When analysed in this manner, peptides containing LD1 and LD2 cause perturbations that 
can be attributed to specific regions on Vt, and are consistent with an interaction between 
Vt and LD1 and LD2.  When compared to LD1 and LD2, the effects on the spectrum from 
LD4 appear very small and were considered to be non-specific.  This result is contrary to 
previous observations where LD4 interacts with Vt (5;80), the data presented here would be 
consistent with little interaction between Vt and LD4.  
 
When paxillin His-LD1/LD2 is titrated with Vt to a 4-fold excess, significant aggregation is 
observed after 12 hours and a large precipitate is formed.  It is believed that the precipitate 
consists of Vt but this needs to be confirmed.  It is possible that paxillin is catalysing Vt 
aggregation under these conditions. 
 
4.3.2  Hydrogen-deuterium exchange shows decreased protection 
against exchange  
 
Hydrogen-deuterium exchange experiments between Vt and LD peptides suggest that 
addition of LD1 and LD2 increases the exchange rate of amides with D2O, such that after 2 
hours in D2O, over 90% of resonances have disappeared from the spectra (Section 3.6.3.5).  
This is contrary to expected and is also different to the result observed with the FAT of 
FAK with LD2 and LD4 (6).   
 
This suggests that LD peptides affect a global property of Vt and is consistent with the 
global chemical shift perturbations seen when Vt is titrated with LD1 and LD2 (Section 
3.6.3).  The reason for this is unknown, but it could be that the structural stability or 
oligomerisation state of Vt is altered leading to increased exchange. 
 
4.3.3  Thermal denaturation is inconclusive but shows that Vt has a 
high melting temperature 
 
Far-UV circular dichroism scans show that thermal denaturation reduces the helicity of Vt, 
and that this is possibly enhanced with the addition of paxillin.  Thermal denaturation 
experiments show that Vt has a high melting temperature (75ºC), and that LD1, LD2 and   230 
His-LD1/LD2 may alter this but not as much as expected (Section 3.6.5).  This high 
melting temperature could be down to stability of Vt helices, or due to higher order 
aggregates forming as Vt denatures which could mask the effects of paxillin.  
 
4.3.4  There is a potential interaction site on Vt face 3-4 
 
It is clear from the data presented in this thesis that the interaction between Vt and paxillin 
is not a simple one.  Chemical shift perturbation data suggests that there are underlying 
effects on Vt other than a simple face-face binding event.  It is possible that Vt is becoming 
destabilised or unfolding when LD motifs are present, and it is possible that aggregation of 
Vt may be occurring.  With these caveats in place, the results from the titrations suggest a 
potential binding interface on Vt.  
 
The binding interface is proposed to reside on Vt face 3-4 (Figure 4.3.1 for LD1, Figure 
4.3.2 for LD2 and Figure 4.3.3 for His-LD1/LD2).  There are two clusters of affected 
residues that consist of a hydrophobic residue surrounded by polar and charged residues.  It 
is interesting that when mapped onto the molecule viewed as the surface potential, two 
separate regions appear, one centred around I948 and one centred around L982.  For the 
LD1 peptide, I948 is surrounded by R945, Q949, K996 and T1000, and L982 is surrounded 
by T962, R963, K966, E967, K970 and E986.  For LD2, K996 is replaced by K952 and 
only has K966, K970, E967, R963 surrounding L982.  For His-LD1/LD2 the affected 
residues include all of the previously stated amino acids plus two unique residues, R978 
and T979. 
 
This potential interface covers a large area of the 3-4 face, the size of this area is estimated 
as 2709Å
2 using the molecular graphics program MOLMOL (269).  The same analysis 
predicts the entire Vt face 3-4 to be 3760Å
2, so the interaction interface covers 72% of this 
Vt face.  The interface predicted by Hoellerer et al. (6) (see Figure 1.5.5) is estimated to 
cover 1960Å
2, which is 52% of the entire Vt face 3-4.  The data presented in this thesis 
would be consistent with a proposed interface that is larger than the predicted data by 
Hoellerer et al. (6).   231 
 
Assuming that LD motifs bind to this interface, it is difficult to imagine how one LD motif 
containing 13 residues in a helical conformation would make all of these contacts.  
Analysis of the LD motif binding to the FAT domain of FAK (6) reveals that the helical 
peptide is 16.6Å in length, this corresponds to approximately three turns of α-helix.  The 
entire length of the interface proposed here is 33.2Å (from Cα R945 to Cα L982) 
corresponding to approximately six helical turns of Vt. 
 
It is possible that a single LD peptide binds to this entire region in an extended 
conformation, alternatively there could be two separate binding sites for LD peptides on 
face 3-4 of Vt (Figure 4.3.4), one surrounding L982 and the other surrounding I948.  An 
estimation of the length of these two sites individually produce a length of 16.0Å and 
16.3Å for site I948 and site L982 respectively.  While it is conceivable that a binding site of 
these dimensions could be occupied by an extended conformation of LD motif, all of the 
evidence so far indicates that LD motifs adopt a helical structure in the target bound state 
(6;7;10;11;87).  It has been shown previously that increasing the helicity of LD4 increases 
the affinity of binding to FAT (87), so LD binding to Vt in an extended conformation 
would constitute an entirely new mode of interaction. 
 
 
In the remainder of this section the implications of a two site binding model vs. an extended 
binding model will be considered.  In the two site model, the site surrounding L982 will be 
called site 1 and the site surrounding I948 will be called site 2 (Figure 4.3.4).  These are 
named according to their position in the full length Vt molecule (Figure 4.5.2). 
 
 
 
 
 
 
 
 
 
   232 
 
 
 
 
Figure 4.3.1 The proposed binding interface between Vt and LD1 on Vt face 3-4 
The surface potential of Vt face 3-4 is shown, blue regions are positively charged and red 
regions are negatively charged. E967 was previously placed on the Vt 2-3 interface but has 
been moved to this face in retrospect.  To indicate the approximate position of the binding 
sites the most exposed atoms of residues that show significant perturbations in the NMR 
spectra  are circled and labelled with their respective amino acid name.  Figure prepared 
using MOLMOL (269). 
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Figure 4.3.2 The proposed binding interface between Vt and LD2 on face 3-4 
The surface potential of Vt face 3-4 is shown, blue regions are positively charged and red 
regions are negatively charged. E967 was previously placed on the Vt 2-3 interface but has 
been moved to this face in retrospect. To indicate the approximate position of the binding 
sites the most exposed atoms of residues that show significant perturbations in the NMR 
spectra  are circled and labelled with their respective amino acid name.  Figure prepared 
using MOLMOL (269). 
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Figure 4.3.3 The proposed binding interface between Vt and His-LD1/LD2 on face 3-4 
The surface potential of Vt face 3-4 is shown, blue regions are positively charged and red 
regions are negatively charged. E967 was previously placed on the Vt 2-3 interface but has 
been moved to this face in retrospect. To indicate the approximate position of the binding 
sites the most exposed atoms of residues that show significant perturbations in the NMR 
spectra  are circled and labelled with their respective amino acid name.  Figure prepared 
using MOLMOL (269). 
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Figure 4.3.4  Two site binding hypothesis vs. extended conformation 
(a) Model showing paxillin LD motifs binding to two sites in Vt as α-helices.  (b) model 
showing one LD motif interacting in an extended conformation.  Vt is shown from face 2-3 
with the binding sites residing on face 3-4.  Yellow boxes represent LD motifs in a helical 
conformation, yellow line represents one LD motif in an extended conformation. 
  
4.3.5  Vt face 5-2 does not provide a convincing binding site 
 
Based on the features determined in FAT binding to LD2 and LD4 (6), it was proposed that 
Vt face 5-2 may also bind to LD motifs.  For this binding surface to become available it 
was recognised that helix 1 of Vt would need to be displaced (6).  The presence of helix 1 
on face 5-2 makes the analysis of this region complex.  The data presented here suggests 
that overall the NH chemical shifts changes were small on Vt face 5-2 with LD1, LD2 and 
LD4 as well as with His-LD1/LD2.   However, some chemical shift perturbations above the 
determined criteria have been observed both on the 5-2 interface and on helix 1.  For LD1 
there were six and for LD2 there were two affected chemical shifts above the criteria on 
this face.  In contrast, for His-LD1/LD2 there were twelve affected chemical shifts (see 
Results, Figure 3.6.14 and Discussion Figure 4.4.1).  This data would suggest that peptides 
LD1 and LD2 alone cannot occupy Vt face 5-2. 
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Figure 4.3.5 shows Vt face 5-2 after removing helix 1 (E880-D917) to show the residues 
that were perturbed by His-LD1/LD2.  Interestingly, the affected residues line the perimeter 
of the proposed binding site rather than in the center of the Vt 5-2 site. This is consistent 
with helix 1 being the predominant occupant of this site even in the presence of an excess 
of His-LD1/LD2. The data presented here does not rule out binding to this face, but there is 
not enough information to propose binding residues specific to LD motifs. Further 
information is needed on this interface before a binding site can be proposed or ruled out 
completely and it may be necessary to create a construct without helix 1 to analyse specific 
perturbations caused by LD motifs. 
 
 
 
 
Figure 4.3.5 Chemical shift perturbations mapped onto Vt face 5-2 with helix 1 
removed.   
The surface potential of Vt face 5-2 is shown, blue regions are positively charged and red 
regions are negatively charged.  Residues E880-D917 have been removed. To indicate the 
approximate position of the binding sites the most exposed atoms of residues that show 
significant perturbations in the NMR spectra  are circled and labelled with their respective 
amino acid name.  Figure prepared using MOLMOL (269)   237 
4.4  Comparison of Vt-LD interactions with other LD binding 
proteins 
 
The FAT domain of FAK interacting with LD2 and LD4 provided the first structural 
insight into the mechanism of LD motif binding (6-9).  The knowledge that the structure of 
Vt was similar to FAT lead to the hypothesis that the LD motif might recognise FAT-like 
folds as part of the motif recognition mechanism (6). Recently, the structure of the Git1 
PBD has been solved (10) which is a four-helix bundle that adopts a similar fold to FAT 
and Vt, and chemical shift perturbation showed that LD motifs LD2 and LD4 would bind to 
a single site on one face of the PBD.   
 
Since the initial characterisation, the field has advanced in several ways.  FAT is known to 
have two binding sites, each on opposite sides of the molecule, which can bind 
simultaneously to LD2 and LD4 (6;9).  The affinity appears to be higher on FAT face 1-4 
for LD2 and LD4 is suggested to prefer face 2-3 (7;207).  It has also been shown that other 
LD motifs can bind to the FAT domain of FAK (personal communication), but determining 
the orientation of LD motifs still remains problematic. The structural homologue, Git1 PBD 
binds LD2 and LD4 but there is only one site on Git1 face 1-4 and the affinity for LD4 is 
slightly higher than for LD2 but still comparable (10).   Finally, the structure of actopaxin 
(α-parvin) has recently been solved in complex with LD1 and provides an alternative 
mechanism of binding distinct from the LD-FAT-like fold recognition (11). 
 
The data presented here between Vt and LD1 and LD2 would be consistent with two 
binding sites on face 3-4 of Vt if the LD peptides bind in a helical fashion.  This is the same 
as face 2-3 of FAT and Git1.  Alternatively there may be one site on Vt face 3-4.   The 
affinity and the orientation of LD motifs with Vt still needs to be determined. 
 
A feature that persists throughout the binding sites of FAT, Git1 and Vt is a solvent 
exposed hydrophobic patch or hydrophobic residue surrounded by charged or polar 
residues.  Figure 4.4.1 shows a comparison of the residues that are involved in the 
interaction for FAT, Git1 and Vt based on a structural sequence alignment.  From this it can   238 
be seen that some of the residue positions are similar, but there is no obvious pattern that 
arises between the three proteins. 
 
 
 
Figure 4.4.1  Sequence alignment based on helical structures of Vt, Git1 PBD and 
FAT domain of FAK and residues affected by LD motifs 
Residues involved in binding LD2 and LD4 for FAT and Git1 shown as blue boxes (6;10), 
residues in Vt perturbed by LD1, LD2 and His-LD1/LD2 (LD1/2) are shown in orange, 
green and brown respectively.  Grey boxes are residues that are either unassigned or could 
not be transferred to the wild-type Vt spectrum. 
 
The binding regions for the LD motifs on FAT, Git1 and Vt are shown in Figure 4.4.2 a, c 
& d.  So far the evidence suggests that LD motifs may recognise the FAT fold but the 
specifics of what determines specificity of motif or binding partner is not clear.  An 
additional insight into LD binding and recognition comes from the recent publication of the 
structure of actopaxin (α-parvin) in complex with LD1 (11).  Actopaxin does not adopt a 
FAT-like four helix bundle but is a CH domain.  It is a known interaction partner of 
paxillin LD1 and LD4, and the predicted PBS sequence was predicted to reside in residues 
K273-A290 (77).  The new data shows that LD1 does not bind to this PBS but to a different 
region consisting of helices αL, αA and αF of the CH2 domain (Figure 4.4.2b).  This is a 
new mode of binding distinct from FAT, and it would be interesting to determine whether 
LD4 binds to actopaxin in the same manner as LD1.   239 
 
 
Figure 4.4.2 Structures of the FAT domain (a), actopaxin CH2 domain (b), Git1 PBD 
(c) and Vt (d) showing LD interaction sites 
The FAT domain is shown in complex with LD2 on both faces, actopaxin is shown in 
complex with LD1, Git1 has the perturbed residues by both LD2 and LD4 in blue, and Vt 
has the proposed resides perturbed by His-LD1/LD2 mapped in purple. 
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Searching for similarities that all of the target sequences share shows that the binding 
interface formed between actopaxin and LD1 contains a hydrophobic surface that interacts 
with the leucine rich face of LD1, and there are three charged/polar residues.  As already 
mentioned, FAT, Git1 and Vt also share these features.  Within the structural families of 
FAT-like folds the binding interface is formed across two helices, for actopaxin the binding 
also occurs across helices, despite the actopaxin CH domain being structurally different to 
the others.   
 
The major difference between all target sequences is the specificity of LD binding and 
number of binding sites.  FAT and Git1 bind to LD2 and LD4 (5-10;80;82;207), actopaxin 
binds to LD1 and LD4 (11;77), and the data presented here suggests that Vt interacts with 
LD1 and LD2.  Currently there is one known interaction site on one helical interface for 
actopaxin and Git1; FAT is different as it has two sites on opposite sides of the molecule 
that can be occupied simultaneously.  On the basis of the large area over which chemical 
shifts were observed, the data presented here suggests that there may be two sites for LD 
motifs on one face of Vt; alternatively there is one site but LD motifs would need to bind in 
extended conformation.  As stated previously, this would constitute a further mode of 
interaction between target sequences and LD motifs.   
 
The question still remains as to how an LD motif recognises its prospective binding site, 
especially now given that the target sequences appear so different?  It could be that LD 
motifs are not specifically seeking their recognition domains but when they are brought 
close in space by other domain interactions they themselves then interact.  In addition to 
LD motifs, paxillin also contains LIM domains and a polyproline motif that may serve as a 
docking site for SH3 domains (68).  FAK also contains polyproline sequences, so one could 
imagine a situation where molecules containing SH3 domains bind to paxillin and FAK and 
bring them close together in space.  This would then enable the FAT-LD interaction to 
ensue and would be consistent with differences between the target sequences whilst LD 
motifs adopt the same conformation. 
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This type of mechanism has been suggested to be like ‘molecular Velcro’; for example the 
binding motif of SH3 domains has a structure that will allow it to be ‘plugged in’ to other 
target proteins in a relatively fast yet non-specific manner and may be involved in 
recruiting other protein molecules (279).  Remembering that the binary LD-target 
interaction is potentially part of a much larger signalling complex within FAs, it could be 
envisaged that other interactions occur that bring the LD motif in close proximity to the 
target sequence so that they transiently interact to elicit a cellular response.  Many of the 
proteins involved in FA signalling consist of multiple interaction domains, and it is likely 
that there are multiple interactions occurring that are in dynamic equilibrium with each 
other (280).  Rather than binary interactions occurring one after another, FAs contain non-
linear networks of interacting proteins (20).   Protein interactions should thus occur when 
molecules encounter one another in space and time, when local concentration is high and 
the physiochemical environment correct for the interaction (281)   
 
4.5  Vt-LD interaction: consequences for the cell 
4.5.1  FAK competition in apoptosis 
 
Compelling evidence for a cellular role of the paxillin-Vt interaction comes from Subauste 
et al. (4).   Here they found that in vinculin null cells, apoptosis could be restored by the 
addition of Vt (811-1066), and this was shown to be due to modulation of the paxillin-FAK 
interaction. 
 
This modulation requires that FAK and Vt can compete for the binding of paxillin, so is 
likely due to the LD motifs in paxillin (4).  The data presented in this thesis suggests that 
LD2 is the motif common to both the FAK and Vt interaction so the competition between 
FAK and Vt may depend on LD2 in particular.  A situation could be imagined where 
paxillin will bind to either FAK or Vt via LD2, and if LD1 finds a target sequence then Vt 
signalling continues, and if LD4 finds a target then FAK signalling ensues. 
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LD4 has previously been shown to be important in the competition between FAK and Git1, 
expression of paxillin lacking LD4 in paxillin-null cells results in an 11-fold decrease in FA 
disassembly (51) and mutations that disrupt the LD4 binding site in FAK reduce paxillin 
binding more than mutations that disrupt the LD2 binding site (9).  One could therefore 
imagine a situation where LD2 is the important motif between FAK and Vt. 
 
Phosphorylation may play a role in competition between FAK and Vt for LD motifs. 
Phosphorylation of LD4 at serine S272 reduces the binding of FAT by destabilising the 
helicity of LD4 (87).  It has also been shown to affect Git1 binding by increasing the 
association with LD4 (10;282).  The switch is therefore controlled by phosphorylation, 
when serine S272 is dephosphorylated paxillin prefers to bind to FAK, and once 
phosphorylated the binding is shifted to more Git1 bound (10).  The phosphorylation state 
of LD2 may affect the binding to FAK and Vt in a similar manner.   
 
For competition to occur, binding affinities need to be comparable.  The FAT domain binds 
two LD motifs on opposite sides.  If Vt binds to two LD motifs on one face then the affinity 
may be similar, and the phosphorylation state could also change the affinities.   
 
4.5.2  Two-site model for Vt-LD interaction: one or two paxillin 
molecules? 
 
If the prediction proves correct that there are two binding sites in Vt for paxillin, a second 
question that arises is how many paxillin molecules will bind to Vt.  Figure 4.5.1 shows 
two possible models for paxillin binding, one where one molecule binds simultaneously to 
both sites and a second where two molecules of paxillin bind via their LD motifs.  It will be 
important to understand the specificity of these two sites to discover whether one is more 
likely to bind LD1 than LD2 or if they are promiscuous.  
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Figure 4.5.1 The two site binding model for Vt-LD motifs showing one paxillin 
molecule binding (a) or two paxillin molecules binding (b) on Vt face 3-4 
Vt is shown from face 2-3 with the binding sites residing on face 3-4.  Yellow boxes 
represent LD motifs in a helical conformation.  (a) one paxillin molecule interacts via two 
LD motifs-here the LD motifs would be different e.g. LD1 and LD2.  (b) two separate 
paxillin molecules bind-in this case the LD motifs could be the same, e.g. LD1 and LD1, or 
they could be different, e.g. LD1 and LD2. 
 
4.5.3  Full length vinculin and paxillin binding 
 
It is important to remember that Vt is part of a much larger 116kDa protein (the crystal 
structure can be seen in Figure 1.3.6).  Vinculin is an important regulatory protein that 
exists in a closed, autoinhibited form (152;153) and an open, active form (156;283).  It is 
subject of much debate which binding partners can activate the full length molecule and the 
question remains as to whether there is a singular molecule that can activate or whether a 
combinatorial input is required (152;155;157;158;160-162).  The major contacts that hold 
this autoinhibited conformation are between Vt and D1 and Vt and D4 (152-155). 
 
If the proposed binding interface in Vt is true, it provides an interesting idea that paxillin 
could be involved in activating vinculin.  Figure 4.5.2 shows full length vinculin with the   244 
proposed LD1 and LD2 binding sites mapped on.  Many of the affected residues are 
exposed to solvent and not buried in the molecule so it is possible that paxillin could bind 
to a closed form of vinculin.  If the two site model is true then site 1 (L982) is accessible 
while some of site 2 surrounding I948 is occluded.  An attractive idea is that one LD could 
bind to site 1 which would destabilise the contact between Vt and D4. This may cause site 2 
to become available which would weaken the Vt-D1 interaction.  This would then allow 
binding of other ligands such as talin1.  
 
 
 
Figure 4.5.2 Full length vinculin showing proposed binding site for LD1 and LD2 
The five domains of vinculin are shown , D1 (red), D2 (green), D3 (blue), D4 (yellow) and 
D5(Vt) (magenta).  Paxillin binding site 1 and 2 is shown in cyan on Vt. 
 
4.5.4  The F-actin binding sites overlap with the proposed LD binding 
sites on Vt 
 
An important interaction within FAs is between vinculin and F-actin (188).  Vt binding 
provides a link between F-actin and the ECM and may play a role in adhesion 
strengthening and actin crosslinking (41;284).  There are two binding sites for F-actin on 
Vt, and Vt contacts two different F-actin monomers (41).  F-actin binding is thought to 
induce dimerisation of Vt by exposing a cryptic dimerisation site which is thought to be a 
mechanism for crosslinking actin (204).     245 
 
The F-actin binding site is deactivated in the autoinhibited form of the full-length molecule 
and F-actin binds with very low affinity (151).  The structure of Vt bound to F-actin reveals 
that one F-actin binding site is available in the closed vinculin conformation and the second 
is partially occluded by vinculin D1.  Steric hindrance between D1 and F-actin prevents the 
second binding site from making full contact with actin. Once bound to Vt, crosslinking of 
actin filaments occurs via activation of the cryptic dimerisation site in Vt, which is believed 
to occur by changes in the N-terminal strap and C-terminal loop (41). 
 
Figure 4.5.3 shows the binding sites of F-actin in relation to the full length vinculin 
molecule and the proposed paxillin LD motif binding sites.   The F-actin sites partially 
overlap with the proposed LD binding sites, suggesting that paxillin and F-actin binding to 
vinculin may be mutually exclusive.  This has implications when searching for the vinculin-
paxillin interaction, if F-actin and LD binding is mutually exclusive it may not be 
appropriate to look at mature FAs where there is already a vinculin-F-actin interaction. 
 
It is interesting to note the similarities between F-actin binding to vinculin and the proposed 
LD binding sites on Vt.  Both proteins bind to a similar region on Vt.  F-actin consists of 
two sites, and there is a possibility that there are two sites for LD binding, one of which is 
partially occluded in the closed conformation.  Janssen et al. (41) suggest that the partial 
accessibility of the F-actin binding site in the autoinhibited full-length is evidence towards 
the combinatorial input model of vinculin activation, where other binding partners act in 
concert to activate vinculin.  Paxillin could work similarly to activate vinculin, and it is 
possible to imagine two different scenarios, one when F-actin is bound with a set of binding 
partners such as talin1 which creates one type of FA signalling event such as FA 
maturation; and a second where paxillin may be bound with other partners to signal a 
different event such as apoptosis.  
 
Another interesting observation by Janssen et al. (41) is the dimerisation interface formed 
by Vt.  The affected regions include the N-terminal strap and C-terminal loop of Vt, and the 
authors found that this dimerisation only occurred after F-actin binding. The data presented   246 
in this thesis showed that when an excess of Vt was added to His-LD1/LD2, large 
aggregates occurred-perhaps a similar dimerisation is occurring when paxillin binds to Vt? 
 
 
 
 
 
Figure 4.5.3 F-actin binding site overlaps partially with proposed LD binding site 
The five domains of vinculin are shown , D1 (red), D2 (green), D3 (blue), D4 (yellow) and 
D5(Vt) (magenta).  Paxillin binding site 1 and 2 is shown in cyan on Vt, and the F-actin 
binding sites are shown in white in the right hand picture 
 
4.5.5  Could the Vt interaction with LD peptides be non-specific? 
 
In a study by Humphries et al. (188) the interaction between Vt and F-actin was shown to 
be crucial, but it was also noted that co-localisation of Vt and paxillin was not observed.  
Paxillin co-localised with Vh but not Vt in vinculin enlarged FAs and the authors suggest 
that there may be very little interaction in cells between Vt and paxillin.  As stated in the 
Introduction (1.4.2) much of the Vt in the cells was associated with actin, and this may 
explain why the paxillin-vinculin interaction could not be identified as the two binding sites 
may be mutually exclusive.  Similarly, it may be that the cellular situation was not 
appropriate for detecting this interaction.  As other studies have provided compelling 
evidence for a Vt-LD interaction (4), this is a new insight into FA complexity.  As we learn 
more about FA assembly, turnover and maturation it may become possible to understand 
the observations in these heterogeneous and dynamic multidomain signalling complexes.    247 
 
The data presented in this thesis points to a specific interaction in vitro between Vt and 
paxillin, but the nature of that interaction appears complex.  It will be of vital importance to 
test the validity of these binding sites, and then search for them specifically in cells in the 
appropriate context.  The observations of Subauste et al. (4) suggest an interaction between 
Vt and paxillin in vivo, but as the full complexity of FA assembly, turnover and maturation 
is emerging more evidence will be required.  The current study has provided hypotheses to 
investigate based on binary interactions which ultimately will need testing in the complex 
cellular environment.  The following sections explore potential experiments that can now 
be embarked upon. 
 
4.6  Future experiments to further the knowledge of the Vt-paxillin 
interaction 
4.6.1  In vitro experiments 
 
Two potential interaction sites for LD motifs on Vt face 3-4 have been proposed based on 
chemical shift perturbation data that is less than ideal.  It is desirable to establish that this 
interaction site is specific to LD peptides.  If it is shown to be specific then it remains to be 
determined whether there is one site or two separate sites and whether there is preference 
for different LD motifs. 
 
An achievable way to study the binding sites would be using paramagnetic labels attached 
to LD peptides.  Similar experiments have been carried out when looking at FAT (7;8) and 
would involve mutating one residue in the LD peptide to a cysteine and reacting this with 
MTSSL ((1-oxy-2,2,5,5-tetramethylpyroline-3-methyl)methanethiosulfonate).  This 
reaction produces an oxidized nitroxide which becomes the paramagnetic centre. A 
previous study (7) made two forms of LD4 where cysteines were either added at the 
beginning of LD4 (A263Cys) or at the end of the peptide (Ser273Cys) and then were spin 
labelled.  For LD1, Met1Cys and Ser13Cys mutants could be created and for LD2, 
Asn141Cys and Asn153Cys could be made. 
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Addition of a paramagnetic spin label increases the relaxation rate of nuclei that are close to 
the label in a distance dependant manner.  Paramagnetic relaxation enhancement (PRE) 
arises due to the dipolar interaction between a nucleus and unpaired electrons of a 
paramagnetic centre (285).  If a paramagnetic group was added to the LD peptides, residues 
that are close in space to the interaction site would be broadened, perhaps completely lost 
from the 
1H-
15N-HSQC spectrum.  These broadened resonances can be assumed to be close 
to the interaction site and directly affected by the ligand.  Any non-specific effects in the 
spectrum should not be affected by the spin label. 
 
It might be possible to test the two sites hypothesis by introducing a paramagnetic label into 
one LD peptide and then carrying out competitive chemical shift perturbation experiments 
by titrating Vt with mixtures of two different LD peptides.  The paramagnetic label would 
reveal the binding site(s) and then the non-spin labelled peptide could be used to out-
compete the spin label. 
 
An additional way to look at the interaction sites is to mutate some of the residues predicted 
to reside in site 1 and site 2 and see whether the 
1H-
15N-HSQC spectrum is affected in the 
same manner when titrated by LD peptides.  This would rely on the spectrum not being 
adversely affected by a point mutation.  If this was effective, mutagenesis could be used to 
make one binding site deficient whilst leaving the second site available which could also be 
useful in determining specificity of LD motifs.   
 
If the Vt face 3-4 interaction interface proves to be true, then it remains to be determined 
whether the LD peptides interact with Vt in an extended conformation or as a helix.  
Crystallisation has not been attempted in this study for fears that the affinity between Vt 
and LD peptides was too low, but perhaps it should be investigated.  Filtered 2D-NOESY 
experiments can be used to filter out proton signals from a doubly labelled protein (Vt) and 
NOEs can be observed from the unlabelled molecule (LD peptide).  Helical peptides will 
produce NH-NH NOEs and extended peptides will produce strong αH to N (i+1) NOEs 
(286).  NOEs can also be observed between labelled and unlabelled molecules by using 
filtered/edited 2D-NOESY experiments.  These can show NOEs occurring between   249 
residues that interact which could shed light on the specific interaction residues.  In 
practice, as there is only a low population of bound LD peptide compared to the free 
peptide, searching for NOEs from a small fraction of species would be difficult.  It may 
also be possible to measure the Cα secondary shifts of labelled LD peptides and see if they 
adopt α-helices but again this may be plagued by the same problem.  Determining how 
these LD motifs interact will be a very difficult problem because of the apparent weak 
affinity. 
 
Vt face 5-2 was predicted to harbour a binding site for LD peptides (6), but the data does 
not currently support this.  Helix 1 occludes this interface in Vt, so removing helix 1 may 
aid this investigation if a stable protein can be produced.  Based on the F-actin data (41), it 
would be interesting to investigate whether face 5-2 or the C-terminal loop and N-terminal 
strap are forming a dimerisation interface for Vt in the presence of paxillin.  
 
To study whether phosphorylation affects binding of LD peptides to Vt, phosphorylated LD 
peptides can be synthesised.  LD4 contains a known phosphorylation site at Ser272 (88), 
but there are serines in the other peptide mimics that although not predicted could be 
phosphorylated.  These are serine S13 in the LD1 peptide and serine S143 in the LD2 
peptide.  Chemical shift perturbation experiments can then be repeated for the 
phosphorylated peptides and effects on the spectrum analysed.   
 
4.6.2  In vivo experiments 
 
Ultimately, the interaction between paxillin and Vt needs to be directly observed in vivo 
and it is difficult to construct detailed experiments until the cellular context is understood.  
If the predicted binding sites in Vt are true and mutants can be made that disrupt binding, 
then experiments can be repeated as in Subauste et al. (4).  They found that vinculin null 
cells could be rescued from apoptosis resistance by Vt, and this was due to the modulation 
of the FAK-paxillin interaction.  A Vt mutant deficient in LD binding should not rescue 
these cells if it is dependant on the LD-Vt interaction.   If the LD2 motif is the important   250 
motif for the competition between FAK and Vt then expression of Vt LD2 mutants should 
reduce paxillin binding and affect the cells’ response to apoptotic stimuli. 
 
The data presented in this thesis is consistent with an overlapping binding site for paxillin 
and F-actin, which means that the interaction between Vt and paxillin may need to be 
hunted in cells where Vt is not directly attached to actin filaments.  This will require precise 
analysis of specific types of FAs, and may need to involve looking at the open and 
autoinhibited forms of vinculin.  FRET between Vt and paxillin may prove valuable in 
deciphering the cellular role of the interaction. 
 
4.7  Conclusions 
 
It is beginning to emerge that LD motifs adopt an α-helical structure when bound to their 
target and interact via their leucine rich face.  However, the target sequences that they bind 
to seem to be different, and may not be due to structural similarities as previously thought.  
A recurring feature between all of these interfaces is a hydrophobic element surrounded by 
polar and charged residues, but how the LD motif specifically determines where it will bind 
is difficult to determine.  It could be that while LD motifs adopt this conformation, the 
target sequences may be very diverse and the interaction occurs due to the binding partners 
being brought into close proximity by other domain interactions that are more dominant, for 
example an SH3 domain binding to polyproline regions or SH2 domains binding to 
phosphorylated tyrosines.  Maybe LD motifs will pave the way in understanding further 
complexities in molecular recognition and uncover mechanisms of recognition that have 
not previously been appreciated. 
 
This thesis has opened doors to further understanding of the vinculin-paxillin interaction 
and has provided new avenues to explore.  A binding interface has been proposed and if 
this is validated will shed new light on the Vt-LD motif interaction.  Ultimately, the cellular 
context needs to be understood; in the meantime studies that strive to understand the 
molecular details of individual interaction partners are vital for progressing our 
understanding of focal adhesion signalling.   251 
 
5  Appendix 
5.1  Vt Sequences 
 
Wild-type Vt in pET-15b with amino acids and numbering.  Restriction sites are shown.   
 
     Bgl II            T7 Promoter 
 AG ATC TCG ATC CCG CGA AAT TAA TAC GAC TCA CTA TAG GGG  
 
lac operator        Xba I 
AAT TGT GAG CGG ATA ACA ATT CCC CTC TAG AAA TAA TTT TGT  
 
         rbs     Nco I 
TTA ACT TTA AGA AGG AGA TAT ACC ATG GGC AGC AGC CAT CAT  
              Met Gly Ser Ser His His 
 
His·Tag            Thrombin Cleavage Site NdeI 
CAT CAT CAT CAC AGC AGC GGC CTG GTG CCG CGC GGC AGC CAT  
His His His His Ser Ser Gly Leu Val Pro Arg￿Gly Ser His 
 
    879 880 881 882 883 884 885 886 887 888 889 890 891 
ATG GAA GAA AAA GAT GAG GAG TTC CCA GAG CAG AAA GCA GGA  
Met Glu Glu Lys Asp Glu Glu Phe Pro Glu Gln Lys Ala Gly 
 
892 893 894 895 896 897 898 899 900 901 902 903 904 905 
GAA GCT ATT AAT CAG CCC ATG ATG ATG GCT GCT AGG CAG TTG  
Glu Ala Ile Asn Gln Pro Met Met Met Ala Ala Arg Gln Leu  
 
906 907 908 909 910 911 912 913 914 915 916 917 918 919 
CAT GAC GAG GCT CGG AAA TGG TCT AGC AAG GGT AAC GAC ATC  
His Asp Glu Ala Arg Lys Trp Ser Ser Lys Gly Asn Asp Ile 
 
920 921 922 923 924 925 926 927 928 929 930 931 932 933 
ATT GCT GCT GCT AAA CGA ATG GCG CTG CTC ATG GCT GAG ATG  
Ile Ala Ala Ala Lys Arg Met Ala Leu Leu Met Ala Glu Met 
 
934 935 936 937 938 939 940 941 942 943 944 945 946 947 
TCA CGC CTG GTG CGA GGA GGC AGC GGA AAC AAG CGT GCC CTC  
Ser Arg Leu Val Arg Gly Gly Ser Gly Asn Lys Arg Ala Leu  
 
948 949 950 951 952 953 954 955 956 957 958 959 960 961  
ATC CAG TGT GCA AAA GAT ATT GCT AAG GCA TCG GAT GAA GTC  
Ile Gln Cys Ala Lys Asp Ile Ala Lys Ala Ser Asp Glu Val 
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962 963 964 965 966 967 968 969 970 971 972 973 974 975 
ACT CGA TTG GCC AAA GAG GTG GCC AAG CAA TGT ACT GAT AAA  
Thr Arg Leu Ala Lys Glu Val Ala Lys Gln Cys Thr Asp Lys 
 
976 977 978 979 980 981 982 983 984 985 986 987 988 989 
CGC ATT AGA ACA AAC CTC TTA CAG GTC TGT GAG CGA ATC CCA  
Arg Ile Arg Thr Asn Leu Leu Gln Val Cys Glu Arg Ile Pro 
 
990 991 992 993 994 995 996 997 998 9991000100110021003 
ACC ATC AGC ACG CAG CTC AAA ATT CTT TCC ACA GTG AAA GCT  
Thr Ile Ser Thr Gln Leu Lys Ile Leu Ser Thr Val Lys Ala 
 
10041005100610071008100910101011101210131014101510161017 
ACC ATG CTG GGC AGG ACT AAC ATC AGC GAT GAA GAA TCA GAA  
Thr Met Leu Gly Arg Thr Asn Ile Ser Asp Glu Glu Ser Glu 
 
10181019102010211022102310241025102610271028102910301031 
CAG GCA ACT GAG ATG TTG GTT CAT AAC GCC CAG AAC CTC ATG  
Gln Ala Thr Glu Met Leu Val His Asn Ala Gln Asn Leu Met 
 
10321033103410351036103710381039104010411042104310441045 
CAG TCT GTG AAG GAA ACT GTG AGA GAA GCT GAA GCA GCA TCC  
Gln Ser Val Lys Glu Thr Val Arg Glu Ala Glu Ala Ala Ser 
 
10461047104810491050105110521053105410551056105710581059 
ATT AAG ATA AGA ACA GAT GCC GGA TTC ACT CTG CGC TGG GTC  
Ile Lys Ile Arg Thr Asp Ala Gly Phe Thr Leu Arg Trp Val 
 
1060106110621063106410651066        BamH I 
AGA AAG ACC CCA TGG TAT CAG TAA CTC GAG GAT CCG GCT GCT  
Arg Lys Thr Pro Trp Tyr Gln End Leu Glu Asp Pro Ala Ala 
 
AAC AAA GCC CGA AAG GAA GCT GAG TTG GCT GCT GCC ACC GCT  
Asn Lys Ala Arg Lys Glu Ala Glu Leu Ala Ala Ala Thr Ala 
 
Bpu1102 I 
GAG CAA TAA CTA GCA TAA CCC CTT GGG GCC TCT AAA CGG GTC  
Glu Gln End 
 
TTG AGG GGT TTT TTG 
 
 
Vt Mutants DNA changes 
I997S: ATT to AGC 
M1022S: ATG to AGC 
∆C: truncated at 1046 ATT to TAG   253 
5.2  Wild-type and mutant amino acid sequences 
 
Wild-type Vt (M879-Q1066) with extra GSH from thrombin cleavage 
 
   879 GSHMEEKDEE FPEQKAGEAI NQPMMMAARQ LHDEARKWSS KGNDIIAAAK RMALLMAEMS   
   935 RLVRGGSGNK RALIQCAKDI AKASDEVTRL AKEVAKQCTD KRIRTNLLQV CERIPTISTQ    
   995 LKILSTVKAT MLGRTNISDE ESEQATEMLV HNAQNLMQSV KETVREAEAA SIKIRTDAGF    
  1055 TLRWVRKTPW YQ 
  
Vt/I997S mutant 
 
   879 GSHMEEKDEE FPEQKAGEAI NQPMMMAARQ LHDEARKWSS KGNDIIAAAK RMALLMAEMS 
   935 RLVRGGSGNK RALIQCAKDI AKASDEVTRL AKEVAKQCTD KRIRTNLLQV CERIPTISTQ 
   995 LKSLSTVKAT MLGRTNISDE ESEQATEMLV HNAQNLMQSV KETVREAEAA SIKIRTDAGF 
  1055 TLRWVRKTPW YQ 
 
Vt/M1022S mutant 
 
   879 GSHMEEKDEE FPEQKAGEAI NQPMMMAARQ LHDEARKWSS KGNDIIAAAK RMALLMAEMS     
   935 RLVRGGSGNK RALIQCAKDI AKASDEVTRL AKEVAKQCTD KRIRTNLLQV CERIPTISTQ    
   995 LKILSTVKAT MLGRTNISDE ESEQATESLV HNAQNLMQSV KETVREAEAA SIKIRTDAGF    
  1055 TLRWVRKTPW YQ 
 
Vt/∆C (879-1045) 
 
   879 GSHMEEKDEE FPEQKAGEAI NQPMMMAARQ LHDEARKWSS KGNDIIAAAK RMALLMAEMS     
   935 RLVRGGSGNK RALIQCAKDI AKASDEVTRL AKEVAKQCTD KRIRTNLLQV CERIPTISTQ    
   995 LKILSTVKAT MLGRTNISDE ESEQATEMLV HNAQNLMQSV KETVREAEAA S 
 
 
5.3   Primers for site directed mutagenesis of Vt. 
 
M1022S 
For:CAG  AAC  AGG  CAA  CTG  AGA  GCT  TGG  TTC  ATA  ACG  CCC  AGA  ACC   (42  bp) 
Rev:GGT  TCT  GGG  CGT  TAT  GAA  CCA  AGC  TCT  CAG  TTG  CCT  GTT  CTG   (42  bp) 
 
I997S 
For:CCA TCA GCA CGC AGC TCA AAA GCC TTT CCA CAG TGA AAG CTA CC(44 bp) 
Rev:GGT AGC TTT CAC TGT GGA AAG GCT TTT GAG CTG CGT GCT GAT GG(44 bp) 
 
C-term 
For:GAG  AGA  AGC  TGA  AGC  AGC  ATC  CTA  GAA  GAT  AAG  AAC  AGA  TGC  CGG(45bp) 
Rev:CCG  GCA  TCT  GTT  CTT  ATC  TTC  TAG  GAT  GCT  GCT  TCA  GCT  TCT  CTC(45bp) 
 
All oligos are presented in the 5' to 3' direction. 
 
M1022SF: 72.7ºC 
M1022SR: 72.7ºC 
I997SF:  72.9ºC 
I997SR:  72.9ºC 
Cterm:   70.7ºC 
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5.4  Paxillin Sequences 
 
His-LD1/LD2 in pET-15b vector.  His tag is not removed so protein has potential to start at 
the Met at the NcoI site. 
 
DNA sequence 
 
atg ggc agc agc cat cat cat cat cat cac agc agc ggc ctg gtg 
ccg cgc ggc agc cat atg gac gac ctc gac gcc ctg ctg gcg gac 
ttg gag tct acc acc tcc cac atc tcc aaa cgg cct gtg ttc ttg 
tcg gag gag acc ccc tac tca tac cca act gga aac cac aca tac 
cag gag att gcc gtg cca ccc ccc gtc ccc cca ccc ccg tcc agc 
gag gcc ctc aat ggc aca atc ctt gac ccc tta gac cag tgg cag 
ccc agc agc tcc cga ttc atc cac cag cag cct cag tcc tca tca 
cct gtg tac ggc tcc agt gcc aaa act tcc agt gtc tcc aac cct 
cag gac agt gtt ggc tct ccg tgc tcc cga gtg ggt gag gag gag 
cac gtc tac agc ttc ccc aac aag cag aaa tca gct gag tct tca 
ccc acc gta atg agc acg tcc ctg ggc agc aac ctt tct gaa ctc 
gac cgc ctg ctg ctg gaa ctg aac gct gta cag cat aac ccg cca 
gga tcc ggc tgc taa 
 
Protein sequence 
 
M G S S H H H H H H S S G L V P R G S H M D D L D A L L A D L E S T T S H I S K 
R P V F L S E E T P Y S Y P T G N H T Y Q E I A V P P P V P P P P S S E A L N G T I 
L D P L D Q W Q P S S S R F I H Q Q P Q S S S P V Y G S S A K T S S V S N P Q D S 
V G S P C S R V G E E E H V Y S F P N K Q K S A E S S P T V M S T S L G S N L S E 
L D R L L L E L N A V Q H N P P G S G C Stop 
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5.5  Chemical shift table for Vt/I997S assignment 
 
Residue  Residue  δ δ δ δHN         δ δ δ δCα α α α         δ δ δ δCβ β β β         δ δ δ δNH        
type  number   (ppm)   (ppm)   (ppm)  (ppm)  
Phe  885  8.71  55.86  38.93  127.02 
Gln  888  8.67  55.60  28.30  123.15 
Lys  889  8.94  54.62  32.71  127.38 
Ala  890  8.51  53.28  17.08  126.14 
Met  898  8.69  60.01  33.67  118.00 
Met  899  7.90  57.80  30.77  120.36 
Met  900  8.80  57.76  -  118.34 
Ala  901  7.73  54.36  16.97  122.37 
Ala  902  8.06  54.90  17.15  121.94 
Arg  903  8.61  58.06  28.58  120.23 
Gln  904  8.02  58.42  27.54  117.27 
Leu  905  7.57  57.77  -  119.96 
His  906  8.68  62.31  -  121.44 
Asp  907  8.94  56.78  39.70  116.45 
Glu  908  7.20  57.79  29.28  118.47 
Ala  909  8.28  54.42  17.95  119.01 
Ser  914  9.54  58.94  63.92  122.79 
Lys  915  8.26  57.35  29.86  125.72 
Gly  916  8.88  45.89  -  114.91 
Asn  917  7.78  51.56  36.42  118.32 
Asp  918  8.86  56.17  40.43  124.27 
Ile  919  7.49  66.19  36.15  120.90 
Ile  920  7.32  60.33  34.20  121.90 
Ala  921  7.94  55.37  17.96  121.03 
Ala  922  7.76  54.68  17.40  121.04 
Ala  923  8.56  55.07  17.37  121.63 
Lys  924  8.32  60.39  32.31  116.63 
Arg  925  7.58  58.95  29.67  118.47 
Met  926  8.83  59.32  33.04  117.89 
Ala  927  8.19  55.30  17.68  121.40 
Leu  928  7.69  57.89  39.61  118.20 
Ala  931  8.01  54.63  17.18  123.92 
Glu  932  7.52  58.64  27.46  121.03 
Met  933  8.91  60.18  31.70  123.73 
Ser  934  8.05  61.75  -  113.48   256 
Residue  Residue  δ δ δ δHN         δ δ δ δCα α α α         δ δ δ δCβ β β β         δ δ δ δNH        
type  number   (ppm)   (ppm)   (ppm)  (ppm)  
Arg  935  7.23  57.63  30.16  120.17 
Leu  936  8.45  56.92  43.30  121.55 
Val  937  7.98  63.59  30.95  109.84 
Arg  938  7.17  53.71  28.31  118.08 
Gly  939  7.46  44.18  -  107.17 
Gly  940  8.06  43.70  -  105.88 
Ser  941  8.76  60.62  62.23  115.35 
Asn  943  8.03  52.46  38.56  118.27 
Lys  944  7.48  60.85  31.76  121.73 
Arg  945  8.29  59.02  28.29  117.54 
Ala  946  8.39  54.14  17.88  122.37 
Leu  947  8.37  58.26  40.35  121.58 
Ile  948  7.45  64.98  37.34  119.24 
Gln  949  8.23  57.88  27.48  119.62 
Cys  950  8.32  62.38  26.23  120.35 
Ala  951  7.75  55.10  17.64  119.42 
Lys  952  7.98  60.01  31.29  119.12 
Asp  953  8.70  57.43  39.82  123.43 
Ile  954  8.89  66.08  36.90  125.22 
Ala  955  8.34  54.70  16.75  125.03 
Lys  956  8.11  59.17  31.34  120.36 
Ala  957  7.69  54.67  16.62  122.55 
Ser  958  8.63  62.48  -  116.45 
Asp  959  8.19  57.02  39.85  125.90 
Glu  960  7.53  58.85  28.57  121.82 
Val  961  8.03  67.27  30.73  118.03 
Thr  962  8.10  67.33  -  114.29 
Arg  963  8.04  59.48  29.30  121.41 
Leu  964  8.04  57.10  41.97  119.19 
Ala  965  8.76  55.12  18.13  122.26 
Lys  966  8.14  59.96  31.29  117.83 
Glu  967  7.36  58.49  27.97  119.94 
Val  968  8.00  65.69  30.66  120.43 
Ala  969  8.39  55.38  16.99  121.73 
Lys  970  7.58  58.56  31.66  114.83 
Gln  971  7.30  54.44  28.33  114.97 
Cys  972  7.55  58.52  27.48  120.63 
Thr  973  8.85  62.59  68.47  120.63 
Asp  974  7.72  53.06  43.05  124.97   257 
Residue  Residue  δ δ δ δHN         δ δ δ δCα α α α         δ δ δ δCβ β β β         δ δ δ δNH        
type  number   (ppm)   (ppm)   (ppm)  (ppm)  
Arg  978  8.42  60.23  30.14  119.48 
Thr  979  7.95  66.48  68.42  113.89 
Asn  980  8.07  55.82  37.10  121.99 
Leu  981  8.51  57.27  40.98  121.01 
Leu  982  8.28  57.69  40.05  118.92 
Gln  983  8.12  58.72  27.59  117.75 
Glu  986  7.76  58.03  28.68  119.82 
Arg  987  7.45  57.30  30.25  116.99 
Ile  988  7.64  67.92  34.38  118.77 
Thr  990  7.15  65.61  68.22  114.21 
Ile  991  7.95  64.65  37.53  123.08 
Ser  992  8.98  61.91  -  116.47 
Thr  993  8.15  67.01  68.05  120.13 
Gln  994  7.61  58.28  27.19  122.97 
Leu  995  8.62  58.45  40.20  121.85 
Lys  996  7.98  60.48  30.87  120.64 
Ser  997  7.95  61.68  -  117.28 
Leu  998  8.99  57.03  41.72  122.05 
Ser  999  8.49  62.95  62.09  117.67 
Thr  1000  7.60  66.70  67.86  119.80 
Lys  1002  8.13  57.20  30.51  119.82 
Ala  1003  8.52  54.75  18.07  120.46 
Thr  1004  7.70  64.53  69.09  109.69 
Met  1005  7.64  56.57  32.70  119.42 
Leu  1006  7.30  56.13  40.56  120.28 
Gly  1007  8.70  45.15  -  109.20 
Arg  1008  7.69  55.63  29.87  120.69 
Asn  1010  8.36  52.88  37.14  119.69 
Ile  1011  7.69  59.57  38.01  118.84 
Ser  1012  8.72  57.59  63.66  122.48 
Asp  1013  8.68  56.20  39.91  124.12 
Glu  1014  8.65  59.39  28.47  120.20 
Glu  1015  7.93  58.81  28.81  120.57 
Ser  1016  8.12  60.29  62.53  115.57 
Glu  1017  8.61  58.62  28.41  122.40 
Gln  1018  8.15  58.54  27.49  120.35 
Ala  1019  7.69  54.76  17.58  121.16 
Thr  1020  7.99  66.89  67.78  116.20 
Glu  1021  8.47  59.33  28.41  122.17   258 
Residue  Residue  δ δ δ δHN         δ δ δ δCα α α α         δ δ δ δCβ β β β         δ δ δ δNH        
type  number   (ppm)   (ppm)   (ppm)  (ppm)  
Met  1022  8.07  58.16  32.19  117.30 
Leu  1023  7.79  58.61  41.19  123.74 
Val  1024  8.70  66.73  30.64  120.68 
His  1025  8.24  58.54  28.98  117.84 
Asn  1026  7.80  57.40  39.72  118.18 
Ala  1027  8.85  55.79  18.42  123.22 
Gln  1028  8.72  59.12  27.81  116.59 
Asn  1029  8.03  55.31  37.12  119.01 
Leu  1030  8.97  58.02  40.22  124.04 
Met  1031  8.25  58.30  33.96  116.49 
Gln  1032  8.20  58.55  27.11  118.74 
Ser  1033  8.32  62.56  -  116.11 
Val  1034  8.52  67.04  30.12  125.02 
Glu  1040  8.54  57.36  28.58  119.69 
Ala  1041  8.90  54.49  16.22  121.98 
Glu  1042  7.26  59.28  25.62  122.65 
Ala  1043  7.15  54.41  16.85  122.82 
Ala  1044  8.20  53.28  18.90  118.50 
Ser  1045  7.37  60.78  62.92  112.96 
Ile  1046  7.03  62.00  37.07  119.42 
Ile  1048  7.34  59.81  39.14  119.82 
Arg  1049  8.52  56.32  30.32  125.80 
Thr  1050  8.31  63.00  68.63  115.24 
Asp  1051  8.35  53.35  39.34  121.05 
Ala  1052  7.59  52.68  18.68  122.38 
Gly  1053  8.22  44.88  -  108.17 
Phe  1054  7.63  57.65  39.77  120.66 
Thr  1055  7.77  60.05  70.78  118.31 
Leu  1056  8.02  53.57  43.01  122.38 
Arg  1057  7.23  54.84  30.50  121.15 
Val  1059  9.60  61.31  34.45  128.45 
Arg  1060  8.89  54.94  29.06  128.99 
Lys  1061  8.11  55.81  31.90  123.45 
Thr  1062  8.09  59.18  69.01  117.66 
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5.6  Regions that differ between the wild-type 
1H-
15N HSQC 
spectrum and the I997S spectrum 
 
   260 
5.7  All assigned wild-type Vt residues affected by chemical shift 
perturbation experiments.  
  
Criteria set:  Percentage intensity decreases ≥50% OR chemical shift differences in the 
proton and nitrogen dimension of 0.03ppm OR 0.2ppm.  Red: specific to His-LD1/LD2 
(compared to peptides LD1 and LD2); orange specific to LD1 peptide (compared to LD2 
peptide); green specific to LD2 peptide (compared to LD1 peptide) 
 
LD1  LD2 
His-
LD1/LD2 
885  890  889 
889  898  898 
898  903  900 
902  905  902 
904  907  903 
905  908  904 
907  909  905 
908  919  907 
909  933  908 
922  937  909 
923  939  918 
924  940  919 
926  941  920 
931  945  921 
934  946  922 
938  947  923 
940  948  924 
941  949  926 
943  950  927 
945  952  932 
946  958  933 
947  959  934 
948  961  935 
949  963  937 
950  965  938 
951  966  939 
953  967  943 
955  968  944 
957  969  945 
LD1  LD2 
His-
LD1/LD2 
959  970  947 
960  973  948 
962  974  949 
963  982  950 
964  990  952 
965  994  953 
966  1000  954 
967  1003  955 
968  1004  957 
969  1005  958 
970  1006  959 
971  1012  960 
974  1013  961 
981  1014  962 
982  1015  963 
986  1017  965 
987  1023  966 
990  1025  967 
992  1026  968 
994  1027  969 
996  1033  970 
1000  1049  971 
1003  1050  972 
1004  1051  974 
1005  1056  978 
1006  1057  979 
1008  1059  981 
1012     982 
1013     987 
LD1  LD2 
His-
LD1/LD2 
1014     990 
1015     991 
1017     992 
1023     994 
1025     996 
1029     1000 
1030     1003 
1033     1004 
1040     1005 
1050     1006 
1057     1012 
1059     1013 
      1014 
      1015 
      1020 
      1023 
      1024 
      1027 
      1030 
      1032 
      1033 
      1034 
      1042 
      1043 
      1044 
      1045 
      1049   261 
 
6  Glossary 
A260  absorbance at 260nm  for measuring DNA absorbance 
A280  absorbance at 280nm  for measuring protein absorbance from 
aromatic amino acids 
Akt1  protein kinase B  serine/threonine protein kinase involved in 
promoting cell survival 
ANK  ankyrin  protein recognition domain-recognition 
mechanism unclear  
Arf  ADP-ribosylation 
factor 
small GTPase involved in actin remodelling 
Arp2/3  actin-related protein 
2/3 
part of the Arp2/3 complex involved in 
nucleation of actin at the leading edge of cells 
ASAP1  Arf GAP containing 
SH3, ANK repeat and 
PH domains 
PIP2 dependant Arf GTPase-activating protein 
involved in actin cytoskeleton regulation 
CH  calponin homology  recognition domain that binds to actin (CH1 
and CH2) CH3 domains may be regulatory and 
may not bind actin 
Crk  C10-regulator of kinase  adaptor protein within FAs 
CrkL  Crk-Like  adaptor protein within FAs 
CSA  chemical shift 
anisotropy 
a local magnetic field caused by electron 
currents in the nucleus in response to the 
external magnetic field that causes relaxation 
Csk  C-terminal Src kinase  tyrosine kinase that inhibits Src family PTKs 
by phosphorylating near the C-termini 
CV  column volume   
δ  chemical shift    The frequency of absorption for a nucleus of 
interest relative to the frequency of absorption 
of a molecular standard 
DOCK180  180-kDa protein 
downstream of Crk 
guanine nucleotide exchange factor for small 
GTPases Rac1 and Cdc42 
E6  E6 oncogene of human 
papilloma virus 
adapters that change the function
 of cellular 
regulatory proteins 
ECM  extracellular matrix  extracellular part of animal tissue containing 
proteins, proteoglycans and polysaccharides 
EDTA  ethylenediaminetetraac
etic acid  
chelating agent 
ELMO  engulfment and cell 
motility  
regulator of DOCK180, the Dock180/ELMO 
complex acts as a bipartite GEF for Rac 
ERK   extracellular signal-
regulated kinases 
(MAPK) 
serine/threonine protein kinase    262 
ERK1  extracellular signal-
regulated kinase 1 
(MAPK3) 
serine/threonine kinase (classical MAP kinases) 
ERK2  extracellular signal-
regulated kinase 2 
(MAPK1) 
serine/threonine kinase (classical MAP kinases) 
FA  focal adhesion  protein assemblies at the cell membrane linking 
cells to the ECM  
FAK  focal adhesion kinase  non-receptor tyrosine kinase and adaptor 
protein 
FAT  focal adhesion 
targeting 
domain of FAK necessary for localisation of 
FAK to FAs 
FB  fibrillar adhesion  elongated mature form of adhesion between the 
cell and the ECM 
FERM  band 4.1 and ezrin, 
radixin, and moesin 
homology 
domain found in many FA proteins, can bind to 
phospholipids and cytoskeletal proteins 
FRAP  fluorescence recovery 
after photobleaching  
optical technique that allows study of diffusion 
of fluorescently tagged molecules  
FRET  förster (fluorescence) 
resonance energy 
transfer  
energy transfer between two chromophores  
FX  focal complex  early adhesion between the cell and the ECM 
GAP  GTPase-activating 
protein 
can bind to activated G-proteins and stimulate 
their GTPase activity.  GEFs reverse this 
GDP  guanosine diphosphate  product of GTP dephosphorylation in signal 
transduction 
GEF  guanine nucleotide 
exchange factors 
catalyses the removal of GDP and replacement 
with GTP 
Git1  G protein-coupled 
receptor kinase 
interacting protein 1 
Arf-GTPase-activating proteins and adaptor 
proteins  
GRAF  GAP for Rho 
associated with focal 
adhesion kinase 
GTPase-activating protein for Rho 
Grb  growth factor receptor-
bound protein  
adaptor protein within FAs 
GST  glutathione-S-
transferase 
affinity tag for protein purification (GST is an 
enzyme that catalyses conjugation of reduced 
glutathione to electrophillic centres)  
GTP  guanosine-5'-
triphosphate  
purine nucleotide required in signal 
transduction where it is converted to GDP 
HIS  histidine tag  affinity tag consisting of histidine.  Binds to 
nickel 
HSQC  heteronuclear single 
quantum correlation  
a two dimensional NMR experiment   263 
HTI  head-tail interaction  interaction that holds vinculin in its 
autoinhibited conformation 
ILK  Integrin-linked kinase  serine/threonine protein kinase that can bind to 
B-integrins 
INEPT  insensitive nuclei 
enhanced by 
polarisation transfer 
method for transferring magnetisation to a 
sensitive nucleus such as protons to an 
insensitive nuclei such as nitrogen 
IpaA  invasion plasmid 
antigen A 
critical for Shigella entry and can bind to 
vinculin 
IPTG  Isopropyl ß-D-1-
thiogalactopyranoside 
molecular mimic of allolactose that induces 
transcription from the lac operon 
JNK  c-Jun N-terminal 
kinase 
MAP kinase responsive to stress stimuli 
Kd  dissociation constant  [P][L]/[PL] 
kDa  kilodaltons  unit of molecular mass 
Kex  exchange rate  in NMR chemical exchange regimes 
kinase  phosphorylation 
enzyme 
transfers phosphate groups from donors such as 
ATP and GTP to target molecules 
L  ligand  substance that can form a complex with another 
molecule 
LB  luria broth  nutritionally rich medium used to grow bacteria 
LD  leucine/aspartate  motif with consensus LDxLLxxL that can bind 
to signalling molecules 
LIM  lin11, isl-1 & mec-3  double zinc finger motif for protein interactions 
MAPK  Mitogen-activated 
protein kinase  
serine/threonine protein kinases 
MEK  MAPK/ERK kinase  phosphorylates MAPK (ERK) 
MEKK1  MEK kinase 1  phosphorylates MEK 
MKK4/7  MAPK kinase 4/7  phosphorylates MAPK (JNK) 
Ni-NTA  nickel-nitrilotriacetic 
acid 
agarose resin by Qiagen for purification of 
6xhis tagged proteins 
NMR  nuclear magnetic 
resonance 
spectroscopic method exploiting the magnetic 
properties of nuclei 
NOE  nuclear Overhauser 
effect  
transfer of magnetisation between nuclei via 
dipolar relaxation 
NOESY  nuclear Overhauser 
enhancement 
spectroscopy  
NMR exploiting the NOE 
N-WASP  N-Wiskott Aldrich 
syndrome protein 
regulates actin cytoskeleton remodeling 
OD600  optical density at 
600nm 
for measuring turbidity of bacterial cultures 
p120RasGap  p120 Ras GTPase 
activating protein 
remodelling the actin cytoskeleton   264 
p130Cas  Crk-associated 
substrate 
adaptor protein within FAs 
PABA1  poly(A)-binding 
protein 1 
mRNA-binding protein that also binds to 
paxillin 
PAK  p21-activated serine-
threonine kinase 
disassembly of actin stress fibers at focal 
adhesions 
PBD  paxillin binding 
domain 
domains based on sequence alignment 
proposed to bind to paxillin 
PBS  Paxillin Binding 
Subdomain 
domains based on sequence alignment 
proposed to bind to paxillin 
PCR  polymerase chain 
reaction 
method of in vitro amplification of DNA using 
thermostable DNA polymerases 
PDB  protein data bank  .pdb file containing coordinates for protein 
structure 
PH  pleckstrin homology  domain that binds to phosphatidlinositol lipids 
PI3K  phosphoinositide 3-
kinase 
enzymes that phosphorylate the 3 position 
hydroxyl group of the inositol ring of 
phosphatidylinositol 
PIP2  phosphatidylinositol 
bisphosphate  
product of cleavage of PIP3 
PIX  Pak-interactive 
exchange factors 
guanine nucleotide exchange factors that 
mediate activation of members of the Rho 
GTPase family 
PKCa  protein kinase C alpha  serine/threonine kinase activated by 
diacylglycerol and Ca2+ 
PKL  paxillin kinase linker   ADP-ribosylation-factor–GTPase activating 
proteins (also called Git2) 
PTK  protein tyrosine kinase  enzymes that phosphorylate proteins at tyrosine 
residues 
PTP-PEST  protein tyrosine 
phosphatase-PEST 
tyrosine phosphatase 
Rac  rac small GTPase  regulatory e.g. induces actin polymerization at 
the cell periphery to produce lamellipodia 
Rac1  rac small GTPase  member of the rac subfamily 
Raf  raf non receptor protein 
kinase (ser/thr) 
serine/threonine kinase that can phosphorylate 
MEK 
Ras  ras small GTPase  responsible for cell proliferation, G-protein, 
active when bound to guanosine triphosphate 
RF  radiofrequency pulse   
Rho  rho small GTPase  responsible for actin dynamics, G-protein, 
active when bound to guanosine triphosphate 
SEC  size exclusion 
chromatography 
also known as gel filtration 
SH2  src homology 2 domain   bind phosphorylated tyrosine residues 
SH3  src homology 3 domain   bind proline rich sequences   265 
SOC  super optimal broth 
plus glucose 
SOB with added glucose (with glucose for 
catabolite repression) 
Sos  Son of sevenless  Guanine nucleotide exchange factor (GEF), 
acts on Ras-GTPases 
Src  src tyrosine kinase  tyrosine kinase 
TALOS  torsion angle likelihood 
obtained from shifts 
and sequence similarity 
program for prediction φ and ϕ angles in 
proteins 
TEMED  Tetramethylethylenedia
mine 
used in SDS-PAGE 
Tm  melting temperature   
TOCSY  total correlation 
spectroscopy  
NMR exploiting J-couplings 
TROSY  transverse relaxation 
optimised spectroscopy  
NMR exploiting cross-relaxation to produce 
higher resolution spectra 
UV  ultraviolet   
VASP  Vasodilator-stimulated 
phosphoprotein 
associated with filamentous actin formation, 
plays a role in cell adhesion and motility 
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